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Trifluoromethanes play an important role in medicinal chemistry, and methods 
that enable the rapid synthesis of trifluoromethanes from common functional groups are 
essential for the synthesis of bioactive compounds. We describe a series of Cu-
catalyzed decarboxylative trifluoromethylation reactions that enable the conversion of 
alcohols to trifluoromethanes. These reactions rely on the efficient generation of 
nucleophilic “Cu–CF3”, and Chapter 1 provides background on the synthesis, stability, 
and reactivity of this organometallic species. In addition, we discuss the use of 
halodifluoroacetates as common, inexpensive, and green precursors to “Cu–CF3”. 
  Cu-catalyzed trifluoromethylation of electrophiles was an appealing, but 
underdeveloped strategy for accessing fluorinated compounds. Chapter 2 describes our 
entry into Cu-catalyzed decarboxylative trifluoromethylation of bromodifluoroacetates. 
We discovered that ligand and catalyst activation played critical roles in the 
development of an efficient Cu-based catalyst system. 
 Trifluoroethylarenes are commonly found in bioactive compounds, and in 
Chapter 3, we describe a straightforward Cu-catalyzed strategy to access this motif 
from benzylic bromodifluoroacetates. A key aspect of this reaction involved the 
generation of active electrophilic species in situ. 
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 In Chapter 4, we describe the ability of ligands to alter the regioselectivity of Cu-
catalyzed trifluoromethylation reactions. Propargylic bromodifluoroacetates are 
converted into a mixture of propargylic trifluoromethanes and trifluoromethylallenes 
using “Cu–CF3”; however, the use of 1,10-phenanthroline inverts the typical 
regioselectivity, and provides trifluoromethylallenes in high yield and selectivity. This is 
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Chapter 1: Nucleophilic Trifluoromethylation Reactions 
1.1. Trifluoromethanes in medicinal chemistry and chemical biology. 
The trifluoromethyl group plays an important role in medicinal chemistry, by 
modulating the distribution, metabolism, and pharmacokinetic (DMPK) properties of 
drug candidates. Trifluoromethanes are incorporated in compounds in order to: 1) block 
metabolic oxidation; 2) alter lipophilicity; 3) adjust pKa of adjacent functional groups; 4) 
perturb bond conformation; and 5) reduce electron density of nearby π-systems. 
Therefore, the development of synthetic methods that convert common functional 
groups to trifluoromethanes and facilitate the selective addition of CF3 into drug 
candidates empowers medicinal chemistry. 
Trifluoromethanes possess unique chemical properties that arise from the 
strength of C–F bonds, high electronegativity of F, and the small steric footprint of F.1 
C–F bonds are much stronger than C–H bonds; therefore, replacing Me groups that are 
prone to oxidative metabolism with CF3 groups increases the biological stability of drug 
candidates (Scheme 1.1A).1,2 Trifluoromethanes also modulate the pKa and H-bonding 
properties of adjacent functional groups, due to the strong electron-withdrawing nature 
of F (Scheme 1.1B).3 In addition, the steric profile of the trifluoromethyl group is similar 
to Et and iPr groups, with an A-value matching the Et group, and a van der Waals radius 




Scheme 1.1. Trifluoromethanes perturb properties that are critical in drug design. 
 
Fluorinated peptidomimetics are important for medicinal chemistry and chemical 
biology, since fluorinated amide mimics are stable towards metabolic degradation.1 
Trifluoroethylamines are isopolar mimics for amides, since the electron-withdrawing CF3 
group is electronically similar to the carbonyl of an amide (Scheme 1.2).4 In addition, the 
CF3 group increases the H-bond donating ability of the amine to more closely match 
that of an amide N–H. Trifluoroethylamines have been used as amide mimics in drug 
candidates, such as odanactib (Scheme 1.2).4 




 Trifluoromethane-containing compounds are also valuable for biological imaging 
techniques such as NMR and PET. Since 19F is a NMR active nucleus that is not found 
in biological systems, fluorinated probes provide high signal to noise ratios, and can be 
easily monitored by 19F NMR spectroscopy. Since 19F NMR shifts are sensitive to local 
electronic environment, fluorinated probes have been used to monitor drug-protein 
binding, and conformational changes in protein and membranes.1e,5 This approach can 
utilize either fluorinated ligands, or proteins that incorporate fluorinated amino acids 
(Scheme 1.3A).1e In a second example, [18F] radiolabeled compounds have also been 
used in PET imaging to monitor the distribution of drugs in animals.1e 
Scheme 1.3. Fluorinated probes are valuable for biological imaging. 
 
1.2. Nucleophilic trifluoromethylation. 
 Nucleophilic trifluoromethylation of electrophiles is a robust strategy for 
accessing many classes of trifluoromethanes. α-Fluoroalkyl nucleophiles possess 
unique properties compared to standard C-based nucleophiles, and the inherent 
instability of fluoroalkylanions creates challenges in organofluorine chemistry. M–CF3 
species are unstable (e.g. M = Li or Mg) and undergo α-fluoride elimination to form MF 
4 
 
and singlet difluorocarbene (:CF2) (Scheme 1.4A).
6,7 Electrostatic lone-pair repulsion 
between the C-based anion and fluorine 2p electrons destabilize the trifluoromethanide 
anion, therefore; M–CF3 species with highly ionic M–C bonds decompose rapidly. In 
addition, fluorophilic metals (e.g. Li or Mg) interact with fluorine electrons, and further 
promote decomposition to MF and :CF2 (Scheme 1.4A).
6,7 Given the instability of many 
M–CF3 complexes, the discovery of reagents that generate 
–CF3 in situ enabled the 
development of nucleophilic trifluoromethylation reactions.  
Scheme 1.4. Instability of M–CF3 species overcome by generation of 
–CF3 in situ. 
 
 Trifluoromethylsilanes are a widely used class of bench stable reagents that 
permit the controlled release of –CF3.
8 This family of compounds reacts with Lewis 
bases (most commonly F–) to generate silicates, which then expel –CF3 (Scheme 1.4B). 
Since decomposition of –CF3 hinders many reactions, the rate of release, and 
stabilization of this species is critical for promoting productive C–C bond forming 
processes. Variables that influence the rate –CF3 release for this reagent system 
include: steric bulk surrounding the Si atom (R3SiCF3: Me, Et, 
iPr), Lewis base of 
activator (MX: X– = F–, MeO–, tBuO–, etc.), solvent, and temperature. In addition, several 




Na+, K+, Cs+, nBu4
+, etc.), solvent, and temperature. –CF3 has been implicated as a 
discrete intermediate in nucleophilic trifluoromethylation reactions, and was 
spectroscopically observed at low temperatures {[K(18-crown-6)]+CF3
–; at –56 to –78 
°C}.7 
 C–C bond-forming, transition metal-free nucleophilic trifluoromethylation is 
generally limited to reactions with carbonyl-type and primary alkyl electrophiles.8 For 
example, trimethyl(trifluoromethyl)silane (TMSCF3, Ruppert-Prakash reagent) reacts via 
1,2-addition with aldehydes, ketones, Weinreb amides, imines, and oxocarbenium 
species (Scheme 1.5A).8 Although trifluoromethylation of carbonyl-type electrophiles is 
robust, reactions with alkyl electrophiles are limited in scope. For example, the 
trifluoromethylation of 1° alkyl iodides has been described;9 however, these reactions 
compete with elimination, and F– substitution pathways (Scheme 1.5B). In addition, 2° 
and 3° electrophiles do not form desired trifluoromethanes, and instead eliminate to 




Scheme 1.5. Trifluoromethylation is facile for carbonyl-type electrophiles, and difficult 
for aliphatic electrophiles. 
 
 Transition-metals, such as Pd, Ni, and Cu, enable nucleophilic 
trifluoromethylation reactions involving C-sp2 electrophiles.10 For Pd- and Ni-mediated 
trifluoromethylation is particularly challenging, due to a high barrier for reductive 
elimination from LnPd
II(Ar)(CF3) and LnNi
II(Ar)(CF3) complexes (Scheme 1.6A).
10 
Recently, the development of biarylphosphine ligands facilitated Pd-catalyzed 
trifluoromethylation of aryl chlorides.11 Specifically, the steric bulk of the ligand 
(BrettPhos) caused an elongation and weakening of the Pd–CF3 bond, and lowered the 
activation energy for reductive elimination (ca. 22 kcal/mol; Scheme 1.6A). In addition, 
the combination of triethyl(trifluoromethyl)silane and KF promoted the release of –CF3 at 
an appropriate rate (Scheme 1.6B). Despite considerable effort, the development of Ni-
catalyzed nucleophilic aromatic trifluoromethylation has not been realized, as reductive 
elimination is too difficult with all ligands studied to date.12 An alternative strategy to 
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enable reductive elimination from Pd and Ni centers involved MII/MIV mediated 
mechanisms (Scheme 1.6C).13 While these studies demonstrated the feasibility of high-
valent metal-mediated fluoroalkylation chemistry, they currently require stoichiometric 
metals, and have lower practical utility.  
Scheme 1.6. Ligands and high-valent reaction manifolds permit trifluoromethylation 




 Cu-promoted trifluoromethylation of aryl electrophiles is facile compared to the 
Pd- and Ni-promoted processes.10 The mechanism of Cu-catalyzed trifluoromethylation 
proceeds via a CuI/CuIII manifold (Scheme 1.7), in which oxidative addition is typically 
the rate determining step (ca. 18 kcal/mol for ArI), and reductive elimination is rapid (ca. 
9 kcal/mol).14 A major challenge in Cu-promoted trifluoromethylation involves generation 
and stabilization of “Cu–CF3” from practical and affordable precursors. Continual 
innovation in reagent strategies to form “Cu–CF3” have improved relative to the first Cu-
mediated trifluoromethylations of aryl electrophiles (1969),15 and eventually enabled Cu-
catalyzed trifluoromethylation (2009).16  
Scheme 1.7. Cu-promoted trifluoromethylation of aryl electrophiles. 
 
1.3. Formation, stability and reactivity of “Cu–CF3”. 
 The ideal trifluoromethylation reaction would use reagents that are inexpensive, 
easy to handle, and environmentally benign. In contrast, many modern strategies for 
trifluoromethylation require specialty chemicals that are expensive and generate excess 
waste (e.g. Togni’s or Umemoto’s reagents, Scheme 1.8A17). In order to enable 
inexpensive and green trifluoromethylation reactions, recent research has focused on 
using more economical and green reagents, such as TMSCF3 and halodifluoroacetates 
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(Scheme 1.8A). Historically, many of these reagents have been used in Cu-mediated 
trifluoromethylation, but modern methods have focused on developing analogous Cu-
catalyzed processes. 
Early strategies for generating “Cu–CF3” utilized difficult to handle and/or toxic 
reagents, and formed ill-defined solution-state complexes. “Cu–CF3” was first created 
through the reductive coupling of Cu0 and gaseous CF3I (Scheme 1.8B, eq 1).
15,18 An 
alternative approach involved transmetalation between Hg(CF3)2 and Cu
0 (eq 2).19 
While this strategy was appealing, since transmetalation can be a highly controlled 
process, the method was impractical, as dialkylmercury reagents are extremely toxic. 
Subsequent efforts to promote transmetallation from other M(CF3)n species proved 
successful, and permitted the spectroscopic detection of “Cu–CF3” for the first time.
20 
This strategy formed Cd(CF3)2 or Zn(CF3)2 from CF2X2 (X = Cl or Br) and M
0, and 
reacted the trifluoromethylmetal species with CuI (eq 3).20 A more appealing strategy 
involved decarboxylation of halodifluoroacetates, which are inexpensive, readily 
available, and easy to handle reagents (eq 4, vide infra).21 Another widely-used method 
of forming “Cu–CF3” has been the reaction of trialkyl(trimethyl)silanes, F
–, and CuI (eq 5, 
vide infra).22 Recently, some difficult transformations have been accomplished using 
Umemoto’s reagent with Cu0/I (eq 6).23 Finally, the use of K[Cu(OtBu)2] (generated from 
CuCl and KOtBu) permits the generation of “Cu–CF3” from precursors, such as 
fluoroform (eq 6),24 trifluoroacetophenone, (eq 8)25, and phenyltrifluoromethylsulfoxide 
(eq 9).26 The cupration of fluoroform was a notable advance, since this gas is an 




Scheme 1.8. Reagents and strategies for the synthesis of “Cu–CF3”. 
 
 “Cu–CF3” is a notoriously unstable and ill-defined mixture of solution state 
fluoroalkylmetal species. Initial 19F NMR analysis of “Cu–CF3” generated from M(CF3)2 
(M = Cd or Zn) and CuI (Scheme 1.8B, eq 3) revealed several fluorinated signals, which 
could be [LnCu–CF3] with different ligands (solvent or halides) or at different aggregation 
states.20 In addition, trifluoromethylcuprate [Cu(CF3)2
+] has been observed in equilibrium 
with trifluoromethylcopper(I).24a Unstabilized “Cu–CF3” fully decomposes within 11 h at 
room temperature to generate higher fluoroalkylcopper species [Cu–(CF2)(n)CF3].
20b 
While the precise mechanism of degradation is not well understood, two pathways have 
been proposed: 1) “Cu–CF3” releases free :CF2, which then inserts into a Cu–CF3 bond 
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to generate “Cu–CF2CF3”; or 2) “Cu–CF3” undergoes α-fluoride elimination to form 
Cu=CF2, and then reacts with another equivalent of “Cu–CF3” (Scheme 1.9A). Several 
factors could further destabilize “Cu–CF3”, including fluorophilic cations, anionic 
nucleophiles, and concentration (Scheme 1.9B).20b,24  




Two strategies have been used to stabilize “Cu–CF3” species: 1) acidification 
using NEt3 • 3HF; and 2) addition of ligands. The first strategy was important for 
stabilizing “Cu–CF3” generated from the cupration of fluoroform. In this process, KO
tBu 
destabilized “Cu–CF3” through fluorophilic cation interactions (shifted equilibrium from 
KOtBu and Cu–CF3
 to +Cu=CF2, MF, and 
–OtBu), and nucleophilic attack of –OtBu to 
produce Cu=C(OtBu)2 (Scheme 1.9B). The addition of NEt3 • 3HF generated 
tBuOH and 
precipitated KF, and formed a solution of “Cu–CF3” that was stable for >1 week 
(Scheme 1.9C).24a Another strategy for stabilizing “Cu–CF3” involved the addition of 
ligands to create well-defined LnCuCF3 species. The first successful example employed 
a NHC ligand, and generated a complex that was air-sensitive, but could be crystalized 
under inert conditions (Scheme 1.9C).27 Later, more stable complexes were synthesized 
using 1,10-phenanthroline28 and PPh3
29 as ligands (Scheme 19C). These bench stable 
reagents are commercially available, and useful for various trifluoromethylation 
reactions. 
Well-defined LnCu–CF3 complexes have been used to gather further data on the 
mechanism of trifluoromethylation reactions. For example, while cuprates are active 
alkylating reagents in non-fluorous copper chemistry,30 trifluoromethylcuprates [Cu–
(CF3)2] are not active species in nucleophilic trifluoromethylation reactions.
31 In solution, 
“Cu–CF3” and [Cu
+(CF3)2] form an equilibrium, which change based on solvent, 
concentration, ligand, and temperature. In PhMe, the trifluoromethylcuprate complex 
[Cu–(CF3)2][Cu
+(SIMes)2] was insoluble, and could be isolated as a well-defined solid 
complex (Scheme 1.10).31 When dissolved in Ph–I, this complex formed an equilibrium 
with [(SIMes)Cu–CF3]. The equilibrium shifted towards [(SIMes)Cu–CF3] at low 
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concentrations, and the rate of conversion of Ph–I to Ph–CF3 increased, which 
implicated [(SIMes)Cu–CF3], rather than [Cu
+(CF3)2] as the active species in 
trifluoromethylation (Scheme 1.10).31 
Scheme 1.10. Trifluoromethylcuprate is inactive in nucleophilic trifluoromethylation 
reactions. 
 
The majority of Cu-promoted nucleophilic trifluoromethylation reactions utilize 
stoichiometric Cu; however, the development of Cu-catalyzed reactions is desirable for 
economic and environmental reasons. Many methods that generate “Cu–CF3” are not 
suitable for catalytic trifluoromethylation reactions, since they require stoichiometric Cu 
(Scheme 1.8B; eq 1 and 6) or a preformed Cu-complex (e.g. K[Cu(OtBu)2]; Scheme 
1.8B; eq 7–9). Two reagent classes, trialkyl(trifluoromethyl)silanes and 
halodifluoroacetates, generate “Cu–CF3” under mild conditions, and have been 
successfully employed in catalytic trifluoromethylation reactions. For the catalytic 
trifluoromethylation of aryl iodides, the combination of TESCF3 and KF effectively 
promoted the gradual release –CF3 in situ, and form a (phen)Cu–CF3 complex (Scheme 
1.11B).16 In this reaction, the ligand selection played an important role, as other 
bidentate N-based ligands provided lower yields of product. The substrate scope for this 
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transformation was limited, and functional groups that react with free –CF3, such as 
acidic groups (deprotonation) and carbonyl groups (1,2-addition), would likely be 
incompatible with the reaction. 
Scheme 1.11. Strategy to create “Cu–CF3” in situ critical for Cu-catalyzed 
trifluoromethylation. 
 
1.4. Halodifluoroacetates as reagents for generation of “Cu–CF3”. 
Halodifluoroacetic acids are an attractive class of reagents that undergo 
decarboxylation to release reactive fluorinated species. While trifluoroacetic acid is the 
least expensive and most desirable reagent in this class, it decarboxylates slowly, and 
has an estimated half-life of 40,000 years at 15 °C in aqueous solution.32 
Trifluoroacetates are synthetically useful fluorinating reagents; however, 
decarboxylation typically requires stoichiometric Cu and reaction temperatures >150 
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°C.33 Other halodifluoroacetatic acids decarboxylate more rapidly (Scheme 1.12A); 
however, metal catalysts, other reagents, and/or high temperatures are required to 
facilitate synthetically useful transformations. 
The mechanism of Cu-promoted decarboxylation of halodifluoroacetates is not 
well understood; however, the process may involve :CF2 intermediates. In the absence 
of Cu, halodifluoroacetates decarboxylate at high temperatures to generate :CF2, which 
reacts with alkenes to form difluorocyclopropanes (Scheme 1.12B).34 For Cu-mediated 
decarboxylation, the following mechanism was proposed: 1) formation of a Cu(I)–
O2CCF2X complex; 2) decarboxylation to generate free :CF2; 3) combination of F
– and 
:CF3 to create 
–CF3; and 4) association of 
–CF3 and Cu to form “Cu–CF3” (Scheme 
1.xC).35 For this process, no evidence of –CF2X was observed; therefore, 
decarboxylation and C–X cleavage were thought to occur in a concerted step.34 Since 
the overall mechanism invoked two reactive fluorinated species, :CF2 and 
–CF3, many 
reactive functional groups could potentially be incompatible with the reaction. For 
example, free –CF3 could react via 1,2-addition with carbonyl groups, and deprotonate 




Scheme 1.12. Cu-promoted decarboxylation of halodifluoroacetates generates “Cu–
CF3”.  
 
 Recent studies support parts of the originally proposed mechanism, but provide 
evidence that reactive species generated from Cu-mediated decarboxylation of 
halodifluoroacetates remain bound to Cu, or do not exit the solvent sphere of Cu. The 
first step of the process likely involves generation of LnCu–O2CCF2X, since a well-
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defined (NHC)Cu–O2CCF2Cl complex was an active trifluoromethylation reagent 
(Scheme 1.12D).36 In addition, LCu=CF2 has been implicated as an intermediate in a 
formal [4 + 1] cycloaddition (Scheme 1.12D).37 Further, Cu-catalyzed decarboxylative 
trifluoromethylation reactions involving bromodifluoroacetates tolerate carbonyl and 
acidic functional groups (chapters 2-4). Taken together, this data suggested that 
decarboxylation is a Cu-centered event, and reactive fluorinated species remain in the 
solvent sphere of Cu. 
 Amongst the various halodifluoroacetate analogs, bromo- and chloro-
difluoroacetates are the most commonly used halodifluoroacetates, since they are 
inexpensive and reactive at low to moderate temperatures (50–120 °C). Traditionally, 
decarboxylative aromatic trifluoromethylation required stoichiometric CuI; however, 
limited examples exist that utilize catalytic Cu.38 For example, the Cu-catalyzed 
decarboxylative trifluoromethylation of an iodopyridine was explored during the process-
scale synthesis of an intermediate in a drug candidate.38a On a small to moderate scale, 
Cu-catalyzed trifluoromethylation was accomplished using MeO2CCF2Cl as a reagent, 
and 20% Cu(I) thiophenes-2-carboxylate with 20% 1,10-phenanthroline as a ligand 
(Scheme 1.13A). Unfortunately, when this Cu-catalyzed reaction was conducted on a 
multi-kilogram scale, the formation and separation of Ar(CF2)nCF3 side products proved 
problematic without chromatography. These byproducts resulted from insertion of :CF2 





Scheme 1.13. Undesired perfluoroalkylation competes with trifluoromethylation in Cu-
catalyzed process. 
 
 Trifluoroacetic acid (TFA) is the ideal trifluoromethylation reagent, since it is an 
incredibly inexpensive bulk chemical, and produces CO2 as the sole byproduct. While 
considerable effort has been invested in developing Cu-promoted trifluoromethylation 
reactions using TFA, Cu-catalyzed process have not been discovered, and Cu-
mediated methods require high temperatures (140–160 °C).36,39 Currently, the best 
reagent system involves heating (phen)Cu–O2CCF3 to 140 °C to facilitate 
trifluoromethylation of aryl bromides and iodides (Scheme 1.14).39  
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Scheme 1.14. LCu–O2CCF3 complexes facilitate trifluoromethylation at high 
temperatures. 
 
1.5. Strategies for converting alcohols to trifluoromethanes. 
Methods that convert alcohols to trifluoromethanes are important for medicinal 
chemistry and chemical biology, since alcohols are a common functional group, and 
trifluoromethanes can modulate the properties of drugs and probes. Alcohols are found 
in natural products, bioactive compounds, screening libraries, and can be synthesized 
from countless organic precursors using well-established chemistry.40 Given the ubiquity 
of alcohols in organic compounds, deoxytrifluoromethylation represents a useful 




Scheme 1.15. Strategies for converting alcohols to trifluoromethanes. 
 
Several strategies for converting alcohols to trifluoromethanes involve multi-step 
sequences that require expensive trifluoromethylation reagents and/or stoichiometric 
metals. The most common approach to deoxytrifluoromethylation involves the following 
four-step protocol: 1) alcohol oxidation to generate an aldehyde or ketone; 2) 1,2-
addition of a trifluoromethyl anion to furnish a 1-substituted-2,2,2-trifluoroethanol; 3) 
conversion of the alcohol to a halide or xanthate; and 4) reduction using Pd/C and H2, or 
Bu3SnH and AIBN (Scheme 1.15A).
41 While this strategy provides a reliable route to 
access trifluoromethanes, it has several undesirable features, including: 1) low yields 
resulting from exponential loss of material during the multi-step process; 2) expense of 
time and labor for each reaction; 3) generation of excess waste from reactions and 
purifications; 4) inefficient oxidation and reduction steps during a redox-neutral net 
transformation; 5) use of stoichiometric metals and/or toxic reagents for redox reactions. 
In contrast, an alternative approach involves converting activated alcohols (allylic, 
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benzylic, propargylic, and α-keto alcohols) into electrophiles (acetates, halides, 
mesylates, xanthates), which undergo trifluoromethylation when treated with 
stoichiometric “Cu–CF3” (Scheme 1.15B). While this strategy provides more 
straightforward access to trifluoromethanes, it has drawbacks, including: 1) use of 
stoichiometric metal, which is economically and environmentally undesirable; 2) limited 
substrate scope based on the electronic nature of the electrophile and functional group 
intolerance with sources of nucleophilic CF3 (vide supra). Recent developments have 
enabled the conversion of electrophiles to trifluoromethanes using catalytic Cu 
(chapters 2–4). 
1.6. Conclusions. 
 Nucleophilic trifluoromethylation is an effective strategy for the synthesis of 
trifluoromethanes. “Cu–CF3” enables trifluoromethylation of various C–sp
2 and C–sp3 
based electrophiles, and advances in the generation and stabilization of this 
organometallic species have created more practical and user-friendly 
trifluoromethylation methods. Halodifluoroacetates serve as attractive reagents for the 
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Chapter 2: Copper-Catalyzed Decarboxylative Trifluoromethylation of  
Allylic Bromodifluoroacetates 
2.1. Methods for the preparation of allylic trifluoromethanes. 
Allylic trifluoromethanes are versatile building blocks, and various strategies have 
emerged for accessing this fluorinated motif.1 Recently, several methods that converted 
alkenes and acids to allylic trifluoromethanes were reported, including: oxidative 
trifluoromethylation of terminal alkenes using TMSCF3 (Scheme 2.1, eq 1);
2 C–H 
activation or radical-mediated trifluoromethylation of terminal alkenes using Cu- or 
photoredox-catalysis and electrophilic trifluoromethylation reagents (eq 2–3);3,4 radical-
mediated trifluoromethylation of styrenes (eq 4);5 Cu-catalyzed trifluoromethylation of 
allylsilanes (eq 5);6 and Cu-catalyzed decarboxylative trifluoromethylation of β,γ-
unsaturated carboxylic acids (eq 6).7 These methods required the use of: 1) 
stoichiometric oxidants (eq 1), which limited functional group tolerance and increased 
waste; or 2) specialty trifluoromethylation reagents (eq 2–6), which increased costs of 
reactions (Togni’s and Umemoto’s reagents: $28,000–23,000/mol). In contrast, an 
alternative strategy for synthesizing allylic trifluoromethanes involved Cu-mediated 
trifluoromethylation of allylic electrophiles (eq 7).8 This approach was appealing, since 
allylic electrophiles are readily accessible from simple building blocks, such as allylic 
alcohols. However, previous methods required use of stoichiometric Cu and/or reagents 
that were toxic, expensive, and difficult to handle. Therefore, we sought to develop a 
green, inexpensive, and user-friendly protocol to convert allylic electrophiles to 




Scheme 2.1. Metal-based construction of allylic trifluoromethanes. 
 
The conversion of allylic electrophiles to trifluoromethanes using “Cu–CF3” is well 
established, and was first reported in 1979 by Kobayashi.8a Early iterations of this 
strategy generated solutions of unstabilized “Cu–CF3” from various fluorinated reagents 
[CF3I, CF2X2, Hg(CF3)2], and then added allylic electrophile to the reaction (Scheme 
2.2A).8a,9,10 These reagents were toxic and/or difficult to handle; therefore, subsequent 
research aimed at developing more efficient and operationally simple methods for 
generating “Cu–CF3”. One improved method involved mixing the Ruppert-Prakash 
reagent (TMSCF3), KF, and CuI to generate “Cu–CF3”, and then adding allylic halides to 
affect trifluoromethylation (Scheme 2.2A).8g  
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The discovery of solid, isolatable, bench-stable, and well-defined “LnCF–CF3” 
complexes improved trifluoromethylation technology.11 Previous methods required 
generation of “Cu–CF3” in the absence of electrophile, and the immediate use of this 
species, since unstabilized “Cu–CF3” degraded within 11 h at 25 °C.
10 Ligand stabilized 
complexes, such as Grushin’s reagent [(PPh3)3Cu–CF3],
11b were air-stable solids that 
reacted with linear and branched allylic electrophiles to furnish linear allylic 
trifluoromethanes (Scheme 2.2B).8f Since linear product arose from both linear and 
branched substrates, a mechanism similar to other Cu-mediated allylic substitution 
reactions12 was proposed: 1) oxidative addition of CuI–CF3 to an allylic electrophile, 
generating a π-allyl intermediate; 2) reductive elimination to form the thermodynamically 
stable linear allylic trifluoromethane [Scheme 2.2E (OA and RE steps)].8f 
 An additional advance in allylic trifluoromethylation involved in situ formation and 
reaction of “Cu–CF3
” with allylic electrophiles. This was realized by decarboxylation of 
halodifluoroacetates in the presence of KF and CuI to generate “Cu–CF3”, which then 
reacted with allylic electrophiles (Scheme 2.2C).8c While this strategy did not require use 
of highly reactive metals or metal-complexes, it was proposed to generate reactive 
fluorinated species, including free trifluoromethyl anion (–CF3) and difluorocarbene 
[:CF2; (Scheme 2.3)]. Therefore, only simple substrates were compatible with this 
protocol. We noted that this strategy theoretically turned over CuI; therefore, we 
reasoned that a catalytic protocol could be realized. In addition, we hypothesized that 
decarboxylative generation of “Cu–CF3” might occur via an inner-sphere process, 
meaning that the reactive fluorinated species would not be free in solution, and the 
protocol would tolerate sensitive functional groups. Prior to publishing our results, an 
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alternative method for Cu-catalyzed allylic trifluoromethylation was reported that used 
TMSCF3 as a source of nucleophilic CF3 (Scheme 2.2D). This report demonstrated a 
limited substrate scope, likely because TMSCF3 and KF generated free 
–CF3, which 
would have destroyed carbonyl- and acidic-functional groups.   




2.2. Conversion of allylic alcohols to trifluoromethanes via Cu-catalyzed decarboxylative 
trifluoromethylation. 
With the goal of converting allylic alcohols to trifluoromethanes, we envisioned an 
attractive approach might involve the conversion of an alcohol to a halodifluoroacetic 
ester, followed by a catalytic decarboxylative trifluoromethylation (Scheme 2.2D). 
Although trifluoromethylation reactions of halodifluoroacetic esters have been 
conducted using stoichiometric CuI,8c–e, 13a–b catalytic reactions have proven elusive over 
many years. In this project, we developed Cu-catalyzed decarboxylative 
trifluoromethylation of allyl bromodifluoroacetates, and distinguished this reaction from 




Initially, we compared the (dis)advantages of using different allylic 
halodifluoroacetates as substrates for decarboxylative trifluoromethylation. We 
discarded trifluoroacetates, since decarboxyation occurs at high temperatures (>140 
°C), and iododifluoroacetates, since they are expensive and sensitive to light. Therefore, 
we evaluated allylic chloro- and bromo-difluoroacetates as inexpensive and moderately 
reactive substrates. During the initial phase of the project, we selected allylic bromo- 
over chloro-difluoroacetates, since bromodifluoroacetates provided higher yields at 
lower temperatures (50 vs 70 °C). Next, we confirmed that allylic bromodifluoroacetates 
are easily accessed via coupling of inexpenive and readily available bromdifluoroacetic 
acid and allylic alcohols (Scheme 2.4). A convenient esterification procedure involved 
activating bromodifluoroacetic acid with oxalyl chloride to generate bromodifluoroacetyl 
chloride, and then addition of allylic alcohol to provide desired product. This operation 
was conducted on a range of allylic alcohols, and generated product esters in moderate 
to good yields (57–93%). Some allylic bromodifluoroacetates were unstable to column 
chromatography, which excluded select substrates from this strategy (vide infra). 
Scheme 2.4. Conversion of allylic alcohols to allylic trifluoromethanes. 
 
A broad screen of catalysts and conditions revealed the optimal conditions for 
Cu-catalyzed allylic trifluoromethylation (Scheme 2.5A). The Cu source was an 
important factor, and CuI salts provided much higher catalyst turnover than CuII and Cu0, 
which supported the proposed CuI/III mechanistic manifold (Scheme 2.5B). Several CuIX 
salts performed similarly (X = I, Br, Cl, thiophene-2-carboxylate, etc.), and CuI was 
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selected, since it is inexpensive, commonly available, and a free-flowing powder. High 
yields were obtained using 10% CuI, and decreasing catalyst loading depressed yields. 
Next, we evaluated F– sources, and determined that KF provided higher yields than CsF 
and NaF. KF is a hygroscopic solid, and since water harmed the reaction, we found that 
using anhydrous KF (flame-dried under vacuum) increased yields. The solvent choice 
and concentration had dramatic effects, and [1 M] DMF provided optimal yields. Polar 
aprotic solvents were required to enable decarboxyation at moderate temperature (50 
°C), and low conversion of substrate was observed in less polar solvents (1,4-dioxane, 
PhMe, etc.). The reaction required concentrated conditions, and diluting the mixture 
resulted in decreased yields. Finally, most cinnamyl-derived substrates fully reacted 
within 8 h at 50 °C, but less electronically activated substrates required reaction times 
up 18 h. 
Bromodifluoroacetate additives were screened to enable catalyst activation and 
overcome “Cu–CF3” decomposition. When optimizing the reaction, substrate 
decomposition without productive product formation was observed at the early stages of 
the reaction. In the absence of additive, we considered the steps required to convert the 
CuI precatalyst into active “LnCu–CF3”: 1) decomposition of cinnamyl 
bromodifluoroacetate to release –O2CCF2Br; 2) Cu ligand exchange to form “LnCu–
O2CCF2Br”; and 3) decarboxylation and addition of F
– to generate “LnCu–CF3” (Scheme 
2.5B). We hypothesized that efficient generation of “LnCu–CF3” was critical for 
preventing substrate decomposition, so we investigated several additives and protocol 
to the facilitate conversion of CuI precatalyst into its active state. In practice, we found 
that heating NaO2CCF2Br, CuI, ligand, and KF in DMF for 10 min prior to the addition of 
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substrate enabled catalyst activation, and prevented unnecessary decomposition of 
substrate. We also noted that if “LnCu–CF3” decomposed and exited the catalytic cycle, 
NaO2CCF2Br could enable the reentry of Cu into the cycle (Scheme 2.5B). 
 





Scheme 2.6. DMEDA outperformed other ligands. 
 
Ligands increase the stability, and alter the reactivity of “Cu–CF3” species, and 
we screen various N-, O-, and P-based ligands, in order to improve our allylic 
trifluoromethylation reactions (Scheme 2.6). We hypothesized that ligands could serve 
three roles in the present reaction: 1) facilitate the formation of “LnCu–CF3”, and improve 
the early phase of the reaction; 2) increase the reactivity of “LnCu–CF3” towards allylic 
electrophiles; and/or 3) increase the stability of “LnCu–CF3”, and disfavor catalyst 
decomposition. In order to determine whether ligands assisted with catalyst activation 
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and reactivity at early time points, we evaluated the impact of ligands on the first 1.5 h 
of the reaction by comparing % conversion to % yield. During initial reaction 
optimization, we observed low yield/conversion ratios due to non-productive substrate 
decomposition; however, the addition of several ligands improved yield/conversion 
(>80%) after 1.5 h (Scheme 2.6). We discovered that many N- and O-based bidentate 
ligands positively impacted the reaction, but P-based ligands suppressed product 
formation. Ethylenediamines were an effective class of ligands, and the alkylation state 
of the amines significantly impacted ligand performance. N,N’-dimethylethylenediamine 
(DMEDA) was better than ethylenediamine (EDA) and N,N,N’,N’-
tetramethylethylenediamine (TMEDA). This data suggested that unhindered amines 
could undergo side-reactions with the substrate, while bulky amines did not effectively 
ligate Cu. The best ligands at the 1.5 h time point were reevaluated at an 8 h time point 
in order to determine their overall impact on the reaction (Scheme 2.6). While several 
bidentate ligands improved yields, DMEDA was selected, based on its performance and 
common availabilty in synthetic chemistry laboratories.14  
A series of control reactions highlighted three parameters that were most critical 
for obtaining high product yields: reaction concentration, ligand, and activation of the 
catalyst (Scheme 2.7). Compared with the optimized reaction conditions (entry 1), 
reactions run at lower concentration (entry 2), or without employing the activation 
procedure (entry 3) provided less efficient catalyst systems based on yield/conversion 
ratios. Employing the activation procedure, the use of CuI/DMEDA provided a less-
active catalyst than that derived from CuI alone at the 1.5 h time point (entries 1, 4); 
however, when the reactions proceed to full conversion, a higher yield of product was 
39 
 
reproducibly obtained using CuI/DMEDA (entries 5–6). Thus, DMEDA could serve to 
stabilize the active catalyst against decomposition near the end of the reaction. 
Scheme 2.7. Sensitivity of Cu-Catalyzed Trifluoromethyation to Concentration, Ligand, 
and Activation of Catalysta 
 
a Reactions were performed with 0.20 mmol 2.1a, 0.050 mmol NaO2CCF2Br, 0.40 mmol 
KF in 0.20 mL DMF at 50 °C for 1.5 h. b Conversion and yield data were determined by 
GC/FID analysis using dodecane as an internal standard. Each data point represents an 
average of 2–4 experiments. c The reactions were run for 8 h instead of 1.5 h. 
A variety of 2-, 3- and 4-substituted cinnamyl bromodifluoroacetates (2.1b–k) 
were compatible with the present reaction (Scheme 2.8). Electron-deficient (2.2b–e) 
and electron-neutral cinnamyl systems (2.2g–h) reacted in good yields, although an 
electron rich substrate provided the product in slightly lower yield (2.2i). In general, 
substrates capable of affording resonance stabilized allyl cations (e.g., 4-NMe2) were 
unstable to both acidic and basic conditions, which limited purification and storage of 
this class of substrates. Aryl (pseudo)halides were well tolerated, and did not undergo 
aromatic trifluoromethylation (2.2b–c, f–g). In addition, compounds bearing 
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heterocycles were tolerated (2.2j–k). Finally, on an 8 mmol scale, over 1.9 g of 2.2b 
was obtained in high yield, which suggests that the present reaction could be amenable 
to larger scale processes. 
Scheme 2.8. Substituted Cinnamyl Bromodifluoroacetates Undergo Decarboxylative 
Trifluoromethylation.a,b 
 
a Reactions were performed with 0.20 mmol 2.1, 0.020 mmol CuI, 0.020 mmol DMEDA, 
0.050 mmol NaO2CCF2Br, 0.40 mmol KF in 0.20 mL DMF at 50 °C for 8 h following 10 
min activation. b Isolated yield. c Reaction conducted on an 8 mmol scale. 
Disubstituted and non-conjugated allylic esters (2.3) containing a diverse array of 
functional groups provided moderate to good yields of E alkene products (2.4, Scheme 
2.9). Substituents at the α and β positions of the styrene were tolerated (2.4a–c), and 
non-conjugated allylic systems displayed good reactivity (2.4d–g). Several aliphatic 
functional groups were compatible with the reaction, including esters, imides, and 
41 
 
benzyl ethers (2.4e–g). Substrates that existed as mixtures of gemetrical isomers 
(2.3e–f, E/Z ca. 4:1) converted to thermodynamically-favored E-allyl trifluoromethane 
products (2.4e–f) in excellent selectivities (E/Z > 19:1). Further, the reaction of a pure Z-
alkene substrate afforded the E product in excellent diastereoselectivity (2.4g). When 
monitoring the reaction by both GC/FID and 19F NMR, slow isomerization of the 
substrate was observed, while the E-product was formed in greater than 15:1 dr 
throughout the course of the reaction. In control reactions, the Z-substrate was stable 
when treated with KF in DMF at 50 °C. These data could implicate the existence of a π-
allyl intermediate that reacts to generate the more stable E-product (Scheme 2.5B).8b 





Scheme 2.9. Disubstituted and Non-Conjugated Allylic Bromodifluoroacetates Undergo 
Decarboxylative Trifluoromethylation.a 
 
a Reactions were performed with 0.20 mmol 2.3, 0.020 mmol CuI, 0.020 mmol DMEDA, 
0.050 mmol NaO2CCF2Br, 0.40 mmol KF in 0.20 mL DMF at 50 °C for 8 h following 10 
min activation. b Determined by 1H NMR. c Determined by 19F NMR. d Isolated yield, 
number in parentheses indicates 19F NMR yield using α,α,α-trifluorotoluene as an 
internal standard. e 18 h. 
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 Several substrates were not compatible with the present strategy, including 
electron-rich cinnamyl substrates (e.g. 4-NMe2), compounds containing basic 
heterocycles, substrates bearing active leaving groups, and 2° allylic 
bromodifluoroacetates (Scheme 2.10). Electron-rich allylic bromodifluoroacetates that 
form highly stabilized π-allyl cations decomposed on silica gel, presumably via a SN1 
mechanism of hydrolysis. In addition, bromodifluoroacetic esters are highly sensitive to 
base-mediated hydrolysis, and substrates that contained basic functional groups (e.g. 
pyridine) in the presence of silica. In the case of a substrate containing a 1° aliphatic 
chloride, a portion of the material underwent a SN2 reaction with free Br
– (released after 
decarboxylation of –O2CCF2Br) and generated 1° aliphatic bromide-containg product. In 
addition, 2° allylic substrates demonstrated poor reactivity under the reaction conditions, 





Scheme 2.10. Classes of substrates incompatible with current trifluoromethylation 
strategy. 
 
2.3. Mechanistic consideration for Cu-catalyzed decarboxylative trifluoromethylation of 
allylic bromodifluoroacetates. 
Using the Cu/DMEDA-based catalyst system, bromodifluoroacetic esters 
provided unique reactivity (Scheme 2.11). A trend of increasing reactivity was observed 
for cinnamyl trifluoroacetate < chlorodifluoroacetate < bromodifluoroacetate (entries 1–
3);15 however, the reaction of cinnamyl difluoroiodoacetate provided a low yield of 
product (entry 4). We hypothesized that I–, generated as a byproduct of the reaction, 
inhibited catalysis. In support of this theory, the addition of exogenous KI to the reaction 
of cinnamyl bromodifluoroacetate decreased the yield of product (entry 5). Combined, 
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these two findings suggest that I– does not participate in the catalytic reaction. In fact, 
the Cu-catalyzed reaction could be conducted in the complete absence of I– (entry 6), a 
key feature that distinguishes the present Cu-catalyzed reaction from previously 
reported Cu-mediated reactions.16  
Scheme 2.11. Unique Reactivity of Allyl Bromodifluoroacetates.a 
 
a Reactions were performed with 0.20 mmol substrate, 0.050 mmol NaO2CCF2Br, 0.40 
mmol KF in 0.20 mL DMF at 50 °C for 1.5 h. b Conversion and yield data were 
determined by GC/FID analysis using dodecane as an internal standard. 
Although thorough mechanistic studies have not been conducted, the present 
Cu-catalyzed reaction likely involves a mechanism distinct from CuI-mediated reactions 
of allyl halodifluoroacetates. For the Cu-catalyzed reaction, the activation procedure 
presumably converts the precatalytic combination of CuI/DMEDA/NaO2CCF2Br/KF into 
the active catalyst, LnCu–CF3 (Scheme 2.12A). LnCu–CF3 can then promote direct 
trifluoromethylation of the substrate without participation of I–. The substitution reaction 
potentially involves a π-allyl intermediate, which has been proposed in other allylic 
substitution reactions using LnCu–CF3 in both stoichiometric
8b and catalytic17 systems. 
In contrast, the Cu-mediated reaction invokes I– as a key feature of the mechanism 
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(Scheme 2.12B).16 In this case, I– participated by converting the bromodifluoroacetic 
ester to an allyl iodide, which then reacted with Cu–CF3.  
Scheme 2.11. Proposed Catalytic Cycle Involving a Reactive Cu–CF3 Species. 
 
2.4. Conclusions. 
In conclusion, a catalytic method for the conversion of allylic alcohols to 
trifluoromethanes via bromodifluoroacetic esters has been developed. Conjugated and 
non-conjugated substrates bearing a variety of functional groups afford α-substituted 
trifluoromethylated products in moderate to good yield and excellent diastereoselectivity 
for the E-stereoisomer. Beneficial aspects of this transformation include: the 1) 
employment of a mild, inexpensive and atom-economical source of CF3 in near-
stoichiometric quantity; 2) development of a shortened strategy for converting readily 
available allylic alcohols into trifluoromethyl analogs; 3) ability to conduct 
trifluoromethylation reactions using only a catalytic quantity of metal. Finally, 
functionalization of the allyl trifluoromethane-based product should be useful for 
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All reactions were performed under an atmosphere of dry N2 using oven-dried 
glassware. Decarboxylative trifluoromethylation reactions were performed in resealable 
15 mL test tubes with PTFE septa. Copper (I) Iodide (98%) and N,N’-
dimethylethylenediamine (DMEDA, 95%) were purchased from commercial sources and 
used without purification. Potassium fluoride was dried in a vacuum oven (180 °C) for a 
minimum of 24 h prior to use. Anhydrous DMF was purchased from commercial sources 
in a sure-seal bottle. All other reagents were purchased from commercial sources and 
used without further purification. All other solvents were used directly from a solvent 
purification system in which solvent was dried by passage through two columns of 
activated alumina under argon. The solvents were transferred via syringe from the 
solvent purification system to the reaction vessel. Reactions were monitored by thin-
layer chromatography (TLC) on UNIPLATE Silica Gel HLF plates, visualizing with 
fluorescence quenching or p-anisaldehyde solution. Flash column chromatography was 
performed using a CombiFlash® RF–4x purification system. Silica gel was purchased 
from Sorbent Technologies (cat. # 30930M-25, 60 Å, 40–63 μm).  
Unless otherwise noted, yields reported are of the isolated material. Gas 
Chromatography (GC) yields in Table 1 were obtained via analysis using an Agilent 
Technologies 7890A GC system with a FID detector and an Agilent Technologies 30 m 
x 0.320 mm i.d. HP–5 capillary column using dodecane as an internal standard.  
Compounds described in the literature were characterized by comparing their 1H NMR 
and 13C NMR spectra, and melting points (m.p.) to the previously reported data. 
Previously unknown compounds were characterized by 1H NMR, 13C NMR, m.p., 
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infrared (IR) spectroscopy, and high-resolution mass spectrometry (HRMS). 1H NMR 
and 13C NMR spectra were recorded on Bruker 400 AVANCE spectrometer (400 and 
100 respectively) or Bruker 500 AVANCE spectrometer (500 and 125 MHz, 
respectively). 19F NMR spectra were recorded on a Bruker 400 AVANCE spectrometer 
(376 MHz). Chemical shifts (δ) for protons are reported in parts per million downfield 
from tetramethylsilane and are referenced to proton resonance of residual CHCl3 in the 
NMR solvent (CHCl3 = 7.27 ppm). Chemical shifts (δ) for carbon are reported in parts 
per million downfield from tetramethylsilane, and are referenced to the carbon 
resonances of the solvent residual peak (CDCl3 = 77.16 ppm). Chemical shifts (δ) for 
fluorine are reported in parts per millions, and are referenced to α,α,α-trifluorotoluene (δ 
= –63.72 ppm) or fluorobenzene (δ = –113.15 ppm). High-resolution mass data were 
recorded on a high-resolution mass spectrometer in the ESI mode. Infrared spectra 
were obtained using a Shimadzu FTIR-8400S Fourier Transform Infrared Spectrometer. 
Melting points (uncorrected) were measured on a Thomas Hoover Capillary Melting 
Point apparatus. 
 
Experimental procedure for the reactions described in Schemes 2.5–7 and 2.11: 
 
Cinnamyl 2,2,2-trifluoroacetate1 
A 50 mL round bottom flask was oven dried and cooled under N2. Cinnamyl alcohol 
(268 mg, 2.00 mmol) was added, then the system was evacuated and backfilled with N2 
three times. DCM (0.010 L) and NEt3 (0.56 mL, 4.0 mmol) were added and the solution 
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was cooled to 0 °C. Trifluoroacetic anhydride (0.36 mL, 2.6 mmol) was injected 
dropwise, then the reaction was warmed to 21 °C and stirred for 2 h. The mixture was 
poured over 1 N HCl (10 mL), washed with water (2 x 10 mL) and then brine (10 mL). 
The organic phase was dried over MgSO4, filtered, and the solvent was removed in 
vacuo. Chromatographic purification (hexanes / EtOAc 1:0 → 50:1) afforded the title 
compound as a colorless oil (366 mg, 80%).  
1H NMR (500 MHz, CDCl3): δ 7.46–7.40 (m, 2 H), 7.39–7.29 (m, 3 H), 6.78 (d, J = 15.8 
Hz, 1 H), 6.31 (dt, J = 15.8, 6.8 Hz, 1 H), 5.00 (d, J = 6.9 Hz, 2 H).  




Cinnamyl alcohol (2.6 mL, 0.020 mol) was added to an oven-dried 100 mL round-
bottom flask. The system was evacuated and backfilled with N2 three times. DMF (0.040 
L) and NEt3 (2.8 mL, 0.020 mol) were injected into the flask, and then 
chlorodifluoroacetic anhydride (3.5 mL, 0.020 mol) was added dropwise. The mixture 
was stirred for 3 h, then the reaction was diluted with Et2O (50 mL). The solution was 
washed with NaHCO3 (aq) (4 x 50 mL). The organic layer solution was dried over MgSO4, 
filtered, and the solvent was removed in vacuo. Chromatographic purification (hexanes : 
EtOAc 1:0 → 4:1) afforded the title compound as a colorless oil (3.6 g, 73%).  
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1H NMR (500 MHz, CDCl3): δ 7.47–7.40 (m, 2 H), 7.39–7.34 (m, 2 H), 7.34–7.29 (m, 1 
H), 6.78 (d, J = 15.8 Hz, 1 H), 6.32 (dt, J = 15.9, 6.7 Hz, 1 H), 5.00 (dd, J = 6.7, 1.3 Hz, 
2 H).  




A one-neck round-bottom flask (flask 1) and a two-neck round-bottom flask (flask 2) 
were oven-dried and cooled under N2. Bromodifluoroacetic acid (3.41 g, 19.5 mmol) 
was added to flask 1 and the system was attached to a bubbler. DCM (0.020 L) was 
added as solvent, then DMF (0.35 mL, 4.5 mmol) was injected. Oxalyl chloride (1.52 
mL, 18.0 mmol) was added dropwise such that steady evolution of gas was maintained 
(2 h). The solution was stirred at 21 °C until the evolution of gas ceased. Cinnamyl 
alcohol (2.01 g, 15.0 mmol) was added to flask 2 and the system was attached to a 
bubbler via a glass adaptor (small-gauge needles clog during acid chloride transfer). 
DCM (0.030 L) and NEt3 (4.18 mL, 30.0 mmol) were added and the solution was cooled 
to 0 °C. The contents of flask 1 were transferred to flask 2 via cannula. Stirring was 
continued for 30 min at 0 °C, then the mixture was poured over 1 N HCl (50 mL). The 
phases were separated, then the organic layer was washed with H2O (50 mL) and brine 
(50 mL). The solution was dried over MgSO4, filtered, and the solvent was removed in 
vacuo. Chromatographic purification (hexanes / EtOAc 49:1) afforded the title 
compound as a faint yellow oil (3.47 g, 79%).  
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1H NMR (400 MHz, CDCl3): δ 7.46–7.40 (m, 2 H), 7.40–7.29 (m, 3 H), 6.79 (dt, J = 15.8, 




A one-neck round-bottom flask (flask 1) and a two-neck round-bottom flask (flask 2) 
were oven-dried and cooled under N2. Iododifluoroacetic acid (466 mg, 2.10 mmol) was 
added to flask 1 and the system was attached to a bubbler. DCM (5.0 mL) was added 
as solvent, then DMF (35 μL, 0.45 mmol) was injected. Oxalyl chloride (0.17 mL, 2.0 
mmol) was added dropwise such that steady evolution of gas was maintained (0.5 h). 
The solution was stirred at 21 °C until the evolution of gas ceased. Cinnamyl alcohol 
(201 mg, 1.50 mmol) was added to flask 2 and the system was attached to a bubbler. 
DCM (5.0 mL) and NEt3 (0.42 mL, 3.0 mmol) were added and the solution was cooled 
to 0 °C. The contents of flask 1 were transferred to flask 2 via cannula. Stirring was 
continued for 30 min at 0 °C, then the mixture was poured over 1 N HCl (10 mL). The 
phases were separated, then the organic layer was washed with H2O (10 mL) and brine 
(10 mL). The solution was dried over MgSO4, filtered, and the solvent was removed in 
vacuo. Chromatographic purification (hexanes / EtOAc 49:1) afforded the title 
compound as a colorless oil (438 mg, 86%).  
1H NMR (500 MHz, CDCl3): δ 7.48–7.42 (m, 2 H), 7.41–7.35 (m, 2 H), 7.35–7.30 (m, 1 
H), 6.81 (d, J = 15.8 Hz, 1 H), 6.33 (dt, J = 15.9, 6.7 Hz, 1 H), 5.01 (dd, J = 6.7, 1.2 Hz, 
2 H).  
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13C{1H} NMR (126 MHz, CDCl3): δ 160.3 (t, J = 28.3 Hz), 136.9, 135.7, 128.9, 128.8, 
127.0, 120.4, 86.6 (t, J = 321.9 Hz), 68.7.  
19F NMR (376 MHz, CDCl3): δ –58.34 (s, 2 F). 
IR (film): 3032, 1765, 1647, 1495, 1448, 1381, 1283, 1148, 1119, 928, 744, 690 cm–1.  




Screening Reactions Using Activation Procedure (Scheme 2.5–7 and 2.10): 
Potassium fluoride (23 mg, 0.40 mmol) was added to a 15 mL screw-top vial. The vial 
was placed in a vacuum oven (180 °C) and dried for a minimum of 24 h. The vial was 
removed from the vacuum oven, capped, and cooled under N2. CuI (3.8 mg, 0.020 
mmol) and sodium bromodifluoroacetate (9.8 mg, 0.050 mmol) were added. The vial 
was evacuated and backfilled with N2 three times. DMEDA (2.2 μL, 0.020 mmol), and 
DMF (0.20 mL) were sequentially injected. The mixture was stirred 10 min at 21 °C 
resulting in a blue/purple mixture. The vial was placed in a 50 °C heating block and 
stirred for 10 min. During this time, the color changed to light yellow and bubbling was 
observed. Cinnamyl halodifluoroacetate (0.200 mmol) was injected and the reaction 
was heated at 50 °C for 1.5 or 8 h. The vial was allowed to cool to 21 °C, and the 
mixture was diluted with EtOAc (3 mL). Dodecane (45.4 μL, 0.200 mmol) was injected 
as a standard, and the solution was stirred to ensure thorough mixing. A small aliquot 
was removed from the vial, placed on a plug of silica gel and eluted with EtOAc (1 mL). 
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The sample was analyzed using GC/FID, and the quantity of substrate and product 
were determined using dodecane as a standard. 
 
Screening Reactions Without Activation Procedure (Scheme 2.7): Potassium 
fluoride (23 mg, 0.40 mmol) was added to a 15 mL screw-top vial. The vial was placed 
in a vacuum oven (180 °C) and dried for a minimum of 24 h. The vial was removed from 
the vacuum oven, capped, and cooled under N2. CuI (3.8 mg, 0.020 mmol) was added, 
then the vial was evacuated and backfilled with N2 three times. DMEDA (2.2 μL, 0.020 
mmol), DMF (0.20 mL), and 1A (58 mg, 0.20 mmol) were sequentially injected. The vial 
was placed in a 50 °C heating block and stirred for 1.5 or 8 h. The vial was allowed to 
cool to 21 °C, and the mixture was diluted with EtOAc (3 mL). Dodecane (45.4 μL, 0.200 
mmol) was injected as a standard, and the solution was stirred to ensure thorough 
mixing. A small aliquot was removed from the vial, placed on a plug of silica gel and 
eluted with EtOAc (1 mL). The sample was analyzed using GC/FID, and the quantity of 
substrate and product were determined using dodecane as a standard. 
 
Experimental procedure for compounds in Scheme 2.8: 
General Procedure A: A round bottom flask and reflux condenser were oven-dried and 
cooled under N2. The acrylic acid derivative (0.010 mol) and anhydrous MeOH (0.050 L) 
were added followed by drop-wise addition of concentrated sulfuric acid (11 mmol). The 
system was placed under a balloon of argon and refluxed overnight. The reaction 
mixture was allowed to cool to room temperature and the solvent was removed in 
vacuo. EtOAc (50 mL) and H2O (20 mL) were added and the phases were separated. 
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The aqueous layer was extracted with EtOAc (2 x 20 mL) then the combined organic 
layers were washed with H2O (20 mL), Na2CO3 (aq) (20 mL), and brine (20 mL). The 
solution was dried over MgSO4, filtered, and the solvent was removed in vacuo to afford 
the desired methyl acrylate.  
 
General Procedure B: A two-neck round-bottom flask and liquid addition funnel were 
oven-dried and cooled under N2. α,β-Unsaturated ester (0.010 mol) was added, then the 
system was evacuated and backfilled with N2 three times. DCM (0.10 L) was added as 
solvent, then the solution was cooled to –78 °C. DIBAL (1.0 M in PhMe, 21 mL, 21 
mmol) was added dropwise over a 60 min period. The solution was warmed to 0 °C 
over a 30 min period, then MeOH (5 mL) was added to quench the reaction. The 
mixture was warmed to 21 °C and stirring continued for 30 min. Rochelle’s salt (aq) (75 
mL) was added to the cloudy mixture and the reaction was vigorously stirred for 12 h. 
The phases were separated and the aqueous phase was extracted with DCM (2 x 75 
mL). The combined organic phases were washed with Na2SO4 (aq) (100 mL) and brine 
(100 mL). The solution was dried over MgSO4, filtered, and the solvent was removed in 
vacuo. Filtration through a pad of silica (Et2O) and removal of solvent afforded the 
desired allylic alcohol. 
 
General Procedure C: A one-neck round-bottom flask (flask 1) and a two-neck round-
bottom flask (flask 2) were oven-dried and cooled under N2. Bromodifluoroacetic acid 
(1.4 mmol) was added to flask 1 and the system was attached to a bubbler. DCM (5 mL) 
was added as solvent, then DMF (0.30 mmol) was injected. Oxalyl chloride (1.3 mmol) 
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was added dropwise such that steady evolution of gas was maintained (0.5–2 h). The 
solution was stirred at 21 °C until the evolution of gas ceased. Allylic alcohol (1.0 mmol) 
was added to flask 2 and the system was attached to a bubbler via a glass adaptor 
(small-gauge needles clog during acid chloride transfer). DCM (5 mL) and NEt3 (2.0 
mmol) were added and the solution was cooled to 0 °C. The contents of flask 1 were 
transferred to flask 2 via cannula. Stirring was continued for 30 min at 0 °C, then the 
mixture was poured over 1 N HCl (10 mL). The phases were separated, then the 
organic layer was washed with H2O (10 mL) and brine (10 mL). The solution was dried 
over MgSO4, filtered, and the solvent was removed in vacuo. Chromatographic 
purification (minimal amount of silica) afforded the desired allylic bromodifluoroacetate.  
 
General Procedure D: Potassium fluoride (23 mg, 0.40 mmol) was added to a 15 mL 
screw-top vial. The vial was placed in a vacuum oven (180 °C) and dried for a minimum 
of 24 h. The vial was removed from the vacuum oven, capped, and cooled under N2. 
CuI (3.8 mg, 0.020 mmol) and sodium bromodifluoroacetate (9.8 mg, 0.050 mmol) were 
added. The vial was evacuated and backfilled with N2 three times. DMEDA (2.2 μL, 
0.020 mmol), and DMF (0.20 mL) were sequentially injected. The mixture was stirred 10 
min at 21 °C resulting in a blue/purple mixture. The vial was placed in a 50 °C heating 
block and stirred for 10 min. During this time, the color changed to light yellow and 
bubbling was observed. Allylic bromodifluoroacetate (0.200 mmol) was injected and the 
reaction was heated at 50 °C for 8 or 18 h. The vial was allowed to cool to 21 °C, and 
the mixture was diluted with EtOAc (3 mL). α,α,α-Trifluorotoluene (24.6 μL, 0.200 mmol) 
was injected as a standard, and an aliquot was removed for 19F NMR analysis. After 
62 
 
determination of the 19F yield, the aliquot was recombined with the reaction mixture. The 
mixture was further diluted with EtOAc (15 mL) and then washed with H2O (15 mL) and 
brine (15 mL). The solution was dried over MgSO4, filtered, and the solvent was 
removed in vacuo. Chromatographic purification and removal of solvent (care was taken 
with lower MW compounds) afforded the desired allylic trifluoromethane. 
 
General Procedure E: Potassium fluoride (16 mmol) was added to a 50 mL round-
bottom flask. The flask was placed in a vacuum oven (180 °C) and dried for a minimum 
of 24 h. The flask was removed from the vacuum oven, equipped with a flushing 
adapter, and cooled under N2. CuI (0.80 mmol) and sodium bromodifluoroacetate (2.0 
mmol) were added. The flask was evacuated and backfilled with N2 three times. 
DMEDA (0.80 mmol), and DMF (8.0 mL) were injected. The mixture was stirred 10 min 
at 21 °C resulting in a blue/purple mixture. The flask was placed in a 50 °C oil bath and 
stirred for 10 min. During this time, the color changed to brown and bubbling was 
observed. Allylic bromodifluoroacetate (8.0 mmol) was injected and the reaction was 
heated at 50 °C for 12 h. The flask was allowed to cool to 21 °C, and the mixture was 
diluted with EtOAc (25 mL). α,α,α-Trifluorotoluene (98.4 μL, 0.800 mmol) was injected 
as a standard, and an aliquot was removed for 19F NMR analysis. After determination of 
the 19F yield, the aliquot was recombined with the reaction mixture. The mixture was 
further diluted with EtOAc (50 mL) and then washed with H2O (50 mL) and brine (50 
mL). The solution was dried over MgSO4, filtered, and the solvent was removed in 






General Procedure A was followed using 3-bromocinnamic acid (3.05 g, 13.4 mmol), 
sulfuric acid (0.79 mL, 15 mmol), and MeOH as solvent (0.050 L). Workup afforded the 
title compound as a colorless solid (3.01 g, 93%).  
m.p.: 54–55 °C.  
1H NMR (500 MHz, CDCl3): δ 7.68 (t, J = 1.8 Hz, 1 H), 7.62 (d, J = 16.0 Hz, 1 H), 7.54–





General Procedure B was followed using 2.1b.2 (2.91 g, 12.1 mmol), DIBAL (1.0 M in 
PhMe, 25.3 mL, 25.3 mmol), with DCM (50 mL) as solvent. Workup and filtration 
through a pad of silica (EtOAc) afforded the title compound as a light yellow oil (2.47 g, 
96%).  
1H NMR (400 MHz, CDCl3): δ 7.54 (t, J = 1.8 Hz, 1 H), 7.38 (ddd, J = 7.9, 2.0, 1.1 Hz, 1 
H), 7.31 (dt, J = 7.8, 1.3 Hz, 1 H), 7.20 (t, J = 7.8 Hz, 1 H), 6.57 (dt, J = 15.9, 1.6 Hz, 1 






General Procedure C was followed using 2.1b.1 (259 mg, 1.22 mmol), 
bromodifluoroacetic acid (299 mg, 1.71 mmol), oxalyl chloride (134 μL, 1.59 mmol), 
DMF (28 μL, 0.37 mmol), triethylamine (0.340 mL, 2.44 mmol), with DCM (15 mL) as 
solvent. Workup and chromatographic purification (hexanes / EtOAc 1:0 → 49:1) 
afforded the title compound as a colorless oil (392 mg, 87%).  
1H NMR (500 MHz, CDCl3): δ 7.59–7.56 (m, 1 H), 7.46–7.42 (m, 1 H), 7.36–7.32 (m, 1 
H), 7.23 (t, J = 7.8 Hz, 1 H), 6.71 (dd, J = 15.9, 1.4 Hz, 1 H), 6.31 (dt, J = 15.9, 6.5 Hz, 1 
H), 5.00 (dd, J = 6.5, 1.3 Hz, 2 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 159.5 (t, J = 31.5 Hz), 137.7, 135.2, 131.7, 130.4, 
129.8, 125.7, 123.0, 122.0, 108.8 (t, J = 314.3 Hz), 68.4.  
19F NMR (376 MHz, CDCl3): δ –61.89 (s, 2 F).  
IR (film): 3063, 2951, 1774, 1591, 1560, 1474, 1377, 1300, 1286, 1167, 1128, 947, 
773, 712 cm–1.  









Entry 1: General Procedure D was followed using 2.2b (74.0 mg, 0.200 mmol), CuI (3.8 
mg, 0.020 mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 
0.050 mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, 
the reaction was heated at 50 °C for 8 h. Workup and chromatographic purification 
(pentane / Et2O 1:0 →  49:1) afforded the title compound as a colorless oil (43.0 mg, 
81%).  
Entry 2: General Procedure E was followed using 2.2b (2.96 g, 8.00 mmol), CuI (152 
mg, 0.800 mmol), DMEDA (86 μL, 0.020 mmol), sodium bromodifluoroacetate (394 mg, 
2.00 mmol), KF (0.93 g, 16 mmol), and DMF (8.0 mL) as solvent. After activation, the 
reaction was heated at 50 °C for 12 h. Workup and chromatographic purification 
(hexanes / EtOAc 49:1) afforded the title compound as a colorless oil (1.89 g, 89%). 
1H NMR (500 MHz, CDCl3): δ 7.54 (t, J = 1.9 Hz, 1 H), 7.41 (ddd, J = 7.9, 2.0, 1.1 Hz, 1 
H), 7.30 (dt, J = 7.7, 1.3 Hz, 1 H), 7.21 (t, J = 7.8 Hz, 1 H), 6.55 (d, J = 15.8 Hz, 1 H), 
6.13 (dt, J = 15.9, 7.2 Hz, 1 H), 3.01 (qdd, J = 10.6, 7.3, 1.4 Hz, 2 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 138.4, 135.9, 131.1, 130.3, 129.5, 128.1 (q, J = 
276.7 Hz), 125.3, 123.0, 119.0 (q, J = 3.6 Hz), 37.8 (q, J = 30.1 Hz).  
19F NMR (376 MHz, CDCl3): δ –67.18 (t, J = 10.7 Hz, 3 F).  
IR (film): 3061, 2928, 2854, 1591, 1564, 1477, 1425, 1366, 1306, 1256, 1140, 1049, 
964, 928, 868, 771, 685, 650 cm–1.  





General Procedure B was followed using 4-chlorocinnamaldehyde (624 mg, 3.75 
mmol), DIBAL (1.0 M in PhMe, 4.1 mL, 4.1 mmol), with DCM (0.040 L) as solvent. 
Workup and filtration through a pad of silica (Et2O) afforded the title compound as a 
colorless solid (594 mg, 94%).  
m.p.: 54–56 °C (lit.14 52–54 °C).  
1H NMR (400 MHz, CDCl3): δ 7.35–7.28 (m, 4 H), 6.59 (dd, J = 15.9, 1.7 Hz, 1 H), 6.35 




General Procedure C was followed using 2.1c.1 (396 mg, 2.35 mmol), 
bromodifluoroacetic acid (575 mg, 3.29 mmol), oxalyl chloride (258 μL, 3.05 mmol), 
DMF (54 μL, 0.70 mmol), triethylamine (654 μL, 4.69 mmol), with DCM (12 mL) as 
solvent. Workup and chromatographic purification (hexanes / EtOAc 1:0 → 49:1) 
afforded the title compound as a colorless oil (707 mg, 93%).  
1H NMR (500 MHz, CDCl3): δ 7.37–7.30 (m, 4 H), 6.74 (d, J = 15.9 Hz, 1 H), 6.29 (dt, J 
= 15.9, 6.6 Hz, 1 H), 4.99 (dd, J = 6.6, 1.3 Hz, 2 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 159.6 (t, J = 31.5 Hz), 135.6, 134.6, 134.1, 129.1, 
128.2, 121.0, 108.8 (t, J = 314.4 Hz), 68.6.  
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19F NMR (376 MHz, CDCl3): δ –61.68 (s, 2 F).  
IR (film): 3030, 2951, 1774, 1491, 1304, 1288, 1169, 1126, 1092, 947, 849, 712 cm–1.  




General Procedure D was followed using 2.1c (65.1 mg, 0.200 mmol), CuI (3.8 mg, 
0.020 mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 
0.050 mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, 
the reaction was heated at 50 °C for 8 h. Workup and chromatographic purification 
(pentane) afforded the title compound as a colorless oil (31.6 mg, 72%).  
1H NMR (400 MHz, CDCl3): δ 7.32 (s, 4 H), 6.57 (dt, J = 15.9, 1.2 Hz, 1 H), 6.10 (dt, J = 
16.0, 7.3 Hz, 1 H), 3.00 (qdd, J = 10.7, 7.2, 1.4 Hz, 2 H).  




General Procedure A was followed using 3-(trifluoromethyl)cinnamic acid (649 mg, 3.00 
mmol), sulfuric acid (0.18 mL, 3.3 mmol), and MeOH as solvent (15 mL). Workup 
afforded the title compound as a colorless oil (658 mg, 95%).  
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1H NMR (400 MHz, CDCl3): δ 7.79–7.76 (m, 1 H), 7.75–7.68 (m, 2 H), 7.67–7.62 (m, 1 
H), 7.53 (t, J = 7.8 Hz, 1 H), 6.52 (d, J = 16.0 Hz, 1 H), 3.84 (s, 3 H).  




General Procedure B was followed using 2.1d.2 (655 mg, 2.85 mmol), DIBAL (1.0 M in 
PhMe, 6.0 mL, 6.0 mmol), with DCM (0.030 L) as solvent. Workup and filtration through 
a pad of silica (Et2O) afforded the title compound as a tan oil (530 mg, 92%).  
1H NMR (400 MHz, CDCl3): δ 7.65–7.61 (m, 1 H), 7.59–7.53 (m, 1 H), 7.53–7.48 (m, 1 
H), 7.47–7.41 (m, 1 H), 6.71–6.62 (m, 1 H), 6.45 (dt, J = 15.9, 5.4 Hz, 1 H), 4.38 (dd, J = 
5.4, 1.7 Hz, 2 H), 1.57–1.52 (m, 1 H).  




General Procedure C was followed using 2.1d.1 (202 mg, 1.00 mmol), 
bromodifluoroacetic acid (245 mg, 1.40 mmol), oxalyl chloride (0.110 mL, 1.30 mmol), 
DMF (23 μL, 0.030 mmol), triethylamine (279 μL, 2.00 mmol), with DCM (0.010 L) as 
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solvent. Workup and chromatographic purification (hexanes / EtOAc 1:0 → 49:1) 
afforded the title compound as a colorless oil (291 mg, 81%).  
1H NMR (400 MHz, CDCl3): δ 7.68–7.65 (m, 1 H), 7.62–7.55 (m, 2 H), 7.52–7.45 (m, 1 
H), 6.81 (d, J = 15.9 Hz, 1 H), 6.39 (dt, J = 15.9, 6.5 Hz, 1 H), 5.02 (dd, J = 6.5, 1.3 Hz, 
2 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 159.5 (t, J = 31.6 Hz), 136.4, 135.1, 131.4 (q, J = 
32.4 Hz), 130.1, 129.4, 125.3 (q, J = 3.8 Hz), 124.1 (q, J = 272.4 Hz), 123.6 (q, J = 3.8 
Hz), 122.5, 108.8 (t, J = 314.4 Hz), 68.23.  
19F NMR (376 MHz, CDCl3): δ –61.57 (s, 2 F), (–113.93)–(–114.03) (m, 1 F).  
IR (film): 3045, 2959, 1778, 1443, 1337, 1306, 1290, 1167, 1126, 1072, 949, 824, 793, 
712, 696, 662, 602 cm–1.  




General Procedure D was followed using 2.1d (71.8 mg, 0.200 mmol), CuI (3.8 mg, 
0.020 mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 
0.050 mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, 
the reaction was heated at 50 °C for 8 h. Workup and chromatographic purification 
(pentane) afforded the title compound as a pale yellow oil (36.2 mg, 71%).  
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1H NMR (400 MHz, CDCl3): δ 7.63 (s, 1 H), 7.59–7.52 (m, 2 H), 7.49–7.44 (m, 1 H), 
6.66 (d, J = 15.9 Hz, 1 H), 6.21 (dt, J = 15.9, 7.2 Hz, 1 H), 3.03 (qdd, J = 10.6, 7.3, 1.4 
Hz, 2 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 137.0, 135.5, 131.3 (q, J = 32.2 Hz), 129.7, 129.3, 
125.9 (q, J = 277.16 Hz), 124.8 (q, J = 3.9 Hz), 124.1 (q, J = 272.6 Hz), 123.3 (q, J = 3.9 
Hz), 119.5 (q, J = 3.6 Hz), 37.8 (q, J = 30.1 Hz).  
19F NMR (376 MHz, CDCl3): δ –63.62 (s, 3 F), –67.00 (t, J = 10.5 Hz, 3 F). 
IR (film): 3047, 3015, 2961, 2932, 1431, 1369, 1333, 1283, 1259, 1204, 1130, 1074, 
966, 932, 814, 789, 696 cm–1. 




General Procedure C was followed using 4-nitrocinnamyl alcohol (179 mg, 1.00 mmol), 
bromodifluoroacetic acid (245 mg, 1.40 mmol), oxalyl chloride (0.110 mL, 1.30 mmol), 
DMF (23 μL, 0.30 mmol), NEt3 (279 μL, 2.00 mmol), with DCM (0.010 L) as solvent. 
Workup and chromatographic purification (hexanes / EtOAc 1:0 → 19:1) afforded the 
title compound as a viscous yellow oil (294 mg, 88%).  
1H NMR (500 MHz, CDCl3): δ 8.24–8.21 (m, 2 H), 7.59–7.55 (m, 2 H), 6.84 (dt, J = 
15.9, 1.4 Hz, 1 H), 6.48 (dt, J = 15.9, 6.3 Hz, 1 H), 5.05 (dd, J = 6.3, 1.4 Hz, 2 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 159.5 (t, J = 31.7 Hz), 147.7, 141.9, 133.8, 127.6, 
125.2, 124.3, 108.7 (t, J = 314.3 Hz), 67.8.  
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19F NMR (376 MHz, CDCl3): δ –61.72 (s, 2 F).  
IR (film): 3109, 3080, 2941, 2851, 1772, 1597, 1518, 1448, 1344, 1304, 1167, 1126, 
949, 860, 822, 743, 710 cm–1.  




General Procedure D was followed using 2.1e (67.2 mg, 0.200 mmol), CuI (3.8 mg, 
0.020 mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 
0.050 mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, 
the reaction was heated at 50 °C for 8 h. Workup and chromatographic purification 
(pentane / Et2O 1:0 →  9:1) afforded the title compound as a yellow oil (38.5 mg, 83%).  
1H NMR (400 MHz, CDCl3): δ 8.22 (d, J = 8.8 Hz, 2 H), 7.55 (d, J = 8.8 Hz, 2 H), 6.71 
(d, J = 15.9 Hz, 1 H), 6.33 (dt, J = 15.9, 7.2 Hz, 1 H), 3.08 (qdd, J = 10.5, 7.2, 1.4 Hz, 2 
H).  
13C{1H} NMR (126 MHz, CDCl3): δ 147.5, 142.5, 134.8, 127.2, 125.7 (q, J = 276.8 Hz), 
124.2, 122.3 (q, J = 3.7 Hz), 37.9 (q, J = 30.3 Hz).  
19F NMR (376 MHz, CDCl3): δ –66.94 (t, J = 10.9 Hz, 3 F).  
IR (film): 3047, 2937, 1659, 1599, 1518, 1429, 1344, 1306, 1250, 1138, 1109, 1051, 
970, 924, 849, 808, 743 cm–1.  






General Procedure A was followed using 2-hydroxycinnamic acid (1.64 g, 10.0 mmol), 
H2SO4 (0.59 mL, 11 mmol), and MeOH as solvent (0.050 L). Workup afforded the title 
compound as a colorless solid (1.66 g, 93%).  
m.p.: 132–136 °C (lit.11 136–137 °C).  
1H NMR (500 MHz, CDCl3): δ 8.03 (d, J = 16.1 Hz, 1 H), 7.48 (dd, J = 7.8, 1.6 Hz, 1 H), 
7.27 – 7.23 (m, 1 H), 6.94 (td, J = 7.6, 1.1 Hz, 1 H), 6.85 (dd, J = 8.1, 1.1 Hz, 1 H), 6.64 




A 100 mL round bottom flask was oven-dried and cooled under N2. Compound 2.1f.3 
(0.96 g, 5.4 mmol) was added then the flask was equipped with a rubber septum. The 
flask was then evacuated and backfilled with N2 three times. DCM (0.020 L) and 2,6-
lutidine (1.26 mL, 10.8 mmol) were injected, and the solution was cooled to –78 °C. 
Trifluoromethanesulfonic anhydride (1.1 mL, 6.5 mmol) was added dropwise, and the 
solution was stirred for 15 min. The flask was allowed to warm to 21 °C, and then stirred 
for 3 h. The reaction was quenched with NH4Cl (aq) (10 mL), then diluted with DCM (40 
mL). The organic phase was washed with H2O (30 mL), brine (30 mL), dried over 
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MgSO4, filtered, and the solvent was removed in vacuo. Chromatographic purification 
(hexanes / EtOAc 1:0 → 9:1) afforded the title compound as a pale tan liquid (1.24 g, 
74%).  
1H NMR (500 MHz, CDCl3): δ 7.89 (d, J = 16.0 Hz, 1 H), 7.71 (dd, J = 7.8, 1.8 Hz, 1 H), 
7.49 (ddd, J = 8.2, 7.4, 1.8 Hz, 1 H), 7.45 – 7.41 (m, 1 H), 7.38 (dd, J = 8.2, 1.3 Hz, 1 
H), 6.52 (d, J = 16.1 Hz, 1 H), 3.84 (s, 3 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 166.5, 147.7, 136.2, 131.8, 128.8, 128.4, 128.1, 
122.4, 122.3, 118.7 (q, J = 320.3 Hz), 52.2.  
19F NMR (376 MHz, CDCl3): δ –74.19 (s, 3 F).  
IR (film): 3070, 3003, 2955, 1724, 1637, 1423, 1213, 1140, 1078, 895, 827, 768 cm–1.  
HRMS (ESI+): exact mass calculated for [M+Na]+ (C11H9F3O5SNa) requires m/z 




General Procedure B was followed using 2.1f.2 (0.82 g, 2.6 mmol), DIBAL (1.0 M in 
PhMe, 5.6 mL, 5.6 mmol), and DCM (0.020 L) as solvent. Workup and chromatographic 
purification (hexanes / EtOAc 1:0 → 2:1) afforded the title compound as a colorless oil 
(0.68 g, 90%).  
1H NMR (500 MHz, CDCl3): δ 7.62 (dd, J = 7.3, 2.2 Hz, 1 H), 7.39–7.31 (m, 2 H), 7.30–
7.28 (m, 1 H), 6.85 (dt, J = 15.9, 1.8 Hz, 1 H), 6.47 (dt, J = 15.9, 5.3 Hz, 1 H), 4.39 (td, J 
= 5.7, 1.8 Hz, 2 H), 1.62–1.58 (m, 1 H). 
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13C{1H} NMR (126 MHz, CDCl3): δ 147.0, 133.8, 130.5, 129.2, 128.6, 127.8, 122.6, 
121.9, 118.7 (q, J = 321.3 Hz), 63.6.  
19F NMR (376 MHz, CDCl3): δ –74.61 (s, 3 F).  
IR (film): 3416, 2960, 1643, 1483, 1450, 1418, 1138, 1072, 891 cm–1.  




General Procedure C was followed using 2A-6-1 (282 mg, 1.00 mmol), 
bromodifluoroacetic acid (245 mg, 1.40 mmol), oxalyl chloride (0.110 mL, 1.30 mmol), 
DMF (23 μL, 0.030 mmol), triethylamine (279 μL, 2.00 mmol), with DCM (0.010 L) as 
solvent. Workup and chromatographic purification (hexanes / EtOAc 1:0 → 19:1) 
afforded the title compound as a colorless oil (378 mg, 86%).  
1H NMR (500 MHz, CDCl3): δ 7.67–7.61 (m, 1 H), 7.43–7.37 (m, 2 H), 7.34–7.29 (m, 1 
H), 6.98 (dt, J = 16.0, 1.5 Hz, 1 H), 6.40 (dt, J = 15.9, 6.2 Hz, 1 H), 5.04 (dd, J = 6.2, 1.5 
Hz, 2 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 159.5 (t, J = 31.7 Hz), 147.1, 130.2, 129.3, 128.7, 
128.0, 127.8, 125.4, 122.1, 118.7 (q, J = 320.6 Hz), 108.7 (t, J = 314.2 Hz), 67.9.  
19F NMR (376 MHz, CDCl3): δ –61.76 (s, 2 F), –74.46 (s, 3 F). 
IR (film): 3067, 3036, 2957, 1780, 1485, 1421, 1294, 1248, 1217, 1138, 951, 891, 825, 
766, 710, 606 cm–1.  
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General procedure D was followed using 2.1f (87.8 mg, 0.200 mmol). Workup and 
chromatographic purification (pentane) yielded the title compound as a colorless oil 
(49.9 mg, 75%).  
1H NMR (400 MHz, CDCl3): δ 7.65–7.59 (m, 1 H), 7.41–7.35 (m, 2 H), 7.33–7.28 (m, 1 
H), 6.83 (d, J = 15.9 Hz, 1 H), 6.22 (dt, J = 15.9, 7.3 Hz, 1 H), 3.07 (qdd, J = 10.6, 7.2, 
1.5 Hz, 2 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 146.9, 129.9, 129.8, 128.9, 128.7, 127.8, 125.7 (q, J 
= 277.0 Hz), 122.5 (q, J = 3.6 Hz), 122.0, 118.7 (q, J = 320.7 Hz), 38.0 (q, J = 30.2 Hz).  
19F NMR (376 MHz, CDCl3): δ –67.04 (t, J = 10.4 Hz, 3 F), –75.08 (s, 3 F).  
IR (film): 3065, 2934, 2858, 1485, 1452, 1423, 1371, 1250, 1217, 1138, 1080, 1049, 
968, 893, 814, 766, 608 cm–1.  






General Procedure A was followed using 4-fluorocinnamic acid (1.66 g, 10.0 mmol), 
H2SO4 (0.59 mL, 11 mmol), and MeOH as solvent (0.050 L). Workup afforded the title 
compound as a colorless solid (1.75 g, 97%).  
m.p.: 44–45 °C (lit.13 45–47 °C).  
1H NMR (400 MHz, CDCl3): δ 7.67 (d, J = 16.0 Hz, 1 H), 7.56–7.49 (m, 2 H), 7.12–7.05 
(m, 2 H), 6.37 (dd, J = 16.0, 0.6 Hz, 1 H), 3.82 (s, 3 H).  




General Procedure B was followed using 2.1g.2 (1.70 g, 9.44 mmol), DIBAL (1.0 M in 
PhMe, 19.8 mL, 19.8 mmol), with DCM (100 mL) as solvent. Workup and filtration 
through a pad of silica (Et2O) afforded the title compound as a colorless solid (1.35 g, 
94%).  
m.p.: 58–60 °C (lit.14 57–58 °C).  
1H NMR (400 MHz, CDCl3): δ 7.36 (m, 2 H), 7.06–6.97 (m, 2 H), 6.64–6.54 (m, 1 H), 
6.29 (dt, J = 15.9, 5.7 Hz, 1 H), 4.33 (dd, J = 5.5, 1.7 Hz, 2 H), 1.48 (s, 1 H).  








General Procedure C was followed using 2.1g.1 (152 mg, 1.00 mmol), 
bromodifluoroacetic acid (245 mg, 1.40 mmol), oxalyl chloride (0.110 mL, 1.30 mmol), 
DMF (23 μL, 0.030 mmol), triethylamine (279 μL, 2.00 mmol), with DCM (0.010 L) as 
solvent. Workup and chromatographic purification (hexanes / EtOAc 1:0 → 49:1) 
afforded the title compound as a colorless oil (187 mg, 60%).  
1H NMR (400 MHz, CDCl3): δ 7.43–7.37 (m, 2 H), 7.09–7.01 (m, 2 H), 6.75 (d, J = 15.8 
Hz, 1 H), 6.23 (dt, J = 15.8, 6.7 Hz, 1 H), 4.99 (dd, J = 6.7, 1.2 Hz, 2 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 163.1 (d, J = 248.5 Hz), 159.6 (t, J = 31.4 Hz), 
135.9, 131.8 (d, J = 3.3 Hz), 128.7 (d, J = 8.2 Hz), 120.1 (d, J = 2.3 Hz), 115.9 (d, J = 
21.7 Hz), 108.8 (t, J = 314.4 Hz), 68.8.  
19F NMR (376 MHz, CDCl3): δ –61.64 (s, 2 F), –113.58 (ddd, J = 13.8, 8.7, 5.4 Hz, 1 F).  
IR (film): 3045, 2957, 2924, 1774, 1655, 1603, 1508, 1450, 1416, 1379, 1290, 1234, 
1169, 1128, 947, 851, 712, 604 cm–1.  




General Procedure D was followed using 2.1g (61.8 mg, 0.200 mmol), CuI (3.8 mg, 
0.020 mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 
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0.050 mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, 
the reaction was heated at 50 °C for 8 h. Workup and chromatographic purification 
(pentane) afforded the title compound as a colorless oil (26.4 mg, 65%).  
1H NMR (400 MHz, CDCl3): δ 7.39–7.34 (m, 2 H), 7.07–7.00 (m, 2 H), 6.58 (d, J = 15.9 
Hz, 1 H), 6.04 (dt, J = 15.8, 7.2 Hz, 1 H), 2.99 (qdd, J = 10.7, 7.2, 1.4 Hz, 2 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 162.7 (d, J = 247.6 Hz), 135.6, 132.5 (d, J = 3.3 Hz), 
128.2 (d, J = 8.1 Hz), 126.0 (q, J = 276.6 Hz), 117.2–117.0 (m), 115.7 (d, J = 21.7 Hz), 
37.8 (q, J = 30.0 Hz).  
19F NMR (376 MHz, CDCl3): δ –67.30 (t, J = 10.9 Hz, 3 F), (–115.03)–(–115.14) (m, 1 
F).  
IR (film): 3045, 3007, 2968, 2932, 1601, 1510, 1429, 1369, 1308, 1258, 1252, 1140, 
1115, 1049, 968, 922, 837, 797, 770 cm–1.  




General Procedure A was followed using 4-methylcinnamic acid (1.62 g, 10.0 mmol), 
sulfuric acid (0.59 mL, 11 mmol), and MeOH as solvent (0.050 L). Workup afforded the 
title compound as a colorless solid (1.68 g, 95%).  
m.p.: 55–56 °C (lit.13 50–52 °C).  
1H NMR (400 MHz, CDCl3): δ 7.68 (d, J = 16.0 Hz, 1 H), 7.44 (d, J = 8.1 Hz, 2 H), 7.20 





General Procedure B was followed using 2.1h.2 (1.68 g, 9.5 mmol), DIBAL (1.0 M in 
PhMe, 20.0 mL, 20.0 mmol), with DCM (0.10 L) as solvent. Workup and filtration 
through a pad of silica (Et2O) afforded the title compound as a colorless solid (1.37 g, 
97%).  
m.p.: 49–52 °C (lit.13 60–61 °C).  
1H NMR (500 MHz, CDCl3): δ 7.30 (d, J = 8.1 Hz, 2 H), 7.16–7.13 (m, 2 H), 6.60 (dt, J = 
15.9, 1.5 Hz, 1 H), 6.33 (dt, J = 15.8, 5.9 Hz, 1 H), 4.33 (td, J = 5.9, 1.5 Hz, 2 H), 2.35 




General Procedure C was followed using 2.1h.1 (148 mg, 1.00 mmol), 
bromodifluoroacetic acid (245 mg, 1.40 mmol), oxalyl chloride (0.110 mL, 1.30 mmol), 
DMF (23 μL, 0.030 mmol), triethylamine (279 μL, 2.00 mmol), with DCM (0.010 L) as 
solvent. Workup and chromatographic purification (hexanes / EtOAc 1:0 → 49:1) 
afforded the title compound as a colorless oil (204 mg, 67%).  
1H NMR (400 MHz, CDCl3): δ 7.35–7.30 (m, 2 H), 7.19–7.15 (m, 2 H), 6.75 (d, J = 15.8 
Hz, 1 H), 6.26 (dt, J = 15.8, 6.8 Hz, 1 H), 4.99 (dd, J = 6.8, 1.1 Hz, 2 H), 2.36 (s, 3 H). 
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13C{1H} NMR (126 MHz, CDCl3): δ 159.6 (t, J = 31.3 Hz), 138.9, 137.1, 132.8, 129.6, 
126.9, 119.2, 108.9 (t, J = 314.4 Hz), 69.1, 21.4.  
19F NMR (376 MHz, CDCl3): δ –61.64 (s, 2 F).  
IR (film): 3047, 3024, 2951, 2921, 1774, 1655, 1514, 1448, 1379, 1304, 1288, 1169, 
1128, 968, 947, 845, 827, 793, 712, 604 cm–1.  




General Procedure D was followed using 2.1h (61.0 mg, 0.200 mmol), CuI (3.8 mg, 
0.020 mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 
0.050 mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, 
the reaction was heated at 50 °C for 8 h. Workup and chromatographic purification 
(pentane) afforded the title compound as a colorless oil (28.2 mg, 71%).  
1H NMR (400 MHz, CDCl3): δ 7.29 (d, J = 8.1 Hz, 2 H), 7.15 (d, J = 8.0 Hz, 2 H), 6.58 
(d, J = 15.9 Hz, 1 H), 6.07 (dt, J = 15.8, 7.2 Hz, 1 H), 2.99 (qdd, J = 10.7, 7.2, 1.4 Hz, 2 
H), 2.36 (s, 3 H).  








General Procedure A was followed using 4-methoxycinnamic acid (891 mg, 5.00 mmol), 
sulfuric acid (0.29 mL, 5.5 mmol), and methanol as solvent (25 mL). Workup afforded 
the title compound as a colorless solid (946 mg, 98%). 
m.p.: 85–87 °C (lit.15 85–87 °C).  
1H NMR (400 MHz, CDCl3): δ 7.66 (d, J = 16.0 Hz, 1 H), 7.54–7.43 (m, 2 H), 6.97–6.86 




General Procedure B was followed using 2.1i.2 (941 mg, 4.90 mmol), DIBAL (1.0 M in 
PhMe, 10.3 mL, 10.3 mmol), with DCM (0.050 L) as solvent. Workup and filtration 
through a pad of silica (Et2O) afforded the title compound as a colorless solid (765 mg, 
95%).  
m.p.: 72–75 °C (lit.15 79–81 °C).  
1H NMR (500 MHz, CDCl3): δ 7.37–7.31 (m, 2 H), 6.90–6.84 (m, 2 H), 6.57 (d, J = 15.9 
Hz, 1 H), 6.25 (dt, J = 15.8, 6.0 Hz, 1 H), 4.31 (td, J = 5.9, 1.5 Hz, 2 H), 3.82 (s, 3 H), 






General Procedure C was followed using 2.1i.1 (164 mg, 1.00 mmol), 
bromodifluoroacetic acid (245 mg, 1.40 mmol), oxalyl chloride (0.110 mL, 1.30 mmol), 
DMF (23 μL, 0.30 mmol), NEt3 (279 μL, 2.00 mmol), with DCM (0.010 L) as solvent. 
Workup and chromatographic purification (hexanes / EtOAc 1:0 → 19:1) afforded the 
title compound as a yellow oil (179 mg, 63%).  
1H NMR (500 MHz, CDCl3): δ 7.41–7.33 (m, 2 H), 6.93–6.84 (m, 2 H), 6.73 (d, J = 15.8 
Hz, 1 H), 6.18 (dt, J = 15.8, 6.9 Hz, 1 H), 4.98 (dd, J = 6.9, 1.1 Hz, 2 H), 3.83 (s, 3 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 160.2, 159.6 (t, J = 31.4 Hz), 137.0, 128.3, 127.9, 
117.9, 114.3, 108.9 (t, J = 314.5 Hz), 69.3, 55.5.  
19F NMR (376 MHz, CDCl3): δ –60.76 (s, 2 F).  
IR (film): 3034, 3003, 2957, 1772, 1607, 1512, 1294, 1250, 1175, 1126, 1034, 945, 829 
cm–1.  




General Procedure D was followed using 2.1i (64.2 mg, 0.200 mmol), CuI (3.8 mg, 
0.020 mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 
0.050 mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, 
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the reaction was heated at 50 °C for 8 h. Workup and chromatographic purification 
(pentane / Et2O 1:0 → 49:1) afforded the title compound as a tan oil (24.8 mg, 57%).
  
1H NMR (400 MHz, CDCl3): δ 7.35–7.30 (m, 2 H), 6.91–6.84 (m, 2 H), 6.55 (d, J = 15.8 
Hz, 1 H), 5.98 (dt, J = 15.9, 7.2 Hz, 1 H), 3.83 (s, 3 H), 2.97 (qdd, J = 10.7, 7.3, 1.4 Hz, 
2 H).  




Two resealable 15 mL test tubes were oven-dried, capped with PTFE septa, and cooled 
under N2. Pd(OAc)2 (4.5 mg, 0.020 mmol) and X-Phos (19.1 mg, 0.0400 mmol) were 
added to tube 1. The tube was evacuated and backfilled with N2 three times. Degassed 
H2O (1.4 μL, 0.080 mmol) and THF (1.0 mL) were injected. The tube was placed in a 60 
°C oil bath for 3 min resulting in a color change of the reaction from deep red to dark 
green. The tube was removed from the oil bath and allowed to cool to 21 °C. Compound 
2.1f.1 (282 mg, 1.00 mmol) and 3-thiopheneboronic acid (192 mg, 1.50 mmol) were 
added to tube 2. The tube was evacuated and backfilled with N2 three time. THF (1 mL) 
and degassed 0.5 M K3PO4 (aq) were injected. The solution in tube 1 was transferred to 
tube 2 via cannula. The reaction was placed in a 40 °C oil bath and vigorously stirred for 
2 h. The tube was removed from the oil bath and cooled to 21 °C. The reaction was 
diluted with Et2O (10 mL) and H2O (5 mL). The phases were separated then the 
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aqueous phase was extracted with Et2O (2 x 15 mL). The combined organic layers were 
washed with brine (25 mL). The organic solution was dried over MgSO4, filtered, and 
the solvent was removed in vacuo. Chromatographic purification (hexanes / EtOAc 1:0 
→ 3:1) afforded the title compound as a viscous brown oil (154 mg, 71%).  
1H NMR (500 MHz, CDCl3): δ 7.60 (dd, J = 7.1, 2.0 Hz, 1 H), 7.41–7.28 (m, 4 H), 7.25 
(dd, J = 3.0, 1.3 Hz, 1 H), 7.16 (dd, J = 4.9, 1.3 Hz, 1 H), 6.75 (dt, J = 15.9, 1.6 Hz, 1 H), 
6.32 (dt, J = 15.8, 5.9 Hz, 1 H), 4.32–4.26 (m, 2 H), 1.40 (bs, 1 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 141.4, 135.7, 135.2, 130.4, 130.1, 129.8, 129.4, 
127.8, 127.7, 126.5, 125.3, 123.6, 64.1.  
IR (film): 3375, 3103, 3057, 3026, 2926, 2856, 1474, 1443, 1364, 1109, 1082, 1009, 
970, 858, 791, 754 cm–1.  




General Procedure C was followed using 2.1j.1 (132 mg, 0.610 mmol), 
bromodifluoroacetic acid (0.15 g, 0.85 mmol), oxalyl chloride (67 μL, 0.79 mmol), DMF 
(14 μL, 0.18 mmol), NEt3 (0.17 mL, 1.2 mmol), with DCM (6.0 mL) as solvent. Workup 
and chromatographic purification (hexanes / EtOAc 1:0 → 19:1) afforded the title 
compound as a colorless oil (129.9 mg, 57%).  
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1H NMR (500 MHz, CDCl3): δ 7.62–7.58 (m, 1 H), 7.41–7.34 (m, 4 H), 7.24 (dd, J = 3.0, 
1.3 Hz, 1 H), 7.15 (dd, J = 4.9, 1.3 Hz, 1 H), 6.92 (dt, J = 15.8, 1.3 Hz, 1 H), 6.25 (dt, J = 
15.8, 6.6 Hz, 1 H), 4.96 (dd, J = 6.5, 1.3 Hz, 2 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 159.6 (t, J = 31.4 Hz), 140.9, 136.2, 135.9, 134.1, 
130.2, 129.4, 128.6, 127.8, 126.6, 125.6, 123.9, 121.5, 108.9 (t, J = 314.5 Hz), 68.9. 
19F NMR (376 MHz, CDCl3): δ –61.65 (s, 2 F).  
IR (film): 3103, 3059, 3026, 2955, 1774, 1474, 1447, 1379, 1169, 1126, 945, 793, 754, 
710 cm–1.  




General Procedure D was followed using 2.1j (74.6 mg, 0.200 mmol), CuI (3.8 mg, 
0.020 mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 
0.050 mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, 
the reaction was heated at 50 °C for 8 h. Workup and chromatographic purification 
(pentane) afforded the title compound as a colorless oil (42.9 mg, 80%).  
1H NMR (400 MHz, CDCl3): δ 7.59–7.53 (m, 1 H), 7.41–7.31 (m, 4 H), 7.24 (dd, J = 3.1, 
1.3 Hz, 1 H), 7.16 (dd, J = 4.9, 1.3 Hz, 1 H), 6.74 (d, J = 15.8 Hz, 1 H), 6.05 (dt, J = 
15.8, 7.3 Hz, 1 H), 2.96 (qdd, J = 10.7, 7.3, 1.4 Hz, 2 H).  
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13C NMR (126 MHz, CDCl3): δ 141.1, 136.3, 135.6, 134.9, 130.0, 129.4, 128.2, 127.7, 
126.6, 126.1 (q, J = 276.7 Hz), 125.4, 123.7, 118.5 (q, J = 3.6 Hz), 37.9 (q, J = 29.7 Hz).  
19F NMR (376 MHz, CDCl3): δ –67.21 (t, J = 11.0 Hz, 3 F).  
IR (film): 3061, 3026, 2926, 1474, 1429, 1364, 1248, 1138, 1053, 970, 858, 791, 754 
cm–1.  




1-Boc-piperazine (224 mg, 1.20 mmol), Pd2dba3 (9.2 mg, 0.010 mmol), and 2-
dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl (9.4 mg, 0.024 mmol) were 
added to an oven dried 15 mL resealable test tube equipped with a PTFE septum. The 
tube was evacuated and backfilled with dry N2 three times. THF (1.0 mL) and LHMDS 
(1.06 M in THF/ethylbenzene, 2.08 mL, 2.20 mmol) were injected and the mixture was 
stirred for 5 min. 2.1b.1 (213 mg, 1.00 mmol) was injected. The tube was placed in a 65 
°C oil bath and the reaction was stirred for 7 h. The tube was removed from the oil bath 
and allowed to cool to 21 °C. The reaction was diluted with EtOAc (15 mL) and washed 
with H2O (15 mL) and brine (15 mL). The organic phase was dried over MgSO4, filtered, 
and the solvent was removed in vacuo. Column chromatography (DCM / MeOH 1:0 → 
19:1) afforded the title compound as a pale yellow solid (213 mg, 67%).  
m.p.: 79–80 °C.  
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1H NMR (400 MHz, CDCl3): δ 7.24 (t, J = 8.2 Hz, 1 H), 6.98–6.92 (m, 2 H), 6.88–6.81 
(m, 1 H), 6.64–6.55 (m, 1 H), 6.36 (dt, J = 15.8, 5.7 Hz, 1 H), 4.33 (td, J = 5.8, 1.5 Hz, 2 
H), 3.64–3.54 (m, 4 H), 3.15 (t, J = 5.2 Hz, 4H), 1.49 (s, 9 H), 1.47–1.42 (m, 1 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 154.9, 151.7, 137.8, 131.6, 129.5, 128.7, 118.7, 
116.3, 115.0, 80.1, 63.9, 49.6, 44.1 (br s), 43.3 (br s), 28.6.  
IR (film): 3391, 2974, 2928, 2858, 2820, 1695, 1597, 1423, 1240, 1167, 1126, 970, 
868, 770 cm–1.  
HRMS (ESI+): exact mass calculated for [M+H]+ (C18H27N2O3) requires m/z 319.2022, 





General Procedure C was followed using 2.1k.1 (187 mg, 0.587 mmol), 
bromodifluoroacetic acid (144 mg, 0.822 mmol), oxalyl chloride (65 μL, 0.76 mmol), 
DMF (14 μL, 0.18 mmol), NEt3 (163 μL, 1.17 mmol), with DCM (6.0 mL) as solvent. 
Workup and chromatographic purification (hexane / EtOAc 1:0 → 9:1) afforded the title 
compound as a viscous yellow oil (0.200 g, 72%).  
1H NMR (500 MHz, CDCl3): δ 7.28–7.23 (m, 1 H), 6.99–6.94 (m, 2 H), 6.91–6.87 (m, 1 
H), 6.74 (dd, J = 15.8, 1.3 Hz, 1 H), 6.29 (dt, J = 15.8, 6.7 Hz, 1 H), 4.99 (dd, J = 6.7, 
1.2 Hz, 2 H), 3.60 (t, J = 5.2 Hz, 4 H), 3.16 (t, J = 5.2 Hz, 4 H), 1.50 (s, 9 H).  
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13C{1H} NMR (126 MHz, CDCl3): δ 159.6 (t, J = 31.4 Hz), 154.9, 151.8, 137.4, 136.6, 
129.7, 120.4, 119.0, 117.2, 115.2, 108.9 (t, J = 314.4 Hz), 80.1, 68.9, 49.5, 44.1 (br s), 
43.2 (br s), 28.6.  
19F NMR (376 MHz, CDCl3): δ –61.62 (s, 2 F). 
IR (film): 2976, 2930, 2858, 2822, 1774, 1691, 1597, 1420, 1286, 1240, 1167, 1126, 
945 cm–1.  
HRMS (ESI+): exact mass calculated for [M+H]+ (C20H26BrF2N2O4) requires m/z 




General Procedure D was followed using 2.1k (95.1 mg, 0.200 mmol), CuI (3.8 mg, 
0.020 mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 
0.050 mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, 
the reaction was heated at 50 °C for 8 h. Workup and chromatographic purification 
(pentane / Et2O 9:1) afforded the title compound as a yellow oil (43.0 mg, 58%).  
1H NMR (500 MHz, CDCl3): δ 7.24 (t, J = 8.0 Hz, 1 H), 6.96–6.90 (m, 2 H), 6.86 (ddd, J 
= 8.3, 2.3, 1.1 Hz, 1 H), 6.58 (d, J = 15.9 Hz, 1 H), 6.09 (dt, J = 15.8, 7.3 Hz, 1 H), 3.59 
(t, J = 5.3 Hz, 4 H), 3.15 (t, J = 5.3 Hz, 4 H), 2.99 (qdd, J = 10.6, 7.2, 1.4 Hz, 2 H), 1.50 
(s, 9 H).  
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13C{1H} NMR (126 MHz, CDCl3): δ 154.9, 151.8, 137.3, 137.1, 129.6, 126.0 (q, J = 
276.7 Hz), 118.7, 117.4 (q, J = 3.6 Hz), 116.7, 114.9, 80.1, 49.6, 44.1 (br s), 43.3 (br s), 
37.8 (q, J = 29.9 Hz), 28.6.  
19F NMR (376 MHz, CDCl3): δ –67.20 (t, J = 10.6 Hz, 3 F).  
IR (film): 2976, 2928, 2858, 2822, 1697, 1597, 1423, 1366, 1248. 1170, 1134, 968, 
870, 773 cm–1.  
HRMS (ESI+): exact mass calculated for [M+H]+ (C19H26F3N2O2) requires m/z 371.1946, 
found m/z 371.1941 (1.3 ppm).  
 
Experimental procedure for compounds in Scheme 2.9: 
 
(E)-3-Phenylbut-2-en-1-ol 
General Procedure B was followed using ethyl trans-β-methylcinnamate (1.83 mL, 10.0 
mmol), DIBAL (1.0 M in PhMe, 21.0 mL, 21.0 mmol), with DCM (7.0 mL) as solvent. 
Workup and filtration through a pad of silica (Et2O) afforded the title compound as a 
faint tan oil (1.16 g, 79%).  
1H NMR (500 MHz, CDCl3): δ 7.45–7.40 (m, 2 H), 7.37–7.32 (m, 2 H), 7.30–7.26 (m, 1 
H), 5.99 (tq, J = 6.8, 1.3 Hz, 1 H), 4.38 (d, J = 6.7 Hz, 2 H), 2.11–2.10 (m, 3 H), 1.58–






General Procedure C was followed using 2.3a.1 (0.440 g, 2.97 mmol), 
bromodifluoroacetic acid (730 mg, 4.2 mmol), oxalyl chloride (0.33 mL, 3.9 mmol), DMF 
(69 μL, 0.89 mmol), NEt3 (0.83 mL, 6.0 mmol), with DCM (15 mL) as solvent. Workup 
and chromatographic purification (hexane / EtOAc 1:0 → 19:1) afforded the title 
compound as a colorless oil (813 mg, 90%). 
1H NMR (400 MHz, CDCl3): δ 7.46–7.42 (m, 2 H), 7.40–7.31 (m, 3 H), 6.00–5.91 (tq, J 
= 7.22, 1.37 Hz, 1 H), 5.08 (d, J = 7.2 Hz, 2 H), 2.24–2.18 (m, 3 H).  
13C{1H} NMR (CDCl3, 126 MHz): δ 160.0, 159.8, 159.5, 143.6, 142.1, 128.6, 128.2, 
126.1, 118.6, 111.5, 109.0, 106.5, 65.3, 16.6. 
19F NMR (376 MHz, CDCl3): δ –60.89 (s, 2 F).  
IR (film): 3034, 2995, 1772, 1643, 1495, 1445, 1381, 1339, 1294, 1169, 1128, 947, 
825, 808, 758, 696 cm–1. 




General Procedure D was followed using 2.3a (61.0 mg, 0.200 mmol), CuI (3.8 mg, 
0.020 mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 
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0.050 mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, 
the reaction was heated at 50 °C for 8 h. Workup and chromatographic purification 
(pentane) afforded the title compound as a colorless oil (21.9 mg, 55%).  
1H NMR (500 MHz, CDCl3): δ 7.44–7.28 (m, 5 H), 5.74 (tq, J = 7.3, 1.4 Hz, 1 H), 3.08–
2.98 (m, 2 H), 2.10 (s, 3 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 142.9, 141.5, 128.5, 127.7, 126.5 (q, J = 276.7 Hz), 
126.0, 115.2 (q, J = 3.4 Hz), 33.8 (q, J = 29.6 Hz), 16.5.  
19F NMR (376 MHz, CDCl3): δ –67.37 (t, J = 9.9 Hz, 3 F).  
IR (film): 3082, 3057, 2928, 2858, 1447, 1364, 1339, 1288, 1254, 1136, 1068, 912, 
872, 758, 696 cm–1.  




General Procedure C was followed using trans-2-methyl-3-phenyl-2-propen-1-ol (432 
μL, 3.00 mmol), bromodifluoroacetic acid (735 mg, 4.20 mmol), oxalyl chloride (0.330 
mL, 3.90 mmol), DMF (0.070 mL, 0.90 mmol), NEt3 (836 μL, 6.00 mmol), with DCM (15 
mL) as solvent. Workup and chromatographic purification (hexane / EtOAc 1:0 → 49:1) 
afforded the title compound as a light yellow oil (853 mg, 93%).  
1H NMR (500 MHz, CDCl3): δ 7.42–7.36 (m, 2 H), 7.34–7.29 (m, 3 H), 6.68–6.64 (m, 1 
H), 4.93 (d, J = 1.1 Hz, 2 H), 1.98 (d, J = 1.5 Hz, 3 H).  
92 
 
13C{1H} NMR (126 MHz, CDCl3): δ 159.6 (t, J = 31.3 Hz), 136.5, 130.9, 130.6, 129.1, 
128.4, 127.4, 108.9 (t, J = 314.5 Hz), 74.0, 15.5.  
19F NMR (376 MHz, CDCl3): δ –61.61 (2 F).  
IR (film): 1772, 1645, 1491, 1447, 1373, 1296, 1167, 1124, 967, 914 cm–1.  




General Procedure D was followed using 2.3b (61.0 mg, 0.200 mmol), CuI (3.8 mg, 
0.020 mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 
0.050 mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, 
the reaction was heated at 50 °C for 8 h. Workup and chromatographic purification 
(pentane) afforded the title compound as a colorless oil (29.4 mg, 74%).  
1H NMR (400 MHz, CDCl3): δ 7.40–7.33 (m, 2 H), 7.30–7.23 (m, 3 H), 6.49 (s, 1 H), 
2.94 (q, J = 10.9 Hz, 2 H), 1.98 (s, 3 H).  









An oven-dried 3 neck 100 mL round-bottom flask was equipped with a reflux condenser, 
liquid addition funnel, and a glass stopper. Mg turnings (175 mg, 7.19 mmol) were 
added to the flask, then the system was evacuated and backfilled with N2 three times. 
THF (15 mL) was added as solvent, and then one bead of I2 was added to the mixture. 
The mixture was vigorously stirred for 1 h. A solution of 2-bromonaphthalene (1.49 g, 
7.19 mmol in 15 mL THF) was added dropwise over 30 min. The reaction was refluxed 
until 2-bromonaphthalene was determined to be consumed by GC analysis (4 h). The 
reaction was cooled to 21 °C then CuI (65 mg, 0.34 mmol) was added to the mixture. 
Propargyl alcohol (0.20 mL, 3.4 mmol) was injected dropwise and the mixture was 
stirred at 21 °C for 30 min. The reaction was refluxed for 12 h, then cooled to 21 °C. 
NH4Cl (aq) (20 mL) was added and the mixture was stirred for 30 min. The reaction was 
diluted with Et2O (25 mL) and the phases were separated. The aqueous layer was 
extracted with Et2O (2 x 25 mL) then the combined organic layers were washed with 
brine (50 mL). The organic solution was dried over MgSO4, filtered, and the solvent was 
removed in vacuo. Column chromatography (hexanes / EtOAc 1:0 → 4:1) afforded the 
title compound as a tan solid (248 mg, 39%).  
m.p.: 90–92 °C.  
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1H NMR (400 MHz, CDCl3): δ 7.92–7.88 (m, 1 H), 7.88–7.80 (m, 3 H), 7.63 (dd, J = 8.6, 
1.9 Hz, 1 H), 7.52–7.45 (m, 2 H), 5.66–5.61 (m, 1 H), 5.49–5.45 (m, 1 H), 4.72–4.65 (m, 




General Procedure C was followed using 2.3c.1 (111 mg, 0.603 mmol), 
bromodifluoroacetic acid (148 mg, 0.84 mmol), oxalyl chloride (66 μL, 0.78 mmol), DMF 
(14 μL, 0.18 mmol), NEt3 (0.17 mL, 1.21 mmol), with DCM (6.0 mL) as solvent. Workup 
and chromatographic purification (hexanes / EtOAc 1:0 → 19:1) afforded the title 
compound as a colorless oil (178 mg, 87%).  
1H NMR (500 MHz, CDCl3): δ 7.89–7.82 (m, 4 H), 7.63–7.57 (m, 1 H), 7.54–7.47 (m, 2 
H), 5.82 (s, 1 H), 5.62–5.55 (m, 1 H), 5.38–5.34 (m, 2 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 159.5 (t, J = 31.6 Hz), 140.6, 134.5, 133.4, 133.3, 
128.5, 128.4, 127.8, 126.7, 126.6, 125.1, 124.0, 117.7, 108.7 (t, J = 314.3 Hz), 69.3.  
19F NMR (376 MHz, CDCl3): δ –62.01 (s, 2 F).  
IR (film): 3057, 2961, 2930, 1776, 1628, 1597, 1506, 1443, 1366, 1292, 1169, 1124, 
984, 953, 937, 858, 818, 752, 709, 602 cm–1.   






General Procedure D was followed using 2.3c (68.2 mg, 0.200 mmol), CuI (3.8 mg, 
0.020 mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 
0.050 mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, 
the reaction was heated at 50 °C for 8 h. Workup and chromatographic purification 
(pentane) afforded the title compound as a colorless oil (26.6 mg, 56%).  
1H NMR (500 MHz, CDCl3): δ 7.90–7.81 (m, 4 H), 7.57 (dd, J = 8.6, 1.8 Hz, 1 H), 7.54–
7.46 (m, 2 H), 5.76 (s, 1 H), 5.49 (s, 1 H), 3.42 (qd, J = 10.5, 1.0 Hz, 2 H).  




Triethyl phosphonoacetate (1.39 mL, 7.00 mmol) was dissolved in THF (75 mL). The 
solution was cooled to –78 °C, then nBuLi (1.8 M in hexanes, 3.9 mL, 7.0 mmol) was 
added dropwise. The reaction was stirred at –78 °C for 45 min, then 2-
phenylpropionaldehyde (1.03 mL, 7.70 mmol) was injected dropwise. The reaction was 
allowed to warm to RT and stirring continued for 5 h. NH4Cl (aq) (40 mL) was added and 
the aqueous layer was extracted with Et2O (3 x 40 mL). The combined organic extracts 
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were washed with brine (50 mL). The solution was dried over MgSO4, filtered, and the 
solvent was removed in vacuo. Column chromatography (hexanes / Et2O 1:0 → 19:1) 
afforded the title compound as a colorless oil (137 mg, 10%).  
1H NMR (500 MHz, CDCl3): δ 7.36–7.31 (m, 2 H), 7.26–7.19 (m, 3 H), 7.12 (dd, J = 
15.7, 6.7 Hz, 1 H), 5.81 (dd, J = 15.6, 1.6 Hz, 1 H), 4.19 (q, J = 7.1 Hz, 2 H), 3.63 (pd, J 




General Procedure B was followed using 2.3d.2 (140 mg, 0.67 mmol), DIBAL (1.0 M in 
PhMe, 1.4 mL, 1.4 mmol), with DCM (0.010 L) as solvent. Workup and filtration through 
a pad of silica (Et2O) afforded the title compound as a colorless solid (89 mg, 82%).  
1H NMR (400 MHz, CDCl3): δ 7.35–7.29 (m, 2 H), 7.25–7.18 (m, 3 H), 5.89 (ddt, J = 
15.4, 6.7, 1.4 Hz, 1 H), 5.68 (dtd, J = 15.4, 5.8, 1.4 Hz, 1 H), 4.18–4.09 (m, 2 H), 3.50 




General Procedure C was followed using 2.3d.1 (60 mg, 0.37 mmol), 
bromodifluoroacetic acid (91 mg, 0.52 mmol), oxalyl chloride (41 μL, 0.48 mmol), DMF 
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(8.6 μL, 0.11 mmol), NEt3 (0.10 mL, 0.74 mmol), with DCM (5.0 mL) as solvent. Workup 
and chromatographic purification (hexanes / EtOAc 1:0 → 49:1) afforded the title 
compound as a colorless oil (98 mg, 83%).  
1H NMR (500 MHz, CDCl3): δ 7.33 (dd, J = 8.3, 6.9 Hz, 2 H), 7.25–7.18 (m, 3 H), 6.11 
(ddt, J = 15.3, 6.5, 1.2 Hz, 1 H), 5.64 (dtd, J = 15.1, 6.6, 1.5 Hz, 1 H), 4.82 (d, J = 6.7 
Hz, 2 H), 3.54 (p, J = 7.0 Hz, 1 H), 1.40 (d, J = 7.0 Hz, 3 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 159.6 (t, J = 31.3 Hz), 144.6, 143.5, 128.7, 127.3, 
126.6, 120.5, 108.9 (t, J = 314.5 Hz), 68.8, 42.1, 20.9.  
19F NMR (376 MHz, CDCl3): δ –61.72 (s, 2 F).  
IR (film): 3061, 3028, 2968, 2932, 2874, 1774, 1493, 1452, 1375, 1294, 1169, 1126, 
947, 825, 804, 760, 700 cm–1.  




General Procedure D was followed using 2.3d (63.8 mg, 0.200 mmol), CuI (3.8 mg, 
0.020 mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 
0.050 mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, 
the reaction was heated at 50 °C for 8 h. Workup and chromatographic purification 
(pentane) afforded the title compound as a colorless oil (33.5 mg, 78%). 
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1H NMR (400 MHz, CDCl3): δ 7.36–7.29 (m, 2 H), 7.26–7.19 (m, 3 H), 5.90 (dd, J = 
15.4, 6.6 Hz, 1 H), 5.44 (dtd, J = 15.5, 7.1, 1.5 Hz, 1 H), 3.51 (p, J = 7.2 Hz, 1 H), 2.81 
(qdt, J = 10.8, 7.1, 1.0 Hz, 2 H), 1.38 (d, J = 7.1 Hz, 3 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 145.1, 142.8, 128.7, 127.3, 126.5, 126.2 (q, J = 
276.5 Hz), 116.7 (q, J = 3.6 Hz), 42.3, 37.5 (q, J = 29.6 Hz), 21.1.  
19F NMR (376 MHz, CDCl3): δ –67.57 (t, J = 10.7 Hz).  
IR (film): 3061, 3028, 2968, 2932, 2876, 1493, 1452, 1431, 1364, 1258, 1138, 1080, 
1061, 970, 760, 700 cm–1.  




A 2-neck 250 mL round-bottom flask, reflux condenser, and flushing adapter were oven-
dried and cooled under N2. Grubbs 1
st generation catalyst (597 mg, 0.725 mmol) was 
added to the flask. The system was evacuated and backfilled with N2 three times. DCM 
(75 mL) was added as solvent. cis-1,4-diacetoxy-2-butene (2.31 mL, 14.5 mmol) was 
injected and the mixture was stirred for 15 min at 21 ° C. 9-decen-1-ol (1.30 mL, 7.29 
mmol) was injected then the reaction was refluxed for 12 h. The solvent was removed in 
vacuo and the crude material was loaded onto silica. Column chromatography (hexanes 
/ EtOAc 1:0 → 7:3) afforded the title compound as a brown liquid (1.20 g, 72%). 
Analysis of the 1H NMR spectrum revealed an E/Z ratio of 79:21.  
99 
 
1H NMR (400 MHz, CDCl3): δ 5.82–5.73 (dtt, J = 15.3, 6.7, 1.1 Hz, 1 H), 5.69–5.49 (m, 
1 H), 4.65–4.60 (m, 2 H : minor diastereomer), 4.54–4.49 (m, 2 H : major diastereomer), 
3.71–3.59 (m, 2 H), 2.07 (m, 5 H), 1.62–1.52 (m, 2 H), 1.44–1.22 (m, 11 H).  
13C{1H} NMR (126 MHz, CDCl3): Major diastereomer: δ 171.1, 136.8, 123.8, 65.5, 63.2, 
32.9, 32.4, 29.5, 29.5, 29.2, 29.0, 25.8, 21.2. Minor diastereomer: δ 171.2, 135.6, 123.4, 
60.6, 27.6 (remaining peaks overlap with major diastereomer).  
IR (film): 3375, 2926, 2854, 1740, 1458, 1379, 1232, 1024, 968 cm–1.  
HRMS (ESI+): exact mass calculated for [M+Na]+ (C13H24O3Na) requires m/z 251.1623, 




Compound 2.e3.2 (217 mg, 0.949 mmol) and 4-(dimethylamino)pyridine (12 mg, 0.10 
mmol) were added to a 25 mL round bottom flask. A bubbler was attached and the 
system was flushed with N2. DCM (0.010 L) and N,N-diisopropylethylamine (0.50 mL, 
2.9 mmol) were injected. The flask was placed in a 0 °C ice bath and allowed to cool. 
Pivaloyl chloride (0.23 mL, 1.9 mmol) was injected and the reaction was stirred for 15 
min. The ice bath was removed and stirring continued for 2 h. MeOH was injected and 
the solution was stirred for 30 min. The solvent was removed in vacuo, then the crude 
oil was dissolved in Et2O (20 mL). The solution was washed with NH4Cl (aq) (10 mL), 
H2O (10 mL), and brine (10 mL). The organic phase was dried over MgSO4, filtered, and 
the solvent was removed in vacuo. The resultant oil was dissolved in MeOH (0.010 L), 
then K2CO3 (13 mg, 0.095 mmol) was added to the flask. The reaction was stirred at 21 
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°C for 12 h. EtOAc (30 mL) and H2O (30 mL) were added and the phases were 
separated. The aqueous layer was extracted with EtOAc (2 x 30 mL). The organic 
layers were combined and washed with brine (45 mL). The solution was dried over 
MgSO4, filtered and the solvent was removed in vacuo. Column chromatography 
(hexane / EtOAc 1:0 → 3:1) afforded the title compound as a tan oil (173 mg, 67%). 
Analysis of the 1H NMR spectrum revealed an E/Z ratio of 78:22.  
1H NMR (500 MHz, CDCl3): δ 5.75–5.51 (m, 2 H), 4.22–4.18 (m, 1 H, minor 
diastereomer), 4.12–4.07 (m, 1 H, major diastereomer), 4.05 (t, J = 6.7 Hz, 2 H), 2.11–
2.01 (m, 2 H), 1.66–1.59 (m, 2 H), 1.41–1.23 (m, 11 H), 1.20 (s, 9 H).  
13C{1H} NMR (126 MHz, CDCl3): Major diastereomer: δ 178.8, 133.6, 129.0, 64.6, 64.0, 
38.9, 32.3, 29.5, 29.3, 29.2, 29.2, 28.7, 27.4, 26.0. Minor diastereomer: δ 133.3, 128.5, 
58.8, 29.7, 27.5 (remaining peaks overlap with major diastereomer).  
IR (film): 3435, 2928, 2854, 1728, 1479, 1285, 1157, 970 cm–1.  
HRMS (ESI+): exact mass calculated for [M+Na]+ (C16H30O3Na) requires m/z 293.2093, 




General Procedure C was followed using 2.e3.1 (153 mg, 0.566 mmol), 
bromodifluoroacetic acid (139 mg, 0.792 mmol), oxalyl chloride (62 μL, 0.74 mmol), 
DMF (13 μL, 0.17 mmol), NEt3 (158 μL, 1.13 mmol), with DCM (6.0 mL) as solvent. 
Workup and chromatographic purification (hexane / EtOAc 49:1) afforded the title 
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compound as a colorless oil (162 mg, 67%). Analysis of the 1H NMR spectrum revealed 
an E/Z ratio of 78:22.  
1H NMR (500 MHz, CDCl3): δ 5.92 (dtt, J = 14.9, 6.8, 1.1 Hz, 1 H, major diastereomer), 
5.80 (dtt, J = 10.9, 7.6, 1.1 Hz, 1 H, minor diastereomer), 5.65–5.56 (m, 1 H), 4.89 (dd, J 
= 7.2, 1.1 Hz, 2 H, minor diastereomer), 4.78 (dd, J = 6.7, 1.0 Hz, 2 H, major 
diastereomer), 4.05 (t, J = 6.6 Hz, 2 H), 2.15 (qd, J = 7.5, 1.6 Hz, 2 H, minor 
diastereomer), 2.09 (qd, J = 7.1, 1.5 Hz, 2 H, major diastereomer), 1.66–1.58 (m, 2 H), 
1.45–1.27 (m, 10 H), 1.20 (s, 9 H).  
13C{1H} NMR (126 MHz, CDCl3): Major diastereomer: δ 178.8, 159.6 (t, J = 31.3 Hz), 
139.9, 121.5, 109.0 (t, J = 314.4 Hz), 69.1, 64.6, 38.9, 32.4, 29.4, 29.3, 29.3, 29.1, 28.7, 
27.4, 26.0. Minor diastereomer: δ 138.6, 120.8, 64.0, 29.5, 29.4, 29.2, 27.8 (remaining 
peaks overlap with major diastereomer).  
19F NMR (376 MHz, CDCl3): δ –61.60 (s, 2 F). IR (film) 2930, 2856, 1776, 1728, 1479, 
1288, 1163, 1126, 947 cm–1.  
HRMS (ESI+): exact mass calculated for [M+Na]+ (C18H29BrF2O4Na) requires m/z 




General Procedure D was followed using 2.e3 (85.5 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 0.050 
mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the 
reaction was heated at 50 °C for 18 h. Workup and chromatographic purification 
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(pentane / Et2O 1:0 →  39:1) afforded the title compound as a light yellow oil (49.0 mg, 
76%).  
1H NMR (500 MHz, CDCl3): δ 5.70 (dt, J = 15.4, 6.8 Hz, 1 H), 5.37 (dtt, J = 15.6, 7.1, 
1.5 Hz, 1 H), 4.05 (t, J = 6.6 Hz, 2 H), 2.77 (qd, J = 10.7, 7.6 Hz, 2 H), 2.05 (qd, J = 7.3, 
1.3 Hz, 2 H), 1.62 (p, J = 6.7 Hz, 2 H), 1.42–1.23 (m, 10 H), 1.20 (s, 9 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 178.8, 138.6, 126.2 (q, J = 276.5 Hz), 117.6 (q, J = 
3.5 Hz), 64.6, 38.9, 37.5 (q, J = 29.5 Hz), 32.6, 29.4, 29.3, 29.1, 29.0, 28.7, 27.4, 26.0.  
19F NMR (376 MHz, CDCl3): δ –66.62 (t, J = 11.2 Hz, 3 F : minor diastereomer), –67.11 
(t, J = 11.1 Hz, 3 F : major diastereomer).  
IR (film): 2930, 2856, 1730, 1481, 1460, 1366, 1285, 1271, 1250, 1155, 1138, 970 cm–
1. 




Compound 2.e3.2 (215 mg, 0.942 mmol), phthalimide (207 mg, 1.41 mmol), and PPh3 
(371 mg, 1.41 mmol) were added to a 25 mL round bottom flask. The system was 
evacuated and backfilled with N2 three times. THF (0.010 L) was added as solvent. The 
flask was placed in a 0 °C ice bath and allowed to cool. Diisopropyl azodicarboxylate 
(0.28 mL, 1.4 mmol) was injected dropwise and the reaction was stirred for 15 min. The 
cold bath was removed and the reaction was stirred at 21 °C for 2 h. The solvent was 
removed in vacuo. Column chromatography (hexanes / EtOAc 1:0 → 3:1) afforded a 
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brown oil. The material was dissolved in MeOH, then K2CO3 was added. The reaction 
was stirred for 12 h at 21 °C. EtOAc (30 mL) and H2O (30 mL) were added and the 
phases were separated. The aqueous layer was extracted with EtOAc (2 x 30 mL). The 
organic layers were combined and washed with brine (45 mL). The solution was dried 
over MgSO4, filtered and the solvent was removed in vacuo. Column chromatography 
(hexane / EtOAc 1:0 → 3:2) afforded the title compound as an amorphous tan solid (249 
mg, 84%). Analysis of the 1H NMR spectrum revealed an E/Z ratio of 80:20.  
1H NMR (500 MHz, CDCl3): δ 7.85 (dd, J = 5.5, 3.1 Hz, 2 H), 7.71 (dd, J = 5.5, 3.0 Hz, 2 
H), 5.73–5.49 (m, 2 H), 4.20 (d, J = 6.7 Hz, 2 H : minor diastereomer), 4.09 (d, J = 5.3 
Hz, 2 H : major diastereomer), 3.70–3.66 (m, 2 H), 2.10–1.99 (m, 2 H), 1.71–1.63 (m, 2 
H), 1.40–1.25 (m, 11 H).  
13C{1H} NMR (126 MHz, CDCl3): Major diastereomer: δ 168.6, 134.0, 133.6, 132.3, 
129.0, 123.3, 64.0, 38.2, 32.3, 29.4, 29.2, 29.2, 29.1, 28.7, 26.9. Minor diastereomer: δ 
133.3, 128.5, 58.8, 29.6, 29.2, 27.5 (remaining peaks overlap with major diastereomer).  
IR (film): 3437, 2926, 2854, 1772, 1711, 1466, 1437, 1396, 1369, 1057, 1003, 970, 719 
cm–1.  
HRMS (ESI+): exact mass calculated for [M+Na]+ (C19H25O3Na) requires m/z 338.1732, 









General Procedure C was followed using 2.3f.1 (230 mg, 0.73 mmol), 
bromodifluoroacetic acid (180 mg, 1.0 mmol), oxalyl chloride (81 μL, 0.96 mmol), DMF 
(17 μL, 0.22 mmol), NEt3 (0.20 mL, 1.5 mmol), with DCM (7.0 mL) as solvent. Workup 
and chromatographic purification (hexane / EtOAc 9:1) afforded the title compound as 
an amorphous tan solid (289 mg, 83%). Analysis of the 1H NMR spectrum revealed an 
E/Z ratio of 79:21.  
1H NMR (500 MHz, CDCl3): δ 7.85 (dd, J = 5.4, 3.0 Hz, 2 H), 7.72 (dd, J = 5.4, 3.0 Hz, 2 
H), 5.91 (dtt, J = 15.3, 6.6, 1.1 Hz, 1 H, major diastereomer), 5.79 (dtt, J = 10.9, 7.6, 1.1 
Hz, 1 H, minor diastereomer), 5.63–5.55 (m, 1 H), 4.88 (dd, J = 7.2, 1.1 Hz, 2 H, minor 
diastereomer), 4.77 (dd, J = 6.7, 1.1 Hz, 2 H, major diastereomer), 3.68 (t, J = 7.3 Hz, 2 
H), 2.14 (qd, J = 7.5, 1.5 Hz, 2 H, minor diastereomer), 2.10–2.05 (m, 2 H, major 
diastereomer), 1.67 (p, J = 7.6 Hz, 2 H), 1.42–1.25 (m, 10 H).  
13C{1H} NMR (126 MHz, CDCl3): Major diastereomer: δ 168.6, 159.6 (t, J = 31.2 Hz), 
139.9, 134.0, 132.3, 123.3, 121.5, 109.0 (t, J = 314.4 Hz), 69.1, 38.2, 32.3, 29.4, 29.21, 
29.21, 29.1, 28.7, 26.9. Minor diastereomer: δ 138.6, 120.8, 64.0, 29.4, 29.3, 27.8.  
19F NMR (376 MHz, CDCl3): δ –61.62 (s, 2 F).  
IR (film): 2930, 2854, 1774, 1713, 1396, 1294, 1169, 1124, 945, 719 cm–1.  
HRMS (ESI+): exact mass calculated for [M+Na]+ (C21 H24BrF2NO4Na) requires m/z 






General Procedure D was followed using 2.3f (94.5 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 0.050 
mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the 
reaction was heated at 50 °C for 18 h. Workup and chromatographic purification 
(hexanes / EtOAc 1:0 →  9:1) afforded the title compound as a light yellow oil (62.3 mg, 
85%). Analysis of the 19F NMR spectrum revealed an E/Z ratio of 97:3.  
1H NMR (500 MHz, CDCl3): δ 7.87–7.82 (m, 2 H), 7.74–7.69 (m, 2 H), 5.68 (dt, J = 
15.3, 6.8 Hz, 1 H), 5.36 (dtt, J = 15.5, 7.1, 1.5 Hz, 1 H), 3.70–3.66 (m, 2 H), 2.76 (qdd, J 
= 10.8, 7.1, 1.2 Hz, 2 H), 2.08–1.99 (m, 2 H), 1.67 (p, J = 7.3 Hz, 2 H), 1.41–1.23 (m, 10 
H).  
13C{1H} NMR (126 MHz, CDCl3): δ 168.6, 138.6, 134.0, 132.3, 126.2 (q, J = 276.5 Hz), 
123.3, 117.6 (q, J = 3.6 Hz), 38.2, 37.5 (q, J = 29.4 Hz), 32.6, 29.4, 29.2, 29.1, 29.0, 
28.7, 26.9.  
19F NMR (376 MHz, CDCl3): δ –67.23 (t, J = 10.9 Hz, 3 F : minor diastereomer), –67.73 
(t, J = 10.8 Hz, 3 F : major diastereomer).  
IR (film): 2928, 2854, 1772, 1715, 1468, 1437, 1396, 1369, 1250, 1134, 1063, 970, 719 
cm–1.  
HRMS (ESI+): exact mass calculated for [M+H]+ (C20H25F3NO2) requires m/z 368.1837, 






General Procedure C was followed using cis-4-benzyloxy-2-buten-1-ol (0.84 mL, 5.0 
mmol), bromodifluoroacetic acid (1.22 g, 7.00 mmol), oxalyl chloride (0.55 mL, 6.5 
mmol), DMF (0.12 mL, 1.5 mmol), NEt3 (1.39 mL, 10.0 mmol), with DCM (35 mL) as 
solvent. Workup and chromatographic purification (hexane / EtOAc 19:1) afforded the 
title compound as a colorless oil (1.17 g, 70%).  
1H NMR (400 MHz, CDCl3): δ 7.41–7.29 (m, 5 H), 5.96 (dtt, J = 11.2, 6.1, 1.3 Hz, 1 H), 
5.80–5.71 (m, 1 H), 4.92 (d, J = 6.9 Hz, 2 H), 4.55 (s, 2 H), 4.19–4.16 (m, 2 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 159.5 (t, J = 31.5 Hz), 137.9, 133.4, 128.6, 128.0, 
128.0, 124.0, 108.8 (t, J = 314.4 Hz), 72.8, 65.8, 64.0.  
19F NMR (376 MHz, CDCl3): δ –61.75 (s, 2 F).  
IR (film): 3065, 3032, 2924, 2858, 1774, 1497, 1454, 1366, 1296, 1167, 1130, 949, 
808, 737, 698, 604 cm–1.  




General Procedure D was followed using 2.3g (94.5 mg, 0.20 mmol), CuI (3.8 mg, 
0.020 mmol), DMEDA (2.2 μL, 0.020 mmol), sodium bromodifluoroacetate (9.8 mg, 
0.050 mmol), KF (23 mg, 0.40 mmol), and DMF (0.20 mL) as solvent. After activation, 
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the reaction was heated at 50 °C for 18 h. Workup and chromatographic purification 
(hexanes / EtOAc 1:0 → 9:1) afforded the title compound as a light yellow oil (62.3 mg, 
85%). Analysis of the 19F NMR spectrum revealed an E/Z ratio of 97:3. 
1H NMR (500 MHz, CDCl3): δ 7.40–7.28 (m, 5 H), 5.87 (dt, J = 15.5, 5.7 Hz, 1 H), 5.70 
(dtt, J = 15.6, 7.1, 1.5 Hz, 1 H), 4.53 (s, 2 H), 4.05–4.03 (m, 2 H), 2.91–2.81 (m, 2 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 138.1, 134.2, 128.6, 127.9, 127.9, 125.9 (q, J = 
276.6 Hz), 120.9 (q, J = 3.5 Hz), 72.5, 70.0, 37.3 (q, J = 29.8 Hz).  
19F NMR (376 MHz, CDCl3): δ –67.15 (t, J = 10.8 Hz, 3 F : minor diastereomer), –67.38 
(t, J = 10.7 Hz, 3 F : major diastereomer).  
IR (film): 3032, 2934, 2854, 1637, 1456, 1354, 1298, 1252, 1136, 1103, 1059, 970 cm–
1.  
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Chapter 3: Copper-Catalyzed Decarboxylative Trifluoromethylation of  
Benzylic Bromodifluoroacetates 
3.1. Introduction to the synthesis of benzylic trifluoromethanes. 
The trifluoromethyl group (CF3) is commonly utilized in medicinal chemistry, 
agricultural chemistry and materials sciences to modulate the physical and biological 
properties of molecules.1,2 Among trifluoromethyl-containing substructures, 
trifluoroethyl(hetero)arenes represent an important motif, with over 30,000 
trifluoroethyl(hetero)arenes possessing documented biological activity or being 
precursors to bioactive compounds.3  Thus, general strategies for preparing this 
substructure are important for accessing biological probes and therapeutics.  
 While classic trifluoromethylation methods are suitable for the synthesis of 
trifluoroethylarenes (e.g. 4-step oxidation/trifluoromethylation/deoxygenation; Chapter 
1.5), unique approaches for the creation of this motif have been developed that utilize 
the proximal aryl group. Specifically, three general strategies for creating 
trifluoroethylarenes include: 1) trifluoroethylation of arenes (Scheme 3.1, eq 1); 2) 
trifluoromethylation of benzylic species (eq 2); and 3) hydrofluorination of 
difluorostyrenes (eq 3).  




Arenes are convenient precursors to trifluoroethylarene, and approaches to affect 
this transformation include: 1) trifluoroethylation of aryl electrophiles (Scheme 3.2A); 2) 
trifluoroethylation of aryl nucleophiles (Scheme 3.2B); and 3) C–H 
activation/trifluoroethylation (Scheme 3.2C). Many of these reactions involved “M–
CH2CF3” species, which were previously thought to be unstable, via decomposition to 
generate MF and difluoroethylene. While “M–CH2CF3” species with high ionic M–C bond 
character rapidly undergo β-fluoride elimination, transition metal “M–CH2CF3” species 
with more covalent M–C bond character are stable intermediates that participate in 
trifluoroethylarylation cross-coupling reactions.4 For example, “Cu–CH2CF3” promoted 
reductive cross-coupling reaction between aryl iodides and 1,1,1-trifluoro-2-iodoethane 
(Scheme 3.2, eq 4).5 In this reaction, a single electron transfer (SET) mechanism may 
form “Cu–CH2CF3”, which then reacted with aryl iodides to generate desired 
trifluoroethylarenes.5b Similarly, “M–CH2CF3” intermediates also promote 
trifluoroethylation reactions between aryl nucleophiles and trifluoroethyl electrophiles 
(eq 5).6 In contrast, an alternative metal-free approach to trifluoroethylation of aryl 
nucleophiles has been developed using 2,2,2-trifluorodiazoethane as a 
trifluoroethylation reagent (eq 6).7  Trifluoroethylation of arenes has also been 
accomplished via C–H functionalization using metal catalysts. C–H 
activation/trifluoroethylation was enabled by amide-based directing groups (eq 7–8)8,9 
and transient directing groups during tandem vinylation/trifluoroethylation of aryl iodides 
(eq 9).10 In addition, other substrate-controlled C–H trifluoroethylations include 
trifluoroethylation of indoles (eq 10)11 and radical C–H trifluoroethylation of 
(hetero)arenes (eq 11).12 
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Scheme 3.2. Methods for the direct conversion of arenes to trifluoroethylarenes. 
 
Aryl aldehydes and ketones have been used as precursors to trifluoroethylarenes 
(Scheme 3.3). One strategy for this transformation involved converting carbonyl groups 
to difluoroalkenes, which have unusual reactivity compared to typical olefins. 
Specifically, the fluorine atoms of difluoroalkenes were highly electron-withdrawing, and 
made the terminal position of the olefin electrophilic (eq 12). Difluorostyrenes were 
particularly reactive, since after nucleophilic attack, they generated benzylically-
stabilized carbanions (eq 12). Finally, trapping of carbanions with electrophiles formed 
trifluoroethylarenes (eq 12). Initially, this concept was realized in a two-step 
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difluoroolefination13/hydrofluorination14 sequence (eq 13). Later, this strategy was 
employed in a one-pot conversion of carbonyls to trifluoroethylarenes (eq 14).15 More 
complex trifluoroethylarenes were generated by Pd-catalyzed fluorination/allylation of 
difluoroalkenes (eq 15).16 An alternative approach for converting carbonyl compounds to 
trifluoroethylarenes involved generation of trifluoroacetophenones, conversion to α-
diazotrifluoromethanes, and Pd-catalyzed reduction to create fluorinated final products 
(eq 16).17 
Scheme 3.3. Conversion of aryl carbonyl compounds to trifluoroethylarenes. 
 
3.2. Nucleophilic trifluoromethylation of benzylic electrophiles.  
A direct strategy for generating trifluoroethylarenes involved trifluoromethylation 
of benzylic electrophiles; however, no general catalytic system could transform a broad 
spectrum of (hetero)benzylic electrophiles. Most systems for benzylic 
trifluoromethylation required either stoichiometric Cu (Scheme 3.4, eq 17),18 or 
exclusively transformed electron-neutral (eq 18)19  or electron-rich substrates (eq 19).20  
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Thus, there was a need for a catalytic system that could transform electron-deficient 
benzylic electrophiles and heterocyclic derivatives into trifluoroethyl(hetero)arenes. 
Herein, we report such a general catalytic system that enabled access to a broad array 
of trifluoroethyl(hetero)arenes (eq 20). Further, we propose a revised mechanism that 
accounts for the expanded functional group tolerance. After the publication of our work, 
a similar strategy for Cu-catalyzed benzylic trifluoromethylation was reported.21 
Scheme 3.4. Trifluoromethylation of Benzylic Electrophiles Typically Requires 
Stoichiometric Copper. 
 
To address the aforementioned gap, we sought to develop a broadly applicable 
catalytic method for converting benzylic electrophiles into trifluoroethyl(hetero)arenes. 
As a starting point for this transformation, we considered Chen’s decarboxylative 
trifluoromethylation of benzyl bromodifluoroacetates using stoichiometric Cu.18f 
Beneficial features of this early system included: 1) facile access to substrates derived 
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from simple benzylic alcohols, which are synthetically accessible and already found in a 
wide variety of synthetic intermediates and building blocks; 2) the formation of just CO2 
and KBr as benign, easily separable by-products. However, this previous transformation 
was not shown to convert a broad spectrum of substrates,18f potentially because the 
proposed mechanism invoked an outer-sphere decarboxylation that generated free –CF3 
(Scheme 3.5).18d–f If generated, this reactive intermediate would react with carbonyl-
based functional groups via 1,2-addition and acidic functional groups via deprotonation, 
which would severely limit the functional group compatibility of the transformation. 
However, we hypothesized that a catalytic inner-sphere decarboxylation might generate 
the critical Cu–CF3 intermediate, which would enable the conversion of substrates 
bearing sensitive carbonyl and acidic functional groups. 
Scheme 3.5. Previously proposed mechanism involves generation of free –CF3. 
 
We hypothesized that the use of ligands could enable Cu-catalyzed benzylic 
trifluoromethylation. Specifically, since benzylic electrophiles are less reactive than 
allylic electrophiles, and unstabilized “Cu–CF3” species decompose rapidly, we aimed to 
identify ligands that stabilized “Cu–CF3” towards degradation. Initially, we tested 
DMEDA, a ligand that promoted Cu-catalyzed allylic trifluoromethylation (Chapter 2). As 
an initial hit, we obtained product formation without catalyst turnover (8% product, 10% 
Cu-cat., Scheme 3.6A), and observed benzylic bromide side-product during GC-MS 
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analysis. We reasoned that bromide, formed from decarboxylation of 
bromodifluoroacetate, reacted with benzylic bromodifluoroacetates to generate benzylic 
bromide side-products or intermediates. We also speculated that decomposition of 
[(DMEDA)Cu–CF3] was more rapid than trifluoromethylation of the benzylic electrophile, 
and that alternate ligands could better stabilize this reactive intermediate. A coworker, 
Dr. Lingui Zhu, extensively screened ligands and conditions, and determined that a 
bulkier ligand, dibenzhydrylethylenediamine (DBHEDA), provided moderate yields of 
trifluoroethylarenes, while suppressing benzylic bromide side-products (Scheme 3.6B). 
Unfortunately, this system still struggled to convert electron-deficient benzylic 
bromodifluoroacetates to trifluoromethanes, and required near-stoichiometric Cu-
loading for difficult substrates.  





 In order to develop a catalyst system that more efficiently converted electron-
deficient benzylic bromodifluoroacetates to trifluoroethylarenes, we reoptimized the 
reaction using 3-phenoxy-benzyl bromodifluoroacetate 3.1l as a substrate (Scheme 
3.7). Previously, MeCN was employed for promoting the reaction that suppressed the 
formation of benzylic bromide side products. We hypothesized that, for this less reactive 
system, a more polar solvent mixture might better stabilize the reaction’s transition 
state. Therefore, we evaluated various solvents and solvent mixtures, and determined 
that a mixture of DMF and MeCN increased both product and benzylic bromide side-
product (Scheme 3.7A). With the change of solvent, we screened various N-, O-, and P-
based ligands. Notably, bulky ligands, such as DBHEDA, bis(methoxy)naphthylene, and 
2-quinolinecarboxaldehyde provided higher yields than ligands with high affinity for Cu, 
such as 1,10-phenanthroline, 8-hydroxyquinoline, and 2,2,6,6-tetramethyl-3,5-
heptanedione (Scheme 3.7B).  While under previously explored reaction conditions, 
ligands appeared to improve benzylic trifluoromethylation, we realized that the revised 
DMF/MeCN solvent combination, bulky ligands might not associate with Cu over the 
course of the reaction. Indeed, control reactions revealed that these bulky ligands 
performed similarly to a ligand-free system. Therefore, we reexamined the mechanism 








Scheme 3.7. Polar solvent mixture more important than ligands in trifluoromethylation of 
electron deficient benzylic bromodifluoroacetates. 
 
We hypothesized that benzylic trifluoromethylation occurs via an analogous 
mechanism to allylic trifluoromethylation, in which oxidative addition (OA) of “Cu–CF3” to 
an allylic electrophile generates a CuIII–π-allyl intermediate, and reductively eliminates 
(RE) to form allylic trifluoromethanes (Scheme 3.8A). While trifluoromethylation of allylic 
electrophiles occurred at 25 °C,22 trifluoromethylation of benzylic electrophiles required 
elevated temperatures (50 to >100 °C).18 Presumably, OA to benzylic electrophiles is 
difficult, since the resulting intermediate is a less stable CuIII–η1-benzyl or partially 
dearomatized CuIII–η3-benzyl intermediate (Scheme 3.8B). Considering potential 
benzylic electrophiles, we observed several benzylic intermediates/side-products 
observed in our reactions. Specifically, benzylic bromide (3.3) and pentafluoropropylaryl 
(3.5) species were generated in many of our reactions, and these products formed in 
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greater yields for benzylic substrates bearing electron-poor aromatic systems (Scheme 
3.8C). Since during OA, positive charge accumulates at the benzylic position, electron-
deficient benzylic electrophiles react more slowly than electron-rich benzylic 
electrophiles. Therefore, for electron-deficient substrates, side-reactions, such as 
decomposition of “Cu–CF3”, became competitive with trifluoromethylation. The formation 
of pentafluoropropylaryl species (3.5) supported this hypothesis, since “Cu–CF3” could 
degrade to generate CuF and “Cu–CF2CF3”, and then react with benzylic electrophiles 
to form 3.5. In addition, benzylic bromides (3.3) could be reaction intermediates that 
persist after “Cu–CF3” fully decomposed.  
Scheme 3.8. Formation of reactive electrophiles is essential for benzylic 
trifluoromethylation. 
 
 We proposed that generating more reactive benzylic electrophiles in situ could 
favor OA and productive trifluoromethylation over decomposition of “Cu–CF3” and 
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generation of undesired side-products. While kinetic data for rates of “Cu–CF3” OA to 
benzylic electrophiles was not known, we assumed the following trend based on 
temperatures required for various benzylic trifluoromethylation reactions: rate of OA for 
Bn–I > Bn–Br > Bn–O2CCF2Br.
18,23 We observed the formation of these more reactive 
benzylic electrophiles (Bn–Br 3.3 and Bn–I 3.4) during reaction optimization and 
speculated that they formed from reactions with Br– (generated upon decarboxylation of 
–O2CCF2Br) and I
– (from CuI; Scheme 3.8D). In order to better understand the role of 
these electrophilic species in the reaction, we conducted a time-course study (Scheme 
3.9) and monitored Bn–O2CCF2Br (red), Bn–Br (green) and Bn–I (pink) intermediates, 
and Bn–CF3 product (blue). We observed three key points from this study: 1) the 
reaction had a 1 h induction period, where substrate decomposed without productive 
formation of intermediates or products;24 2) formation of product did not occur prior to 
generation of BnBr or BnI intermediates; and 3) steady-state concentrations of BnBr 
(ca. 7%) and BnI (ca. 3%) were established after several hours. Based on this 
information, we identified two aims to improve the reaction: 1) overcome the induction 
period by generating active nucleophile or electrophile; and 2) increase the steady-state 
concentration of Bn–I, which would react with “Cu–CF3” faster than Bn–Br or Bn–O-




Scheme 3.9. Substrate decomposed and reactive intermediates slowly formed with 
20% I–-loading. 
 





We reasoned that the induction period in benzylic trifluoromethylation was 
caused by slow conversion of unreactive Bn–O2CCF2Br to reactive Bn–Br or Bn–I 
(Scheme 3.8D). Under the standard reaction conditions (20% CuI, 40% MeO2CCF2Br, 4 
equiv KF), reactive nucleophiles (I– or Br–) did not exist freely in solution. Therefore, a 
reaction to generate free nucleophiles (I– or Br–) was required to initiate 
trifluoromethylation (e.g. CuI + KF  CuF + KI; decomposition of Me– or Bn–O2CCF2Br 
to generate Br–). To overcome this problem, we hypothesized that the addition of 
exogenous I– would facilitate the conversion of Bn–O2CCF2Br to Bn–I. After 
investigating several I– sources and loadings, we determined that the addition of 25% KI 
reduced the induction period from 1 h to <5 min, and improved reaction yields (61% 
yield w/o KI, 74% w/KI, Schemes 3.9–10). The addition of KI also increased the steady-
state of Bn–I (ca. 7%), which promoted productive trifluoromethylation relative to 
decomposition of “Cu–CF3”. We also tested several procedures that assist with the 
generation of “Cu–CF3” at the start of the reaction; however, these methods had no 
benefit on the reaction. Taken together, this data implicates that the generation of 
reactive Bn–I (or less reactive Bn–Br) is the essential step for initiating benzylic 
trifluoromethylation. 
We conducted a series of reaction to identify the key features of the current 
reaction, and highlight improvements to previous systems (Scheme 3.11). Chen’s 
original reaction of 3.1a with stoichiometric CuI provided trifluoroethylarene 3.2a in 71% 
yield;18f however, according to the previous protocol, 3.1a was slowly added to the 
reaction mixture over 2 h, which can be labor intensive and operationally challenging for 
small scale reactions.18f To explore a more user-friendly protocol, we charged the vessel 
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with the full quantity of 3.1a at the outset of the reaction. Using stoichiometric CuI, this 
procedure lowered the yield of 3.2a and formed benzylic bromide 3.3a as a side product 
(entry 1). Adapting conditions that effectively catalyzed the decarboxylative 
trifluoromethylation of allylic bromodifluoroacetates (cat. CuI, DMEDA, NaO2CCF2Br, 
DMF) also provided poor yields of 3.2a (entry 2), along with several side products in 2–
10% yield (Bn–CF2CF3, Bn–I, Bn–F, Bn–Bn, and Bn–O2CCF3). Using a DMF-ligated 
system, and MeO2CCF2Br as an additive,
18d a modest yield of 3.2a was observed, and 
benzylic bromide 3.3a was identified as the major side-product (entry 3). The formation 
of 3.3a could be suppressed by replacement of DMF with MeCN, but this change also 
afforded a less active system (entry 4). Based on these observations, we hypothesized 
that the use of a DMF/MeCN solvent mixture would provide an active system that would 
minimize the formation of 3.3a. Indeed, employment of a 1:1 mixture of DMF/MeCN 
improved the yield of desired product 3.2a, and minimized formation of the benzylic 
bromide side-product 3.3a (entry 5). 
Scheme 3.11. Solvent and I– Critical for Developing a Cu-catalyzed Reaction.a 
 
aReactions were performed with 0.20 mmol of 3.1a, 0.080 mmol of QO2CCF2Br, 0.80 
mmol of KF, 0.20 mL of solvent. Conversion and yield data were determined by GC/FID 
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analysis, and represent the average of a minimum of two independent experiments; b80 
°C; cNo side-products > 2% were detected by GC/FID analysis. 
In addition to the solvent, the presence of I– had a profound effect on the present 
reaction. In previous reports of Cu-mediated trifluoromethylation of benzylic 
bromodifluoroacetates, stoichiometric quantities of I– played an essential role in 
generating the desired products.18f In contrast, a recent Cu-catalyzed 
trifluoromethylation of allylic bromodifluoroacetates could occur in the complete absence 
of I–.25a Thus, for the present system, the loading of I– merited investigation. Addition of 
catalytic KI (45% total I–) provided the highest yield of desired product 3.2a, and 
minimized formation of benzylic bromide 3.3a and other side-products (< 2% by GC and 
19F NMR analysis; entry 6). In contrast, complete removal of I– from the system 
{[Cu(MeCN)4]PF6} decreased the yield of trifluoroethylarene, and generated additional 
bromide 3.3a (entry 7). However, the catalytic activity using [Cu(MeCN)4]PF6 could be 
restored by reintroducing 45% I– to the system (entry 6 vs. entry 8). Further increase of 
the I– content beyond 45% decreased the yield of desired product 3.2a (entry 9). In 
addition, removal of the MeO2CCF2Br additive from the system resulted in decreased 
yield of 3.2a, and increased benzyl bromide 3.3a (entry 10). Ultimately, we selected a 
general system that employed 20% CuI, 25% KI, 40% MeO2CCF2Br and super-
stoichiometric KF in MeCN/DMF (1:1), which minimized the formation of side-products 







Scheme 3.12. Copper-catalyzed decarboxylative trifluoromethylation tolerates important 
functional groups and heterocycles.a,b 
 
a0.25 mmol 3.1b–s, 0.050 mmol CuI, 0.063 mmol KI, 0.10 mmol MeO2CCF2Br, 1.0 
mmol KF, 0.13 mL DMF, 0.13 mL MeCN; bThe yields represent the average of two 
independent experiments; c6.0 mmol scale, single experiment. 
The present Cu-catalyzed reaction tolerated a broad array of useful functional 
groups (Scheme 3.12), including: ethers (3.2b, 3.2e–f, 3.2l), a secondary amide (3.2c), 
a substituted aniline (3.2d), an aryl bromide (3.2e), an alkene (3.2h), a mesylate (3.2j), 
esters (3.2k, 3.2n), and a ketone (3.2m). Substrates bearing (pseudo)ortho substituents 
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provided lower yields of products (3.2e–f, 3.2q–s), and a sterically hindered 2,6-
disubstitued benzylic electrophile afforded product in modest yield (3.2g). The present 
reaction also tolerated heterobenzylic substrates that incorporated N, O, and S atoms 
(3.2o–s). When the reaction was conducted on gram-scale, the yield of the reaction was 
maintained (3.2b), which indicates that this process would be useful for the preparation 
of larger quantities of target trifluoroethyl(hetero)arene compounds. 
3.3. Mechanistic considerations for Cu-catalyzed decarboxylative trifluoromethylation of 
benzylic electrophiles. 
The broad functional group compatibility implicates a metal-centered 
decarboxylation that does not involve solvent-separated reactive intermediates. If free in 
solution, –CF3 (pka = 27 in H2O)
26 would react with sensitive functional groups. However, 
the tolerance of carbonyls (3.2k, 3.2m–o) and an acidic amide (3.2c, pka ca. 13.8 in 
H2O),
27 suggest that free –CF3 must not exist in solution. Additionally, in the reaction of 
3.1m–n, 19F NMR spectra of the crude reaction mixtures did not show products deriving 
from 1,2-addition or addition-elimination processes. Further, the reaction of 3.1a was 
conducted in the presence of 2-naphthaldehyde (1.0 equiv) with minimal loss of yield 
(68%) and no evidence of 1,2-addition of –CF3 to the aldehyde, further discounting the 
existence of free –CF3 in solution.
28 Thus, decarboxylation must be a process that either 
converts Cu–O2CCF2Br to Cu–CF3 directly at the metal-center, or that keeps reactive 
–
CF3 within the solvent cage surrounding Cu. This proposed mechanism likely explains 




Circumstantial evidence implicates that, as previously suggested,18f the present 
reaction may involve in situ conversion of Bn–O2CCF2Br to a Bn–I intermediate prior to 
trifluoromethylation. First, the catalytic system required I– for turnover, and added I– 
facilitated the transformation (vide supra). Second, a steady-state concentration of Bn–I 
persisted throughout the course of the reaction, and the experiment conducted with KI 
showed higher [Bn–I] than the experiment conducted without KI.28 Third, the electronic 
nature of the arene ring noticeably perturbed the reactivity of the substrates, with 
electron-rich substrates (3.2b–f) providing higher yields than electron-neutral (3.2i–l) 
and electron-deficient substrates (3.2j–k). The latter trend may suggest that the benzylic 
position develops cationic character at a transition state of the reaction, which may 
implicate a SN1- or SN2-like step in the mechanism. Based on these pathways, the more 
slowly reacting electron-deficient electrophiles may allow decomposition of Cu–CF3
29 to 
compete with productive trifluoromethylation, thus providing decreased yields for the e–-
deficient substrates. Combined, these data fit a mechanism in which Bn–O2CCF2Br 
converts to Bn–I, prior to undergoing trifluoromethylation (Scheme 3.13). Further, the 
added I– may play an additional role by converting the less reactive Bn–Br side product 
into a more active Bn–I electrophile. Regardless, the loading of I–enabled optimal 
performance of the catalytic system, and for any given substrate, future users may wish 




Scheme 3.13. Iodide plays an essential role in benzylic trifluoromethylation. 
 
To illustrate the utility of this protocol, the Cu-catalyzed decarboxylative 
trifluoromethylation of benzylic bromodifluoroacetates was applied to an intermediate in 
the synthesis of a fluorinated Tebufenpyrad analogue possessing acaricidal activity 
(Scheme 3.14). In a previous report, alcohol 3.4 was transformed into fluorinated 
intermediate 3.9 through a 4-step procedure that employed stoichiometric Mn and Sn 
and afforded product in 31% overall yield.30 In contrast, the present 2-step procedure 
converted 3.4 to 3.9 in 60% total yield utilizing catalytic Cu. Thus, the present protocol 
demonstrated several desirable traits including: 1) improvement of overall yield of 
trifluoroethylheteroarene; 2) avoidance of oxidation and reduction reactions; 3) 
decrease in time and resource costs; 4) reduction of metal-containing waste products 
(stoichiometeric Mn and Sn vs. catalytic Cu). These attractive features should be useful 




Scheme 3.14. Copper-catalyzed reaction improves access to target compounds.a–f 
 
aMnO2, MeCN, reflux, 75%; 
bMe3SiCF3, TBAF (cat.) THF, rt, 90%; 
cPhOC(S)Cl, DMAP, 
4 Å M.S., PhMe, 50–60 °C, 61%; dn-Bu3SnH, AIBN (cat.), PhMe, 80 °C, 75%; 
e3.4, 
HO2CCF2Br, (COCl)2, DMF, NEt3, DCM, –10 °C, 82%; 
f0.25 mmol (Het)ArCH2O2CCF2Br 
(3.8), 0.050 mmol CuI, 0.063 mmol KI, 0.10 mmol MeO2CCF2Br, 1.0 mmol KF, 0.13 mL 
DMF, 0.13 mL MeCN, 70 °C, 24 h, 73%. 
3.4. Conclusions. 
In conclusion, two key features, solvent and I–, enabled a Cu-catalyzed 
decarboxylative trifluoromethylation of benzylic and heterobenzylic 
bromodifluoroacetates. This transformation provided trifluoroethylarenes and 
heteroarenes from readily available alcohols through a simple and robust two-step 
procedure. The protocol transformed a variety of benzylic bromodifluoroacetates, 
including electron-deficient and heterocyclic substrates, and substrates bearing 
carbonyl groups and acidic protons. The expanded functional group compatibility 
supports a metal-centered decarboxylation event, that does not seem to generate free –
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CF3 in solution. We envision that this system will be useful for accessing biological 
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Unless otherwise noted, reactions were performed using oven-dried glassware 
under an atmosphere of dry N2. Trifluoromethylation reactions were performed in 
resealable 15 mL test tubes sealed with PTFE septa. All other reactions were performed 
in round-bottom flasks, which were sealed with rubber septa. Stainless steel syringes 
were used to transfer air- or moisture-sensitive liquid reagents. Reactions were 
monitored by thin-layer chromatography (TLC) on UNIPLATETM Silica Gel HLF 250 
micron glass plates precoated with 230–400 mesh silica impregnated with a fluorescent 
indicator (250 nm), visualizing by quenching of fluorescence, KMnO4 solution, or p-
anisaldehyde solution. Silica gel for chromatographic purifications was purchased from 
Sorbent Technologies (cat. #30930M-25, 60 Å, 40–63 μm). 
Commercial reagents were purchased and used as received with the following 
exceptions. Anhydrous potassium fluoride (KF) and potassium iodide (KI) were dried in 
a vacuum-oven at 200 °C for 24 h and stored in a N2 filled glovebox. Use of non-
anhydrous KF resulted in decreased yields of desired products. In the absence of a 
glovebox, comparable yields were obtained by flame-drying KF and KI under vacuum, 
and using standard Schlenk techniques. Anhydrous N,N′-dimethylformamide (DMF),  
acetonitrile (MeCN), methanol (MeOH), dichloromethane (DCM), tetrahydrofuran (THF), 
and triethylamine (NEt3) were dispensed from a solvent purification system, in which the 
solvent was dried by passage through two columns of activated alumina under argon. 
Some benzylic alcohols were acquired by reduction of the corresponding aldehydes 
using NaBH4 (1.5 equiv) in anhydrous MeOH at 0 °C or the corresponding carboxylic 
acid using lithium aluminum hydride (2.0 equiv) at 0 °C.  
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Proton nuclear magnetic resonance (1H NMR) spectra were recorded at 400 or 
500 MHz. Carbon nuclear magnetic resonance (13C NMR) spectra were recorded at 101 
or 126 MHz. Fluorine nuclear magnetic resonance (19F NMR) spectra were recorded at 
376 MHz. Chemical shifts (δ) for protons are reported in parts per million (ppm) 
downfield from tetramethylsilane, and are referenced to the proton resonance of 
residual CHCl3 in the NMR solvent (δ = 7.27 ppm). Chemical shifts (δ) for carbon are 
reported in parts per million downfield from tetramethylsilane, and are referenced to the 
carbon resonances of the solvent peak (δ = 77.16 ppm). Chemical shifts (δ) for fluorine 
are reported in parts per millions, and are referenced to PhCF3 (δ = –63.72 ppm). NMR 
data are represented as follows: chemical shift (ppm), multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, sept = septet, m = multiplet), coupling constant in Hertz 
(Hz), and integration. 
Exact mass determinations were obtained by the following methods; electron 
impact ionization (EI) on a ZG analytical ZAB mass spectrometer, electrospray 
ionization (ESI) on a Waters LCT PremierTM mass spectrometer, or atmospheric-
pressure chemical ionization (APCI–hexane/PhMe) on a Waters Q-Tof PremierTM, for 
which sample plus near mass internal exact mass standard were dissolved in hexane, 
and hexane or PhMe/hexane were used as ionization solvent. Melting points were 







Synthesis of Benzylic Bromodifluoroacetates: 
General Procedure A 
HO2CCF2Br (1.45 equiv) was added to a round-bottom flask, which was sealed with a 
rubber septum and attached to an oil bubbler. DCM and DMF were injected, and the 
solution was cooled to 0 °C. Oxalyl chloride (1.4 equiv) was injected (caution: evolution 
of noxious gas), and after 5 min, the mixture was allowed to warm to rt. After 2 h, the 
mixture was cooled to 0 °C, and a solution of benzylic alcohol (1.0 equiv) and NEt3 (2–3 
equiv) in DCM was added. The reaction was monitored by TLC analysis, and after 
consumption of the benzylic alcohol (usually within 1–2 h), the reaction was quenched 
with water, and the aqueous layer was extracted with DCM or EtOAc (4x). The 
combined organic layers were washed with brine, dried over Na2SO4, and filtered. After 
the removal of solvent, the residue was purified by flash column chromatography to 
afford bromodifluoroacetates 3.1a–s. 
 
 
4-Methylbenzyl 2-bromo-2,2-difluoroacetate1  
General Procedure A was followed using 4-methylbenzyl alcohol (1.5 g, 12 mmol). 
Workup and chromatographic purification (hexanes) afforded the title compound as a 
colorless oil (2.9 g, 87%). 
1H NMR (400 MHz, CDCl3): δ 7.31 (d, J = 8.0 Hz, 2 H), 7.22 (d, J = 7.9 Hz, 2 H), 5.33 
(s, 2 H), 2.38 (s, 3 H).  
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General Procedure A was followed using 4-(benzyloxy)benzyl alcohol (0.65 g, 3.0 
mmol). Workup and chromatographic purification (hexanes/EtOAc, 1:0→19:1) afforded 
the title compound as a colorless solid (0.88 g, 79%).  
m.p.: 64–65 °C.  
1H NMR (400 MHz, CDCl3): δ 7.51–7.31 (m, 7 H), 7.01 (d, J = 8.4 Hz, 2 H), 5.31 (s, 2 
H), 5.10 (s, 2 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 159.7, 159.6 (t, J = 31.6 Hz), 136.7, 130.8, 128.8, 
128.3, 127.6, 125.9, 115.2, 108.9 (t, J = 314.5 Hz), 70.2, 69.9.  
19F NMR (376 MHz, CDCl3): δ –60.7 (s, 2 F).  
IR (film): 2945, 2866, 1769, 1609, 1585, 1518, 1454, 1302, 1246, 1161, 1126, 1018, 
955, 870, 814, 742, 706, 613 cm–1. 








General Procedure A was followed using N-[4-(hydroxymethyl)phenyl] pivalamide  (0.83 
g, 4.0 mmol). Workup and chromatographic purification (hexanes/EtOAc, 1:0→25:4) 
afforded the title compound as a yellow solid (1.2 g, 85%).  
m.p.: 86–87 °C.  
1H NMR (400 MHz, CDCl3): δ 7.61–7.56 (m, 2 H), 7.42 (s, 1 H), 7.39–7.34 (m, 2 H), 
5.31 (s, 2 H), 1.32 (s, 9 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 176.9, 159.5 (t, J = 31.4 Hz), 139.1, 129.9, 129.1, 
120.2, 108.8 (t, J = 314.3 Hz), 69.6, 39.8, 27.7.  
19F NMR (376 MHz, CDCl3): δ –60.8 (s, 2 F).  
IR (film): 3292, 2975, 1771, 1655, 1599, 1520, 1460, 1294, 1157, 955, 820, 700, 604 
cm–1. 
HRMS (APCI–hexane/PhMe): m/z [M+H]+ calcd for C14H17BrF2NO3: 364.0360; found: 









General Procedure A was followed using [3-(dibenzylamino)phenyl]methanol (0.83 g, 
4.0 mmol). Workup and chromatographic purification (hexanes/EtOAc, 1:0→21:4) 
afforded the title compound as a yellow solid (1.2 g, 85%).  
m.p.: 67–68 °C.  
1H NMR (400 MHz, CDCl3): δ 7.41–7.34 (m, 4 H), 7.33–7.25 (m, 6 H), 7.25–7.18 (m, 1 
H), 6.80–6.72 (m, 3 H), 5.27 (s, 2 H), 4.71 (s, 4 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 159.5 (t, J = 31.4 Hz), 149.6, 138.2, 134.6, 129.8, 
128.9, 127.2, 126.7, 116.6, 113.1, 111.9, 108.8 (t, J = 314.3 Hz), 70.3, 54.3.  
19F NMR (376 MHz, CDCl3): δ –60.7 (s, 2 F).  
IR (film): 3028, 2866, 1774, 1605, 1582, 1495, 1452, 1294, 1167, 1122, 953, 775, 733, 
694 cm–1. 
HRMS (APCI–hexane/PhMe): m/z [M]+ calcd for C23H20BrF2NO2: 459.0645; found: 









General Procedure A was followed using (2-bromo-3,4-dimethoxyphenyl) methanol2 
(0.94 g, 3.8 mmol). Workup and chromatographic purification (hexanes/EtOAc, 
1:0→9:1) afforded the title compound as a viscous, colorless oil [1.3 g, 83% (after 
correction for 10 mol% solvent impurity)].  
1H NMR (400 MHz, CDCl3): δ 7.20 (d, J = 8.5 Hz, 1 H), 6.90 (d, J = 8.5 Hz, 1 H), 5.41 
(s, 2 H), 3.90 (s, 3 H), 3.88 (s, 3 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 159.4 (t, J = 31.5 Hz), 154.6, 147.1, 126.5, 125.8, 
120.2, 111.2, 108.8 (t, J = 314.4 Hz), 69.6, 60.7, 56.3.  
19F NMR (376 MHz, CDCl3): δ –60.61 (s, 2 F).  
IR (film): 2943, 2839, 1772, 1595, 1493, 1410, 1296, 1122, 1036, 941, 806, 750, 702 
cm–1. 
HRMS (APCI–hexane/PhMe): m/z [M]+ calcd for C11H10Br2F2O4: 401.8914; found: 









General Procedure A was followed using [2-(benzyloxy)phenyl]methanol (0.70 g, 3.3 
mmol). Workup and chromatographic purification (hexanes/EtOAc, 1:0→19:1) afforded 
the title compound as a colorless solid (1.1 g, 88%).  
m.p.: 45–46 °C.  
1H NMR (400 MHz, CDCl3): δ 7.48–7.32 (m, 7 H), 7.05–6.97 (m, 2 H), 5.49 (s, 2 H), 
5.16 (s, 2 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 159.6 (t, J = 31.3 Hz), 157.1, 136.7, 130.8, 130.5, 
128.7, 128.2, 127.3, 122.3, 120.9, 112.1, 108.9 (t, J = 314.5 Hz), 70.2, 65.9.  
19F NMR (376 MHz, CDCl3): δ –60.44 (s, 2 F).  
IR (film): 3034, 1774, 1605, 1498, 1452, 1379, 1296, 1250, 1165, 1126, 1024, 949, 
806, 754, 696 cm–1. 










General Procedure A was followed using mesitylmethanol (0.60 g, 4.0 mmol). Workup 
and chromatographic purification (hexanes/EtOAc, 1:0→19:1) afforded the title 
compound as a colorless solid (1.1 g, 88%).  
m.p.: 45–46 °C.  
1H NMR (500 MHz, CDCl3): δ 6.92 (s, 2 H), 5.45 (s, 2 H), 2.39 (s, 6 H), 2.31 (s, 3 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 159.9 (t, J = 31.2 Hz), 139.7, 138.7, 129.4, 126.9, 
108.9 (t, J = 314.7 Hz), 65.2, 21.2, 19.6.  
19F NMR (376 MHz, CDCl3): δ –60.51 (s, 2 F).  
IR (film): 3011, 2974, 2957, 2922, 2866, 1772, 1614, 1583, 1448, 1375, 1302, 1288, 
1167, 1126, 1032, 951, 912, 851, 771, 700 cm–1. 
HRMS (APCI–hexane/PhMe): m/z [M]+ calcd for C12H13BrF2O2: 306.0067; found: 










General Procedure A was followed using (E)-(4-styrylphenyl) methanol3 (0.72 g, 3.4 
mmol). Workup and chromatographic purification (hexanes) afforded the title compound 
as a colorless solid (1.1 g, 86%).  
m.p.: 75–76 °C.  
1H NMR (400 MHz, CDCl3): δ 7.56 (t, J = 7.5 Hz, 4 H), 7.45–7.36 (m, 4 H), 7.34–7.28 
(m, 1 H), 7.21–7.09 (m, 2 H), 5.38 (s, 2 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 159.6 (t, J = 31.6 Hz), 138.5, 137.1, 132.6, 129.9, 
129.2, 128.9, 128.1, 127.9, 127.0, 126.8, 108.9 (t, J = 314.4 Hz), 69.7.  
19F NMR (376 MHz, CDCl3): δ –60.7 (s, 2 F).  
IR (film): 3026, 1772, 1514, 1448, 1383, 1296, 1165, 1126, 966, 949, 866, 818, 704, 
690 cm–1. 
HRMS (APCI–hexane/PhMe): m/z [M]+ calcd for C17H13BrF2O2: 366.0067; found: 









General Procedure A was followed using (naphthalen-2-yl)methanol (0.63 g, 4.0 mmol). 
Workup and chromatographic purification (hexanes) afforded the title compound as a 
colorless solid (1.1 g, 88%).  
m.p.: 32–33 °C.  
1H NMR (400 MHz, CDCl3): δ 7.95–7.83 (m, 4 H), 7.58–7.53 (m, 2 H), 7.51 (d, J = 8.7 
Hz, 1 H), 5.54 (s, 2 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 159.6 (t, J = 31.5 Hz), 133.6, 133.2, 130.9, 129.0, 
128.4, 128.3, 127.9, 127.0, 126.8, 125.8, 108.9 (t, J = 315.0 Hz), 70.1.  
19F NMR (376 MHz, CDCl3): δ –60.68 (s, 2 F).  
IR (film): 3056, 2964, 1774, 1508, 1375, 1296, 1171, 1124, 947, 854, 816, 750, 698 
cm–1. 
HRMS (APCI–hexane/PhMe): m/z [M]+ calcd for C13H9BrF2O2: 313.9754; found: 









General Procedure A was followed using 4-(hydroxymethyl)phenyl methanesulfonate 
(1.4 g, 7.1 mmol). Workup and chromatographic purification (hexanes/EtOAc, 1:0→4:1) 
afforded the title compound as a colorless solid (2.4 g, 95%).  
m.p.: 48–49 °C.  
1H NMR (400 MHz, CDCl3): δ 7.52–7.47 (m, 2 H), 7.38–7.33 (m, 2 H), 5.38 (s, 2 H), 
3.19 (s, 3 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 159.4 (t, J = 31.7 Hz), 149.7, 132.9, 130.4, 122.6, 
108.7 (t, J = 314.4 Hz), 68.7, 37.7.  
19F NMR (376 MHz, CDCl3): δ –60.79 (s, 2 F).  
IR (film): 3033, 2941, 1774, 1606, 1506, 1456, 1420, 1371, 1298, 1178, 1153, 1122, 
970, 872, 835, 710, 679 cm–1. 











General Procedure A was followed using 4-(hydroxymethyl)phenyl benzoate (0.57 g, 
2.5 mmol). Workup and chromatographic purification (hexanes/EtOAc, 1:0→9:1) 
afforded the title compound as a colorless solid (0.79 g, 82%).  
m.p.: 65–66 °C.  
1H NMR (400 MHz, CDCl3): δ 8.27–8.18 (m, 2 H), 7.71–7.63 (m, 1 H), 7.58–7.46 (m, 4 
H), 7.32–7.27 (m, 2 H), 5.39 (s, 2 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 165.1, 159.5 (t, J = 31.6 Hz), 151.7, 133.9, 131.2, 
130.3, 130.1, 129.3, 128.8, 122.4, 108.8 (t, J = 314.3 Hz), 69.2.  
19F NMR (376 MHz, CDCl3): δ –60.74 (s, 2 F).  
IR (film): 3065, 1776, 1740, 1601, 1510, 1452, 1379, 1298, 1265, 1204, 1123, 1061, 
1024, 951, 876, 804, 706, 604 cm–1. 










General Procedure A was followed using (3-phenoxyphenyl)methanol (0.69 g, 3.4 
mmol). Workup and chromatographic purification (hexanes/EtOAc, 1:0→19:1) afforded 
the title compound as a colorless oil (0.99 g, 80%). 
1H NMR (400 MHz, CDCl3): δ 7.40–7.34 (m, 3 H), 7.18–7.10 (m, 2 H), 7.07–7.00 (m, 4 
H), 5.33 (s, 2 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 159.5 (t, J = 31.6 Hz), 158.0, 156.7, 135.4, 130.4, 
130.0, 123.9, 122.9, 119.5, 119.3, 118.3, 108.7 (t, J = 314.4 Hz), 69.2.  
19F NMR (376 MHz, CDCl3): δ –60.83 (s, 2 F).  
IR (film): 3065, 3040, 2964, 1778, 1585, 1489, 1448, 1377, 1301, 1259, 1213, 1173, 
1122, 945, 874, 847, 777, 692, 604 cm–1. 
HRMS (APCI–hexane/PhMe): m/z [M]+ calcd for C15H11BrF2O3: 355.9860; found: 










General Procedure A was followed using (3-(hydroxylmethyl)phenyl)(phenyl)-
methanone. Workup and chromatographic purification (hexanes/EtOAc, 1:0→21:4) 
afforded the title compound as a pale yellow oil (1.6 g, 88%).  
1H NMR (400 MHz, CDCl3): δ 7.88–7.77 (m, 4 H), 7.67–7.59 (m, 2 H), 7.58–7.47 (m, 3 
H), 5.43 (s, 2 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 196.1, 159.4 (t, J = 31.5 Hz), 138.3, 137.3, 133.9, 
132.9, 132.3, 130.9, 130.2, 130.0, 129.1, 128.5, 108.7 (t, J = 314.3 Hz), 69.2.  
19F NMR (376 MHz, CDCl3): δ –60.81 (s, 2 F).  
IR (film): 3065, 3040, 2964, 1778, 1585, 1489, 1448, 1377, 1301, 1259, 1213, 1173, 
1122, 945, 874, 847, 777, 692, 604 cm–1. 
HRMS (APCI–hexane/PhMe): m/z [M+H]+ calcd for C16H12BrF2O3: 368.9938; found: 










General Procedure A was followed using methyl 4-(hydroxymethyl) benzoate (0.55 g, 
3.3 mmol). Workup and chromatographic purification (hexanes/EtOAc, 1:0→19:1) 
afforded the title compound as a colorless oil (0.91 g, 85%).  
1H NMR (400 MHz, CDCl3): δ 8.08 (d, J = 7.9 Hz, 2 H), 7.47 (d, J = 8.0 Hz, 2 H), 5.41 
(s, 2 H), 3.94 (s, 3 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 166.6, 159.4 (t, J = 31.7 Hz), 138.3, 130.9, 130.2, 
128.1, 108.6 (t, J = 314.2 Hz), 68.9, 52.4.  
19F NMR (376 MHz, CDCl3): δ –60.86 (s, 2 F).  
IR (film): 2955, 1778, 1724, 1616, 1437, 1379, 1283, 1171, 1111, 1020, 955, 847, 756, 
708, 602 cm–1. 
HRMS (APCI–hexane/PhMe): m/z [M]+ calcd for C11H9BrF2O4: 321.9652; found: 









General Procedure A was followed using tert-butyl 3-(hydroxymethyl)-1H-indole-1-
carboxylate (1.2 g, 3.0 mmol). Workup and chromatographic purification 
(hexanes/EtOAc, 1:0→9:1) afforded the title compound as a colorless solid (0.91 g, 
85%).  
m.p.: 47–49 °C.  
1H NMR (400 MHz, CDCl3): δ 8.18 (d, J = 8.3 Hz, 1 H), 7.77 (s, 1 H), 7.64 (dt, J = 7.8, 
1.0 Hz, 1 H), 7.39 (ddd, J = 8.5, 7.2, 1.3 Hz, 1 H), 7.31 (td, J = 7.6, 1.1 Hz, 1 H), 5.54 (d, 
J = 0.7 Hz, 2 H), 1.69 (s, 9 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 159.7 (t, J = 31.5 Hz), 149.5, 135.7, 128.9, 127.1, 
125.2, 123.3, 119.2, 115.6, 113.3, 108.8 (t, J = 314.5 Hz), 84.5, 62.0, 28.3.  
19F NMR (376 MHz, CDCl3): δ –60.7 (s, 2 F).  
IR (film): 3126, 3055, 2980, 2934, 1774, 1736, 1610, 1597, 1572, 1452, 1389, 1371, 
1358, 1292, 1273, 1259, 1231, 1159, 1128, 1092, 1020, 945, 854, 768, 746, 704 cm–1. 
HRMS (APCI–hexane/PhMe): m/z [M]+ calcd for C16H16BrF2NO4: 403.0231; found: 







General Procedure A was followed using (1-phenyl-1H-pyrazol-4-yl)methanol4 (0.87 g, 
5.0 mmol). Workup and chromatographic purification (hexanes/EtOAc, 1:0→4:1) 
afforded the title compound as a colorless solid (1.5 g, 89%).  
m.p.: 60–61 °C.  
1H NMR (400 MHz, CDCl3): δ 8.07 (s, 1 H), 7.81 (s, 1 H), 7.71–7.66 (m, 2 H), 7.51–7.44 
(m, 2 H), 7.36–7.30 (m, 1 H), 5.36 (s, 2 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 159.7 (t, J = 31.7 Hz), 141.7, 139.8, 129.7, 128.2, 
127.2, 119.5, 116.0, 108.9 (t, J = 314.5 Hz), 61.0.  
19F NMR (376 MHz, CDCl3): δ –60.90 (s, 2 F).  
IR (film): 3057, 2970, 1774, 1514, 1489, 1375, 1292, 11689, 1122, 1067, 943, 887, 
842, 771, 736, 692, 660 cm–1. 










General Procedure A was followed using (2-phenylfuran-3-yl)methanol5 (0.52 g, 3.0 
mmol). Workup provided the title compound as a yellow oil (0.93 g, 93%).  
1H NMR (400 MHz, CDCl3): δ 7.66–7.59 (m, 2 H), 7.51–7.45 (m, 3 H), 7.43–7.37 (m, 1 
H), 6.61 (d, J = 1.9 Hz, 1 H), 5.40 (s, 2 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 159.7 (t, J = 31.6 Hz), 153.4, 142.1, 129.9, 129.1, 
128.7, 126.6, 113.56, 113.54, 108.8 (t, J = 314.6 Hz), 62.6.  
19F NMR (376 MHz, CDCl3): δ –60.75 (s, 2 F).  
IR (film): 3057, 2970, 1774, 1514, 1489, 1375, 1292, 11689, 1122, 1067, 943, 887, 
842, 771, 736, 692, 660 cm–1. 




General Procedure A was followed using dibenzo[b,d]thiophen-4-ylmethanol (1.2 g, 5.6 
mmol). Workup and chromatographic purification (hexanes)  provided the title 
compound as a colorless solid (1.9 g, 89%).  
m.p.: 90–91 °C.  
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1H NMR (400 MHz, CDCl3): δ 8.22–8.15 (m, 2 H), 7.94–7.86 (m, 1 H), 7.57–7.47 (m, 4 
H), 5.63 (s, 2 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 159.6 (t, J = 31.7 Hz), 139.24, 139.15, 136.6, 135.4, 
127.7, 127.37, 127.33, 124.90, 124.86, 123.0, 122.6, 122.0, 108.7 (t, J = 314.5 Hz), 
68.7.  
19F NMR (376 MHz, CDCl3): δ –60.52 (s, 2 F).  
IR (film): 3064, 2931, 1778, 1585, 1443, 1408, 1298, 1180, 1136, 1047, 982, 941, 883, 
827, 789, 746, 710, 669 cm–1. 
HRMS (APCI–hexane/PhMe): m/z [M]+ calcd for C15H9BrF2O2S: 369.9475; found: 




General Procedure A was followed using [1-(methylsulfonyl)-1H-indol-2-yl]methanol6 
(1.1 g, 5.0 mmol). Workup and chromatographic purification (hexanes/EtOAc 1:0→9:1)  
provided the title compound as a grey solid (1.1 g, 70%).  
m.p.: 87–88 °C.  
1H NMR (400 MHz, CDCl3): δ 8.05 (dt, J = 8.3, 1.0 Hz, 1 H), 7.66–7.61 (m, 1 H), 7.47–
7.40 (m, 1 H), 7.38–7.31 (m, 1 H), 6.91 (s, 1 H), 5.69 (s, 2 H), 3.19 (s, 3H).  
13C{1H} NMR (101 MHz, CDCl3): δ 158.8 (t, J = 31.7 Hz), 137.2, 131.7, 128.3, 126.5, 
124.3, 122.0, 114.8, 114.1, 108.7 (t, J = 314.3 Hz), 62.7, 41.1.  
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19F NMR (376 MHz, CDCl3): δ –60.63 (s, 2 F).  
IR (film): 3028, 1778, 1452, 1369, 1292, 1175, 1121, 964, 916, 823, 771, 748, 719, 685 
cm–1. 
HRMS (APCI–hexane/PhMe): m/z [M]+ calcd for C12H10BrF2NO4S: 380.9482; found: 




HO2CCF2Br (0.27 g, 1.5 mmol) was added to a round-bottom flask, which was sealed 
with a rubber septum and attached to an oil bubbler. DCM (6.0 mL) and DMF (0.30 mL) 
were injected, and the solution was cooled to –10 °C. Oxalyl chloride (0.13 mL, 1.5 
mmol) was injected (caution: evolution of noxious gas), and after 5 min, the mixture was 
allowed to warm to rt. After 2 h, the mixture was cooled to –10 °C, and a solution of [5-
(furan-2-yl)-1-methyl-1H-pyrazol-3-yl]methanol7 (0.19 g, 1.0 mmol) and NEt3 (0.38 mL, 
2.7 mmol) in DCM (1.5 mL) was added. After 2.5 h, the reaction was quenched with 
water, and the aqueous layer was extracted with EtOAc (4 x 10 mL). The combined 
organic layers were washed with brine, dried over Na2SO4, and filtered. 
Chromatographic purification (hexanes/EtOAc 1:0→3:2)  provided the title compound as 
a yellow solid (0.29 g, 82%).  
m.p.: 39–40 °C.  
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1H NMR (400 MHz, CDCl3): δ 7.54–7.52 (m, 1 H), 6.59 (d, J = 3.4 Hz, 1 H), 6.57 (s, 1 
H), 6.52 (dd, J = 3.4, 1.8 Hz, 1 H), 5.36 (s, 2 H), 4.05 (s, 3 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 159.6 (t, J = 31.6 Hz), 144.4, 144.2, 143.1, 135.7, 
111.7, 109.1, 108.8 (t, J = 314.9 Hz), 105.4, 63.5, 39.0.  
19F NMR (376 MHz, CDCl3): δ –60.64 (s, 2 F).  
IR (film): 3128, 1776, 1531, 1475, 1448, 1362, 1302, 1163, 1124, 1011, 947, 903, 885, 
800, 741, 702 cm–1. 
HRMS (APCI–hexane/PhMe): m/z [M + Na]+ calcd for C11H9BrF2N2O3Na: 356.9662; 
found: 356.9648 (3.9 ppm).  
 
Synthesis of Trifluoroethyl(hetero)arenes: 
General Procedure B (solid substrates) 
An oven-dried 15 mL screw-top vial was sealed with a PTFE septum and cooled under 
an atmosphere of dry N2. CuI (9.5 mg, 0.050 mmol) and (hetero)benzyl 
bromodifluoroacetate (0.25 mmol) were added to the vial, which was transferred into a 
N2-filled glovebox. Anhydrous KF (58.1 mg, 1.00 mmol) and anhydrous KI (10.4 mg, 
0.0625 mmol) were added to the vial, which was sealed with a PTFE septum and 
removed from the glovebox. MeCN (125 μL), MeO2CCF2Br (11.0 μL, 0.100 mmol) and 
DMF (125 μL) were injected into the vial, which was placed in a pre-heated hot plate (70 
°C) and stirred for 24 h. After cooling to room temperature, the mixture was diluted with 
EtOAc or Et2O (25 mL). The mixture was washed with H2O (20 mL) and brine (20 mL). 
The organic phase was dried over Na2SO4, filtered, and the solvent was removed in 
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vacuo. The residue was purified via silica gel chromatography to provide the 
corresponding trifluoroethyl(hetero)arene.  
 
General Procedure C (liquid substrates) 
An oven-dried 15 mL screw-top vial was sealed with a PTFE septum and cooled under 
an atmosphere of dry N2. CuI (9.5 mg, 0.050 mmol) was added to the vial, which was 
transferred into a N2-filled glovebox. Anhydrous KF (58.1 mg, 1.00 mmol) and 
anhydrous KI (10.4 mg, 0.0625 mmol) were added to the vial, which was sealed with a 
PTFE septum and removed from the glovebox. MeCN (125 μL), MeO2CCF2Br (11.0 μL, 
0.100 mmol), (hetero)benzyl bromodifluoroacetate (0.25 mmol), and DMF (125 μL) were 
injected into the vial, which was placed in a pre-heated hot plate (70 °C) and stirred for 
24 h. After cooling to room temperature, the mixture was diluted with EtOAc or Et2O (25 
mL). The mixture was washed with H2O (20 mL) and brine (20 mL). The organic phase 
was dried over Na2SO4, filtered, and the solvent was removed in vacuo. The residue 
was purified via silica gel chromatography to provide the corresponding 
trifluoroethyl(hetero)arene. 
 
Each decarboxylative trifluoromethylation was run twice, and the yields in manuscript 
refer to the average of two runs. The procedures described below represent one 
individual run. ArCH2CF2CF3 was observed as a minor side-product (<2%) in many 







General Procedure B was followed using 3.1b (92.8 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/Et2O 39:1) afforded the title compound as a 
colorless solid (55.7 mg, 84%).  
m.p.: 78–79 °C (lit.8 82–84 °C).  
1H NMR (400 MHz, CDCl3): δ 7.48–7.39 (m, 4 H), 7.39–7.33 (m, 1 H), 7.27–7.21 (m, 2 
H), 7.01–6.96 (m, 2 H), 5.09 (s, 2 H), 3.33 (q, J = 10.8 Hz, 2 H).  
19F NMR (376 MHz, CDCl3): δ –66.4 (3 F, t, J = 10.9 Hz).  
 
Gram-scale Decarboxylative Trifluoromethylation: An oven-dried 25 mL Schlenk 
flask was sealed with a rubber septum and cooled under an atmosphere of dry N2. CuI 
(0.23 g, 1.2 mmol) was added to the vial, which was transferred into a N2-filled 
glovebox. Anhydrous KF (1.4 g, 24 mmol) and anhydrous KI (0.25 g, 1.5 mmol) were 
added to the flask, which was sealed with a rubber septum and removed from the 
glovebox. The flask was attached to a Schlenk line, and remained open to an 
atmosphere of dry N2 for the remainder of the reaction (CAUTION: CO2 (g) is generated 
during the course of the reaction; therefore, the reaction should either be conducted in a 
pressure-rated vessel, or open to an inert atmosphere). MeCN (3.0 mL), MeO2CCF2Br 
(0.26 mL, 2.4 mmol), 3.1b (2.2 g, 6.0 mmol), and DMF (3.0 mL) were injected into the 
flask, which was placed in a pre-heated oil bath (70 °C) and stirred for 24 h. After 
cooling to room temperature, the mixture was diluted with EtOAc (75 mL). The mixture 
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was washed with H2O (75 mL) and brine (75 mL). The organic phase was dried over 
Na2SO4, filtered, and the solvent was removed in vacuo. The residue was purified via 
silica gel chromatography (hexanes/Et2O 39:1) to provide 3.2b as a colorless solid (1.4 




General Procedure B was followed using 3.1c (91.0 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/EtOAc 1:0→9:1) afforded the title compound as 
a colorless solid (52.8 mg, 81%).  
m.p.: 132–133 °C. 
1H NMR (400 MHz, CDCl3): δ 7.54 (d, J = 8.4 Hz, 2 H), 7.37 (s, 1 H), 7.25 (d, J = 8.3 
Hz, 2 H), 3.33 (q, J = 10.8 Hz, 2 H), 1.32 (s, 9 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 176.8, 138.1, 130.8, 125.9 (q, J = 3.0 Hz), 125.8 (q, 
J = 276.7 Hz), 120.2, 39.76, 39.74 (q, J = 29.8 Hz), 27.7.  
19F NMR (376 MHz, CDCl3): δ –65.65 (t, J = 10.8 Hz, 3 F).  
IR (film): 3317, 2978, 2873, 1654, 1599, 1522, 1412, 1315, 1265, 1244, 1138, 1072, 
905, 806, 698, 656 cm–1. 






General Procedure B was followed using 3.1d (115 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/DCM 1:0→17:3) afforded the title compound as 
a colorless oil (80.6 mg, 91%).  
1H NMR (400 MHz, CDCl3): δ 7.40–7.33 (m, 4 H), 7.32–7.25 (m, 6 H), 7.17 (t, J = 7.9 
Hz, 1 H), 6.73 (dd, J = 8.4, 2.7 Hz, 1 H), 6.70–6.64 (m, 2 H), 4.68 (s, 4 H), 3.26 (q, J = 
11.0 Hz, 2 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 149.6, 138.4, 131.2 (q, J = 2.8 Hz), 129.6, 128.8, 
127.1, 126.8, 126.0 (q, J = 277.0 Hz), 118.6, 114.3, 112.3, 54.3, 40.7 (q, J = 29.5 Hz).  
19F NMR (376 MHz, CDCl3): δ –65.68 (t, J = 10.9 Hz, 3 F).  
IR (film): 3061, 3030, 2922, 2860, 1605, 1582, 1499, 1452, 1358, 1259, 1132, 1078, 
1028, 991, 964, 922, 777, 729, 696 cm–1. 




General Procedure C was followed using 3.1e (101 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/DCM 1:0→17:3) afforded the title compound as 
a colorless oil (57.9 mg, 78%).  
165 
 
1H NMR (400 MHz, CDCl3): δ 7.10 (d, J = 8.5 Hz, 1 H), 6.87 (d, J = 8.6 Hz, 1 H), 3.88 
(s, 3 H), 3.86 (s, 3 H), 3.60 (q, J = 10.6 Hz, 2 H).  




General Procedure B was followed using 3.1f (92.8 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/DCM 1:0→19:1) afforded the title compound as 
a colorless oil (50.7 mg, 76%).  
1H NMR (400 MHz, CDCl3): δ 7.54–7.30 (m, 7 H), 7.07–6.93 (m, 2 H), 5.15 (s, 2 H), 
3.57 (q, J = 11.0 Hz, 2 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 157.2, 137.0, 132.0, 129.6, 128.7, 128.1, 127.3, 
126.3 (q, J = 277.3 Hz), 120.9, 119.3 (q, J = 2.8 Hz), 112.2, 70.3, 33.7 (q, J = 30.2 Hz).  
19F NMR (376 MHz, CDCl3): δ –65.34 (t, J = 10.9 Hz, 3 F).  
IR (film): 3005, 2943, 1595, 1494, 1406, 1360, 1285, 1246, 1138, 1092, 1036, 947, 
901, 806, 766, 681, 646 cm–1. 







General Procedure C was followed using 3.1g (76.8 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes) afforded the title compound as a colorless oil 
(22.4 mg, 46%).  
1H NMR (400 MHz, CDCl3): δ 6.91 (s, 2 H), 3.48 (q, J = 10.8 Hz, 2 H), 2.35 (s, 6 H), 
2.29 (s, 3 H). 
13C{1H} NMR (126 MHz, CDCl3): δ 138.3, 137.7, 129.4, 126.9 (q, J = 278.3 Hz), 125.6 
(q, J = 2.47 Hz), 33.6 (q, J = 29.6 Hz), 21.0, 20.4 (q, J = 2.1 Hz).  
19F NMR (376 MHz, CDCl3): δ –63.8 (t, J = 10.8 Hz, 3 F).  
IR (film): 3007, 2964, 2926, 2868, 2856, 1614, 1481, 1450, 1427, 1381, 1352, 1306, 
1248, 1202, 1130, 1099, 1026, 941, 910, 854, 833, 804, 735, 654 cm–1. 




General Procedure B was followed using 3.1h (91.8 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/EtOAc 1:0→9:1) afforded the title compound as 
a colorless solid (39.2 mg, 60%).  
m.p.: 135–136 °C.  
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1H NMR (400 MHz, CDCl3): δ 7.59–7.51 (m, 4 H), 7.41 (t, J = 7.5 Hz, 2 H), 7.36–7.29 
(m, 3 H), 7.17–7.14 (m, 2 H), 3.40 (q, J = 10.8 Hz, 2 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 137.4, 137.2, 130.6, 129.45 (q, J = 2.9 Hz), 129.41, 
128.8, 128.0, 127.9, 126.8, 126.7, 125.9 (q, J = 276.9 Hz), 40.1 (q, J = 29.8 Hz).  
19F NMR (376 MHz, CDCl3): δ –65.81 (t, J = 10.8 Hz, 3 F).  
IR (film): 3022, 1448, 1429, 1420, 1356, 1258, 1147, 1119, 1078, 964, 908, 820, 792, 
754, 739, 692, 658 cm–1. 




General Procedure B was followed using 3.1i (78.8 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes) afforded the title compound as a colorless solid 
(42.3 mg, 81%).  
m.p.: 51–53 °C.  
1H NMR (400 MHz, CDCl3): δ 7.90–7.81 (m, 3 H), 7.79 (s, 1 H), 7.55–7.48 (m, 2 H), 
7.42 (d, J = 8.4 Hz, 1 H), 3.55 (q, J = 10.8 Hz, 2 H).  








General Procedure B was followed using 3.1j (89.8 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/DCM 1:0→2:3) afforded the title compound as a 
colorless solid (43.5 mg, 69%).  
m.p.: 75–76 °C.  
1H NMR (400 MHz, CDCl3): δ 7.36 (d, J = 8.5 Hz, 2 H), 7.29 (d, J = 8.6 Hz, 2 H), 3.39 
(q, J = 10.7 Hz, 2 H), 3.15 (s, 3 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 149.1, 132.0, 129.6 (q, J = 3.0 Hz), 125.6 (q, J = 
276.8 Hz), 122.4, 39.6 (q, J = 30.1 Hz), 37.5.  
19F NMR (376 MHz, CDCl3): δ –65.36 (t, J = 10.7 Hz, 3 F).  
IR (film): 3031, 2945, 1608, 1502, 1456, 1421, 1361, 1302, 1177, 1153, 1132, 974, 
876, 832, 707, 681 cm–1. 




General Procedure B was followed using 3.1k (96.3 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/EtOAc 1:0→19:1) afforded the title compound as 
a colorless solid (49.6 mg, 71%).  
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m.p.: 84–85 °C.  
1H NMR (400 MHz, CDCl3): δ 8.25 (d, J = 7.6 Hz, 2 H), 7.68 (t, J = 7.4 Hz, 1 H), 7.55 (t, 
J = 7.7 Hz, 2 H), 7.40 (d, J = 8.3 Hz, 2 H), 7.26 (d, J = 8.3 Hz, 2 H), 3.43 (q, J = 10.8 Hz, 
2 H).  




General Procedure C was followed using 3.1l (89.3 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/DCM 1:0→19:1) afforded the title compound as 
a colorless oil (41.9 mg, 67%).  
1H NMR (400 MHz, CDCl3): δ 7.41–7.29 (m, 3 H), 7.14 (t, J = 7.4 Hz, 1 H), 7.09–6.95 
(m, 5 H), 3.35 (q, J = 10.8 Hz, 2 H).  




General Procedure C was followed using 3.1m (92.3 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/DCM 1:0→3:1) afforded the title compound as a 
colorless oil (40.9 mg, 62%).  
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1H NMR (400 MHz, CDCl3): δ 7.85–7.71 (m, 4 H), 7.62 (t, J = 7.4 Hz, 1 H), 7.57–7.45 
(m, 4 H), 3.45 (q, J = 10.7 Hz, 2 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 196.3, 138.2, 137.4, 134.2, 132.8, 131.8, 130.6 (q, J 
= 2.9 Hz), 130.2, 130.0, 128.8, 128.5, 125.7 (q, J = 276.9 Hz), 40.2 (q, J = 29.8 Hz).  
19F NMR (376 MHz, CDCl3): δ –65.66 (t, J = 10.7 Hz, 3 F).  
IR (film): 3063, 3036, 2947, 1661, 1597, 1585, 1578, 1448, 1362, 1319, 1308, 1288, 
1256, 1209, 1138, 1101, 1076, 986, 968, 932, 906, 870, 852, 813, 783, 714, 640, 602 
cm–1. 




General Procedure C was followed using 3.1n (80.8 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/EtOAc 1:0→9:1) afforded the title compound as 
a colorless oil [(29.5 mg, 51% (after correction for 5 mol% ArCH2Br side-product)].  
1H NMR (400 MHz, CDCl3): δ 8.07–8.02 (m, 2 H), 7.39 (d, J = 8.1 Hz, 2 H), 3.93 (s, 3 
H), 3.44 (q, J = 10.7 Hz, 2 H).  






General Procedure B was followed using 3.1o (101 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/EtOAc, 39:1) afforded the title compound as a 
colorless solid (58.1 mg, 78%).  
m.p.: 79–80 °C.  
1H NMR (500 MHz, CDCl3): δ 8.17 (d, J = 6.7 Hz, 1 H), 7.61 (s, 1 H), 7.56 (d, J = 7.8 
Hz, 1 H), 7.37 (ddd, J = 8.4, 7.2, 1.3 Hz, 1 H), 7.30 (ddd, J = 8.1, 7.3, 1.1 Hz, 1 H), 3.51 
(qd, J = 10.6, 0.9 Hz, 2 H), 1.69 (s, 9 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 149.6, 135.4, 130.0, 125.93 (q, J = 276.9 Hz), 
125.92, 124.9, 123.0, 119.0, 115.5, 109.5 (q, J = 3.3 Hz), 84.2, 30.5 (q, J = 31.7 Hz), 
28.3.  
19F NMR (376 MHz, CDCl3): δ –65.57 (t, J = 10.7 Hz, 3 F).  
IR (film): 3057, 2982, 2934, 1736, 1452, 1375, 1350, 1277, 1259, 1229, 1153, 1138, 
1101, 1016, 914, 856, 770, 744 cm–1. 









General Procedure B was followed using 3.1p (82.8 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/EtOAc 1:0→9:1) afforded the title compound as 
a colorless solid (47.2 mg, 83%).  
m.p.: 45–46 °C.  
1H NMR (500 MHz, CDCl3): δ 7.90 (s, 1 H), 7.70–7.65 (m, 3 H), 7.49–7.42 (m, 2 H), 
7.33–7.28 (m, 1 H), 3.36 (q, J = 10.7 Hz, 2 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 141.6, 140.0, 129.6, 127.0, 126.9, 125.7 (q, J = 
276.2 Hz), 119.3, 111.8 (q, J = 3.3 Hz), 30.1 (q, J = 31.7 Hz).  
19F NMR (376 MHz, CDCl3): δ –66.02 (t, J = 10.7 Hz, 3 F).  
IR (film): 3153, 3109, 3053, 2943, 1601, 1576, 1506, 1464, 1404, 1387, 1348, 1259, 
1213, 1138, 1084, 1043, 1018, 955, 906, 862, 835, 808, 756, 692, 660 cm–1. 




General Procedure C was followed using 3.1q (82.8 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/EtOAc 1:0→19:1) afforded the title compound as 
a colorless oil (31.2 mg, 55%). 
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1H NMR (500 MHz, CDCl3): δ 7.61–7.57 (m, 2 H), 7.51–7.44 (m, 3 H), 7.41–7.36 (m, 1 
H), 6.53 (s, 1 H), 3.45 (q, J = 10.5 Hz, 2 H).  
13C{1H} NMR (126 MHz, CDCl3): δ 152.1, 142.0, 130.5, 128.9, 128.3, 126.8, 126.1 (q, J 
= 277.0 Hz), 113.5, 109.8 (q, J = 3.3 Hz), 31.3 (q, J = 31.0 Hz).  
19F NMR (376 MHz, CDCl3): δ –66.81 (t, J = 10.7 Hz, 3 F).  
IR (film): 3055, 2937, 2856, 1599, 1487, 1447, 1433, 1362, 1298, 1273, 1254, 1140, 
1105, 1082, 1053, 1032, 908, 887, 835, 764, 743, 692, 671, 650, 604 cm–1. 




General Procedure B was followed using 3.1r (92.8 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/EtOAc 1:0→19:1) afforded the title compound as 
a colorless solid (40.9 mg, 61%).  
m.p.: 102–103 °C.  
1H NMR (400 MHz, CDCl3): δ 8.21–8.13 (m, 2 H), 7.92–7.85 (m, 1 H), 7.54–7.42 (m, 4 
H), 3.69 (q, J = 10.6 Hz, 2 H).  






General Procedure B was followed using 3.1s (95.5 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/EtOAc 9:1→2:1) afforded the title compound as 
a colorless solid (42.6 mg, 61%).  
m.p.: 95–96 °C.  
1H NMR (400 MHz, CDCl3): δ 8.03–7.99 (m, 1 H), 7.64–7.59 (m, 1 H), 7.41 (ddd, J = 
8.4, 7.2, 1.4 Hz, 1 H), 7.34 (td, J = 7.5, 1.1 Hz, 1 H), 6.80 (s, 1 H), 4.04 (q, J = 10.2 Hz, 
2 H), 3.13 (s, 3 H).  
13C{1H} NMR (101 MHz, CDCl3): δ 136.8, 129.4 (q, J = 3.5 Hz), 129.0, 125.5, 125.2 (q, 
J = 277.1 Hz), 124.2, 121.3, 114.3, 113.1, 40.9, 32.8 (q, J = 31.7 Hz).  
19F NMR (376 MHz, CDCl3): δ –64.76 (t, J = 10.2 Hz, 3 F). 
IR (film): 3022, 2934, 1452, 1366, 1331, 1304, 1275, 1254, 1234, 1175, 1153, 1082, 
1057, 1022, 962, 924, 899, 818, 771, 748, 727, 665, 636, 554, 513 cm–1. 










General Procedure B was followed using 3.8 (83.8 mg, 0.250 mmol). Workup and 
chromatographic purification (hexanes/EtOAc 1:0→4:1) afforded the title compound as 
a yellow oil (42.6 mg, 73%).  
1H NMR (400 MHz, CDCl3): δ 7.51 (dd, J = 1.9, 0.8 Hz, 1 H), 6.57 (dd, J = 3.4, 0.8 Hz, 1 
H), 6.51 (dd, J = 3.4, 1.8 Hz, 1 H), 6.48 (s, 1 H), 4.02 (s, 3 H), 3.45 (q, J = 10.8 Hz, 2 H).  
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Chapter 4: Regioselective Cu-Catalyzed Decarboxylative Trifluoromethylation of 
Propargylic Bromodifluoroacetates to Generate 
Propargylic Trifluoromethanes and Trifluoromethylallenes 
4.1. Cu-promoted trifluoromethylation of propargylic electrophiles provides propargylic 
trifluoromethanes and trifluoromethylallenes. 
 Copper-mediated and -catalyzed nucleophilic trifluoromethylation is a popular 
strategy for accessing CF3-based products.
1 While the fundamental reactivity of Cu–CF3 
with sp2- and activated sp3-electrophiles has long been established,2 recent advances 
greatly improved the practical utility and economic viability of these methods.3–5 One 
important advancement involved the use of ligands to stabilize the reactive Cu–CF3 
species, and to accelerate reactions with electrophiles.3,5,6 These two features allowed 
reactions to proceed under milder conditions that tolerated a broad array of functional 
groups and heterocycles.3,5,6 While many of these new Cu-mediated and -catalyzed 
trifluoromethylation reactions displayed excellent chemoselectivity, ligands have not 
previously influenced regiochemical outcomes of reactions. Herein, we studied the 
effect of ligands on the trifluoromethylation of propargyl halodifluoroacetates, and report 
the first example of a regioselective trifluoromethylation reaction in which a ligand 
overrode the intrinsic reactivity of unligated “Cu–CF3” with electrophiles. Further, we 
showed that the products can serve as useful synthetic building blocks by providing 
access to 2° trifluoromethanes that otherwise, would be difficult to synthesize. 
 Propargyl electrophiles, including –Br,7–9 –Cl,8–11 –OMs,12 –OTs,10 –OAc,13 and –
O2CCF2X (X = F, Cl, Br),
8,14,15c reacted using either catalytic11,15c or stoichiometric7–10,12–
14 “Cu–CF3” to generate propargyl and/or allenyl products with minimal control of 
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regiochemistry (Scheme 4.1). Unsubstituted propargyl electrophiles provided 
trifluoromethylallene;9,10,14 however, reactions of substituted substrates displayed 
distinct selectivities. In most cases, the product distribution was dictated by the 
substitution pattern of the substrate, where 1° electrophiles provided propargyl products, 
and 2° and 3° electrophiles provided allenyl products (eq 1–2).7,10–14 In contrast, a 
Cu/PPh3-based system depended on reaction temperature to dictate the regioisomeric 
ratio of branched and linear products (eq 3–4).8 However, for many cases, the intrinsic 
reactivity of the substrate overrode the control by temperature, and thus, many allenyl 
products were not accessible.8  




4.2. Cu-catalyzed trifluoromethylation of propargylic halodifluoroacetates to generate 
propargylic trifluoromethanes. 
 Given our interest in developing Cu-catalyzed decarboxylative 
trifluoromethylation reactions, we were intrigued by a single report in which 
unsubstituted propargyl chlorodifluoroacetate converted to trifluoromethylallene in the 
presence of stoichiometric Cu (Scheme 4.1C).14  In order to establish whether this 
strategy could be applied to substituted propargylic substrates, we investigated the 
reactivity of 3-phenylpropynyl chlorodifluoroacetate (4.1a–Cl). Initially, we treated this 
substrate with stoichiometric CuI using the previously reported conditions,14 and 
obtained a 1.7 : 1 mixture of propargyl (4.2a) : allenyl (4.3a) products (Scheme 4.1D). 
Next, we established that Cu could serve as a catalyst for this process, and using 10% 
CuI, observed a turnover number of 1.5 (Scheme 4.1D). 
 We aimed to develop a Cu-catalyzed decarboxylative trifluoromethylation 
reaction that would selectively provide propargylic trifluoromethanes (4.2) over 
trifluoromethylallenes (4.3). Initially, we investigated reactions of different 
halodifluoroacetates, and determined that propargylic bromodifluoroacetates (4.1a) 
were more reactive than chlorodifluoroacetates (4.1a–Cl). Using stoichiometric CuI, 
propargylic bromodifluoroacetates reacted at lower temperatures than 
chlorodifluoroacetates (Br: 50 °C; Cl: 100 °C); however, similar yields of 
trifluoromethylated products were obtained [Br: 57% (Scheme 4.2, entry 1); Cl: 48% 
(Scheme 4.1D)]. Using catalytic CuI (10%), a more pronounced difference between 
substrates was noted [Br: 65% (Scheme 4.2, entry 2); Cl: 15% (Scheme 4.1D)]. Based 
on previous our previous work with allylic trifluoromethylation (Chapter 2), we 
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hypothesized that the addition of N,N’-dimethylethylenediamine (DMEDA), and the use 
of an activation procedure might improve the reaction. While the use of DMEDA alone 
was harmful to the reaction (entry 3), possibly because of side-reactivity between the 
diamine and substrate, using DMEDA with an activation procedure provided 75% of 
trifluoromethane-containing product and a 2.7 : 1 ratio of 4.2a : 4.3a (Table 1, entry 4). 
We hypothesized that the activation procedure, which involved heating CuI, DMEDA, 
KF, and NaO2CCF2Br in DMF at 50 °C for 10 min prior to the addition of substrate, 
facilitated the formation of an active (DMEDA)Cu–CF3 species (Chapter 2) and 
circumvented an induction period where the substrate was destroyed via non-productive 
pathways. 
Scheme 4.2. Catalytic decarboxylative trifluoromethylation improved by DMEDA and an 
activation procedure.a 
 
a Reactions were performed with 0.20 mmol 4.1a, and 0.40 mmol KF in 0.20 mL of DMF. 
b Activation involved heating CuI, DMEDA, NaO2CCF2Br, and KF in DMF for 10 min 
prior to injection of 4.1a. c Combined yield of 4.2a and 4.3a as determined by 19F NMR 
analysis, using α,α,α-trifluorotoluene as an internal standard. d Determined by 19F NMR 
analysis. e 0.30 mmol KF, 1.2 mL of THF, 60 °C, 20 h. f 0.30 mmol of TMSCF3 was 
added to the reaction. 
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 Attempted optimization of several other parameters did not improve the yield and 
selectivity for formation of 4.2a. A broad screen of N-, O-, and P-based ligands revealed 
that most ligands provided similar regioselectivity, and that DMEDA provided the highest 
yield of products. In addition, the regioselectivity was not dramatically influenced by 
temperature, and isomerization between alkynes and allenes was not observed upon 
prolonged heating. Incomplete conversion of starting material was observed at 8–10 h 
time points; therefore, an extended reaction time of 14 h was selected for the general 
reaction conditions. 
 Several important features of the Cu-catalyzed trifluoromethylation of propargylic 
bromodifluoroacetates are highlighted by comparing this system to the recently reported 
Cu-catalyzed trifluoromethylation of propargylic chlorides. Specifically, 1° propargylic 
chlorides were converted to propargyl trifluoromethanes using Cu(I) thiophene-2-
carboxylate (CuTC; 5 mol%), TMSCF3 (1.5 equiv), and KF (1.5 equiv) in THF at 60 °C. 
For the trifluoromethylation of propargylic bromodifluoroacetates, we screened several 
Cu-sources, and determined that CuI provided slightly higher yields than other CuI salts, 
such as CuTC (Scheme 4.2, entry 4 vs entry 5). Changing from DMF to less polar 
solvents, such as THF, completely ablated reactivity (entry 6). Highly polar solvents are 
required to facilitate decarboxylation of bromodifluoroacetate at moderate temperatures 
(<70 °C), and we concluded that “Cu–CF3” was not generated in THF. In addition, 
propargylic bromodifluoroacetates displayed different reactivity than propargylic 
chlorides, and conditions that converted propargylic chlorides to trifluoromethanes (73% 
yield; 5% CuTC, 1.5 equiv TMSCF3, and 1.5 equiv KF in THF at 60 °C for 20 h)
11 failed 
to similarly convert propargylic bromodifluoroacetates (<5% yield; entry 7). 
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 The CuI/DMEDA-catalyzed trifluoromethylation of propargyl 
bromodifluoroacetates (4.1) tolerated many useful and important functional groups. 
Electron-donating aryl ethers provided trifluoromethane-containing products in moderate 
yield (Scheme 4.3, entries 1–2). A variety of carbonyl containing functional groups were 
compatible with the reaction conditions, including: esters, ketones, carbamates, and 
trifluoroacetamides (entries 3–6). In addition, the successful reaction of the 
trifluoroacetamide provided the desired product, albeit in low yield, which provides 
additional evidence that Cu–CF3 species tolerate protic functional groups (entry 6).
16 
When conducted on an increased scale (7 mmol), the present reaction provided a 
typical yield by 19F NMR (entry 9). In addition to aromatic substrates, an aliphatic 
substrate also afforded trifluoromethylated product in moderate yield, and displayed 
distinct regioselectivity compared to the aromatic substrates (entry 10). Based on the 
similarity of propargyl bromodifluoroacetates and cinnamyl bromodifluoroacetates, and 
the identical catalyst systems employed for decarboxylative trifluoromethylation, it is 
anticipated that other functional groups, including aryl bromides and triflates, 
thiophenes, anilines, and phthalimides would also be tolerated under the reaction 
conditions.15a While attempts were made to separate regioisomeric products, we were 
unable to achieve sufficient separation via standard silica gel chromatography to enable 







Scheme 4.3. CuI/DMEDA-catalyzed reaction tolerates important functional groups.a 
 
a Reactions were performed with 0.20 mmol 4.1, 0.020 mmol CuI, 0.020 mmol DMEDA, 
0.050 mmol NaO2CCF2Br, and 0.40 mmol KF in 0.20 mL DMF at 50 °C for 14 h 
following 10 min activation. b Isolated yield of a purified mixture of regioisomers 4.2 and 
4.3; number in parentheses represents the combined yield of 4.2 and 4.3 as determined 
by 19F NMR analysis, using α,α,α-trifluorotoluene as an internal standard. c Ratio of 
regioisomers in isolated material as determined by 1H NMR analysis; ratio in 
parentheses represents ratio of isomers in the crude reaction mixture as determined by 
19F NMR analysis. d Reaction conducted on a 7 mmol scale. 
 Using the standard reaction conditions, a 2° propargyl substrate (4.1b) was less 
reactive than 1° substrates, and provided 16% of trifluoromethylated product after 12 h 
at 50 °C. However, under more forcing conditions (70 °C and 24 h), both propargyl 
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trifluoromethane (4.2b) and trifluoromethyl allene (4.2c) were formed (Scheme 4.4). For 
the reaction of propargyl bromodifluoroacetates, both 1° and 2° substrates provided 
similar regiochemical outcomes, and propargylic trifluoromethanes were observed as 
major products (Schemes 4.3–4). In contrast, previous Cu–catalyzed 
trifluoromethylation reactions of propargyl electrophiles displayed substrate dependent 
regioselectivity, with 1° electrophiles providing propargyl trifluoromethanes, and 2° 
electrophiles yielding trifluoromethyl allenes (Scheme 4.1A).11 
Scheme 4.4. Cu-catalyzed decarboxylative trifluoromethylation of secondary propargyl 
bromodifluoroacetates displays atypical reactivity. 
 
 The present Cu–DMEDA-based catalyst system demonstrated unique 
chemoselectivity compared to other Cu-based catalyst systems. Several Cu–CF3 
complexes commonly react with aryl iodides under mild reaction conditions to furnish 
trifluoromethylarenes (Scheme 4.5A).3a,17  In order to determine whether propargylic 
trifluoromethylation could be selectively achieved in the presence of aryl iodides, an 
exogenous aryl iodide was added to a standard decarboxylative trifluoromethylation 
reaction.  The addition of 1 equivalent of aryl iodide 4.4 had no effect on the yield or 
selectivity of the reaction (Scheme 4.5B). GC analysis of the reaction revealed that 92% 
of the aryl iodide remained unconsumed. In addition, <1% of trifluoromethylarene 4.5 
was observed, which demonstrated the unique reactivity of this system. In order to 
confirm that substrates containing aryl iodides were compatible with the reaction 
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conditions, 4-iodophenylpropynyl bromodifluoroacetate (4.1c) was subjected to 
decarboxylative trifluoromethylation. As expected, a good yield (80%) of 
trifluoromethylated products 4.2c and 4.3c was obtained with typical regioselectivity (2.1 
: 1, Scheme 4.5C). Again, only trace amounts (<1%) of aromatic trifluoromethyl products 
were observed. 
Scheme 4.5. Propargylic trifluoromethylation is selectively accomplished in the 
presence of aryl iodides. 
 
4.3. Regioselective ligand-controlled Cu-catalyzed trifluoromethylation of 
bromodifluoroacetates to generate trifluoromethylallenes. 
 We hypothesized that ligands could control the regioselectivity of 
trifluoromethylation of propargylic bromodifluoroacetates as described in the previous 
section. Many N-, O- and P-based ligands provided propargyl products with the same 
modest regioselectivity as unligated “Cu–CF3” (ca. 3:1 alkyne : allene; Scheme 4.6A). 
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However, the use of 1,10-phenanthroline-based and 2,2’-bipyridine-based ligands 
reversed the regioselectivity of the transformation, and afforded trifluoromethylallene 
4.3a with high regioselectivity (<1:8; Scheme 4.6B). For these bipyridines and 
phenanthrolines, the use of ligands bearing electron-donating aliphatic and methoxy 
groups did not significantly modulate the selectivity of reactions. Thus, the geometric 
influence of the bipyridyl substructure presumably controlled the regioselectivity of the 
transformation. Since electron-donating groups decreased the activity of the catalysts, 
1,10-phenanthroline (phen) and terpyridine (terpy) were identified as the optimal ligands 
for the current transformation. 




 Employing phen as a ligand, various 1° propargyl bromodifluoroacetates were 
converted to 1,1-disubstituted trifluoromethylallenes with good to excellent selectivity 
(Scheme 4.7). Initial efforts focused on the synthesis of 1-aryl-1-trifluoromethylallenes, 
which could not be selectively accessed via other Cu-mediated or -catalyzed 
processes,7–14 and otherwise required multi-step sequences that afforded low yields of 
product.18 Propargyl electrophiles conjugated with electron-rich, -neutral, and -deficient 
aromatic moieties all formed allene products in excellent selectivity (4.3d–g, j–m).19 
When the reaction was conducted on a gram-scale, good yield and excellent selectivity 
were maintained (4.3o). In contrast to substrates bearing m- and p-substituted aryl 
moieties, substrates bearing o-substituted aryl systems afforded products in lower 
selectivity (ca. 10:1; 4.3h–i). Using phen as a ligand, a 1° aliphatic-substituted substrate 
was not effectively converted to product; however, the use of terpy as a ligand provided 
trifluoromethylallene 4.3n in synthetically useful yield and selectivity. The reaction 
tolerated many important functional groups, including carbonyl groups (4.3d–e, k, m), 
nitro groups (4.3g–h), nitriles (4.3i), and ethers (4.3l). The carbonyl-containing groups 
are particularly interesting, because they are prone to react with free CF3
– to provide 
β,β,β-trifluoroethyl alcohols.1d,4,20 Since products of 1,2-addition were not observed in 
these reactions, free –CF3 must not have existed in solution. Therefore, generation of 
the reactive (phen)Cu-CF3 species likely involved an inner-sphere process that did not 





Scheme 4.7. Reactions of primary propargyl bromodifluoroacetates generated 1,1-
disubstituted trifluoromethylallenes.a 
 
a Conditions: 4.1d–o (1 equiv), CuI (10 mol %), phen (10 mol %), NaO2CCF2Br (25 mol 
%), KF (2 equiv), DMF (1.0 M), 50 °C, 14 h. The numbers in parentheses represent the 
ratios of 4.2 : 4.3 in purified product as determined by 1H NMR spectroscopy. b 1:12 
Mixture of 4.2 : 4.3 prior to chromatographic purification as determined by 19F NMR 
spectroscopy. c Terpy (10 mol %) employed as a ligand. d Reaction conducted on a 7 
mmol scale. 
 Utilizing similar reaction conditions to those used for 1° bromodifluoroacetates, 2° 
and 3° propargyl electrophiles were also regioselectively converted to di-, tri-, and tetra-
substituted trifluoromethylallenes in high regioisomeric ratios (Scheme 4.8). Generally, 
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2° 1-aryl propargyl substrates provided 1,3-disubstituted trifluoromethylallenes in 
synthetically useful yields and excellent selectivities (4.3p–s). In addition, the standard 
conditions converted a 2° substrate to a trisubstituted allene product (4.3t); however, the 
standard conditions did not effectively transform several challenging substrates. For 
example, substrates bearing aliphatic groups at the α position reacted sluggishly, and 
provided low yields of allene products (4.3u–y). For these less reactive 2° and 3° alkyl-
substituted bromodifluoroacetates, the use of terpyridine as a ligand and/or more forcing 
conditions (60 °C, 24 h) facilitated the formation of trisubstituted (4.3u–v, x) and 
tetrasubstituted (4.3w) allenes. Notably, the decarboxylative trifluoromethylation 
reaction tolerated aryl bromides (4.3p–r, t), which can undergo Cu-catalyzed 
nucleophilic trifluoromethylation under similar conditions.3a Although substrates bearing 
free amines decomposed under the reaction conditions, protection of these groups as 
amides, carbamates, and sulfonamides permitted catalyst turnover (4.3k, m, v–w). 
Finally, the catalyst system tolerated several important heterocycles, including indole 
(4.3m), pyrazole (4.3s), and furan (4.3s), which may be useful for the design of 











Scheme 4.8. Reactions of substituted propargyl bromodifluoroacetates provided di-, tri- 
and tetra-substituted trifluoromethylallenes. 
 
a Conditions: 4.1p–y (1 equiv), CuI (10 mol %), phen (10 mol %), NaO2CCF2Br (25 mol 
%), KF (2 equiv) DMF (1.0 M), 50 °C, 14 h. The numbers in parentheses represent the 
ratios of 4.2 : 4.3 in purified product as determined by 1H NMR spectroscopy. b 60 °C, 
24 h. c Terpy (10 mol %) employed as a ligand. d Estimated by 19F NMR spectroscopy. 
4.4. Trifluoromethylallenes form via propargylic halide intermediates. 
 We conducted a series of experiments to better understand the mechanism 
through which propargylic bromodifluoroacetates convert to trifluoromethylallenes. First, 
we hypothesized that (phen)Cu–CF3, a stable, well-defined complex, was the active 
trifluoromethylating species, and was generated via decarboxylation/fluorination of 
bromodifluoroacetate (Scheme 4.9A). Additionally, we envisioned that several 
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electrophilic species could react with this (phen)Cu–CF3 intermediate, including: 
propargylic bromodifluoroacetates (Scheme 4.9B, Path A); propargylic halides (Path B); 
or allenyl halides (Path C). To determine whether these species formed under the 
reaction conditions, we treated propargyl trifluoroacetate (selected instead of 
bromodifluoroacetate to avoid decarboxylation and release of Br–) with KBr or KI in DMF 
at 50 °C, and observed the formation of propargylic halides (Scheme 4.9C). Notably, we 
did not detect allenyl halides by GC/MS or NMR analysis under various reaction 
conditions. Next, treating propargylic electrophiles with stoichiometric (phen)Cu–CF3 
provided modest yields of trifluoromethylallenes for propargylic bromides and iodides, 
but not for trifluoroacetates (Scheme 4.9D). We do not believe that this process 
proceeds via a radical mechanism, since radical traps [TEMPO, 3,5-di-tert-butyl-4-
methylphenol (BHT), or 1,4-dinitrobenzene (DNB)] did not significantly inhibit the 
reaction (Scheme 4.9D). In addition, these radical trapping reagents did not dramatically 
impact the yield or selectivity of either phen- or DMEDA-ligated Cu-catalyzed 
trifluoromethylation reactions. These experiments implicate the mechanism in Path B, in 
which propargylic bromodifluoroacetates convert to propargylic halides, and then react 









Scheme 4.9. (phen)Cu–CF3 converted propargylic halides to trifluoromethylallenes. 
 
4.5. Trifluoromethylallenes are useful fluorinated building blocks. 
 Allenes serve as a useful building block for accessing complex substructures,21 
and in recent years, considerable attention focused on both the synthesis of allenes,22 
and transformations of allene-based building blocks.23 Given the synthetic potential of 
allenes, trifluoromethylallenes should be useful synthetic precursors for various 
fluorinated motifs. However, few modern transformations of trifluoromethylallenes have 
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been disclosed,18c, 24 which restricted the use of these fluorinated substructures as 
intermediates in synthetic sequences. To showcase the potential synthetic utility of 
trifluoromethylallenes, 4.3o was subjected to metal-catalyzed hydrofunctionalization 
reactions to generate C–B,25 C–O,26 C–N,27 and C–C18c bonds (Scheme 4.10). In all 
cases, the reactions of 4.3o provided products (4.6–9) in good yields and excellent 
regioselectivity,28 with minimal optimization of previously reported systems.29 In most 
cases, the regioselectivities of the transformations matched those of previous reports;25–
26 however, the product of the hydroamination reaction did not match the predicted 
regiochemical outcome,27 indicating that some reactions of trifluoromethylallenes may 
generate unique products (Scheme 4.9, d). Nonetheless, all functionalization reactions 
provide trifluoromethyl-containing products that would otherwise be challenging to 
prepare. 
Scheme 4.10. Direct conversion of trifluoromethylallenes to functionalized 
trifluoromethylated motifs. 
 
a B2(pin)2 (1.1 equiv), CuCl (5 mol %), IPr•HCl (5 mol %), NaO
tBu (40 mol %), MeOH (6 
equiv), THF, 23 °C. b 2-phenylethanol (1.1 equiv), AuIPrCl (10 mol %), AgOTf (10 mol 
%), PhMe, 23 °C. c (CH2O)n (2 equiv), RuHCl(CO)(PPh3)3 (5 mol %), dppm (5 mol %), 
iPrOH (4 equiv), PhMe, 105 °C. d Imidazole (1.2 equiv), [PdCl(C3H5)]2 (2.5 mol %), dppf 




 In conclusion, the use of bipyridyl-derived ligands overrode the intrinsic 
regioselectivity of Cu-catalyzed trifluoromethylation reactions of propargyl electrophiles, 
and provided di-, tri-, and tetra-substituted trifluoromethylallenes bearing synthetically 
important functional groups. More broadly, this transformation was the first example of a 
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Unless otherwise noted, all reactions were performed using oven-dried 
glassware under an atmosphere of dry N2. Trifluoromethylation reactions were 
performed in resealable 15 mL screw-top vial sealed with PTFE septa. All other 
reactions were performed in round-bottom flasks, which were sealed with rubber septa. 
Stainless steel syringes were used to transfer air- or moisture-sensitive liquid reagents. 
Reactions were monitored by thin-layer chromatography (TLC) on UNIPLATETM Silica 
Gel HLF 250 micron glass plates precoated with 230–400 mesh silica impregnated with 
a fluorescent indicator (250 nm), visualizing by quenching of fluorescence, KMnO4 
solution, or p-anisaldehyde solution. A CombiFlash® RF–4x purification system was 
used for chromatographic purifications. Silica gel was purchased from Sorbent 
Technologies (cat. #30930M-25, 60 Å, 40–63 μm). 
Unless otherwise noted, reagents were purchased from commercial sources, and 
used as received. Anhydrous potassium fluoride (KF) was dried in a vacuum-oven at 
200 °C for at least 24 h prior to use. Anhydrous N,N′-dimethylformamide (DMF), 
acetonitrile (CH3CN), methanol (MeOH), dichloromethane (DCM), tetrahydrofuran 
(THF), and triethylamine (NEt3) were dispensed from a solvent purification system, in 
which the solvent was dried by passage through two columns of activated alumina 
under argon.  
Proton nuclear magnetic resonance (1H NMR) spectra, and carbon nuclear 
magnetic resonance (13C NMR) spectra were recorded on a Bruker 500 AVANCE 
spectrometer (500 and 126 MHz, respectively) or a Bruker 400 AVANCE spectrometer 
(400 and 101 MHz, respectively). Fluorine nuclear magnetic resonance (19F NMR) 
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spectra were recorded on a Bruker 400 AVANCE spectrometer (376 MHz). Chemical 
shifts (δ) for protons are reported in parts per million (ppm) downfield from 
tetramethylsilane, and are referenced to the proton resonance of residual CHCl3 in the 
NMR solvent (δ = 7.27 ppm). Chemical shifts (δ) for carbon are reported in ppm 
downfield from tetramethylsilane, and are referenced to the carbon resonances of the 
solvent peak (δ = 77.16 ppm). Chemical shifts (δ) for fluorine are reported in ppm, and 
are referenced to PhCF3 (δ = –63.72 ppm). NMR data are represented as follows: 
chemical shift (ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, sept = 
septet, m = multiplet), coupling constant in Hertz (Hz), and integration. 
Exact mass determinations were obtained by the following methods; electron 
impact ionization (EI) on a ZG analytical ZAB mass spectrometer, electrospray 
ionization (ESI) on a Waters LCT PremierTM mass spectrometer, or atmospheric-
pressure chemical ionization (APCI–hexane/PhMe) on a Waters Q-Tof PremierTM, for 
which sample plus near mass internal exact mass standard were dissolved in hexane, 
and hexane or PhMe/hexane were used as ionization solvent. Low-resolution mass data 
(CI) were recorded on a Shimadzu GCMS-QP2010 SE mass spectrometer. Infrared 
spectra were measured using a Shimadzu FTIR-8400S Fourier Transform Infrared 
Spectrometer. Uncorrected melting points were measured on a Thomas Hoover 







Synthesis of Propargyl Alcohols: 
General Procedure A: 
An oven-dried Schlenk flask was charged with iodoarene (1.0 equiv), CuI (0.040 equiv), 
Pd(PPh3)2Cl2 (0.020 equiv), and a magnetic stir bar. The flask was evacuated and 
backfilled with N2 three times. MeCN (1 M) was injected, and the suspension was 
cooled to –10 °C. NEt3 (4.5 equiv) was injected dropwise, and the mixture was stirred at 
–10 °C for 10 min. Propargyl alcohol (1.1 equiv) was injected dropwise, and the mixture 
was allowed to warm to rt. The reaction was monitored by TLC, and upon consumption 
of starting iodoarene (typically < 4 h), the solvent was removed in vacuo. The crude 
mixture was dissolved in EtOAc, and filtered through a pad of silica (eluted with 
additional EtOAc). The solvent was removed in vacuo, and the crude material was 
purified by flash chromatography to afford the 3-arylpropargyl alcohol.  
 
General Procedure B: 
An oven-dried Schlenk flask was charged with benzaldehyde (1.0 equiv), and a 
magnetic stir bar. The flask was evacuated and backfilled with N2 three times. THF was 
injected, and the solution was cooled to 0 °C. Ethynylmagnesium bromide (0.5 M in 
THF, 1.2–1.5 equiv) was injected dropwise, and the reaction was stirred at 0 °C for 1 h. 
The mixture was allowed to warm to rt, and monitored by TLC. After consumption of the 
aldehyde, the reaction was quenched with NH4Cl(aq.), and diluted with EtOAc. The 
organic phase was washed with H2O and brine, dried over Na2SO4, and filtered. The 
solvent was removed in vacuo, and chromatographic purification of the resulting residue 





General procedure A was followed using 4-iodoacetophenone (2.46 g, 10.0 mmol), CuI 
(76 mg, 0.40 mmol), Pd(PPh3)2Cl2 (0.14 g, 0.20 mmol), NEt3 (6.3 mL, 45 mmol), 
propargyl alcohol (0.64 mL, 11 mmol) and MeCN (0.010 L) as solvent. Chromatographic 
purification (hexanes / EtOAc 1:0 → 4:1) afforded the title product as a yellow solid 
(1.23 g, 71%).  
m.p.: 74–76 °C (lit.1 76–77).  
1H NMR (400 MHz, CDCl3):  7.967.88 (m, 2 H), 7.567.49 (m, 2 H), 4.54 (s, 2 H), 




General procedure A was followed using ethyl 3-iodobenzoate (2.76 g, 10.0 mmol), CuI 
(76 mg, 0.40 mmol), Pd(PPh3)2Cl2 (0.14 g, 0.20 mmol), NEt3 (6.3 mL, 45 mmol), 
propargyl alcohol (0.64 mL, 11 mmol) and MeCN (0.010 L) as solvent. Chromatographic 
purification (hexanes / EtOAc 1:0 → 4:1) afforded the title product as a yellow solid 
(1.99 g, 98%).  
m.p.: 47–49 °C (lit.2 48–50 °C).  
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1H NMR (400 MHz, CDCl3):  8.13 (t, J = 1.7 Hz, 1 H), 8.01 (dt, J = 7.9, 1.4 Hz, 1 H), 
7.61 (dt, J = 7.6, 1.4 Hz, 1 H), 7.41 (t, J = 7.8 Hz, 1 H), 4.52 (d, J = 6.1 Hz, 2 H), 4.39 (q, 




General procedure A was followed using 4-iodobenzotrifluoride (2.72 g, 10.0 mmol), CuI 
(76 mg, 0.40 mmol), Pd(PPh3)2Cl2 (0.14 g, 0.20 mmol), NEt3 (6.3 mL, 45 mmol), 
propargyl alcohol (0.64 mL, 11 mmol) and MeCN (0.010 L) as solvent. Chromatographic 
purification (hexanes / EtOAc 1:0 → 5:1) afforded the title product as yellow crystals 
(1.84 g, 92%).  
m.p.: 35–37 °C (lit.1 35–36 °C).  
1H NMR (400 MHz, CDCl3): δ 7.60–7.54 (m, 4 H), 4.53 (s, 2 H), 1.68 (s, 1 H).  




General procedure A was followed using 1-iodo-3-nitrobenzene (2.49 g, 10.0 mmol), 
CuI (76 mg, 0.40 mmol), Pd(PPh3)2Cl2 (0.14 g, 0.20 mmol), NEt3 (6.3 mL, 45 mmol), 
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propargyl alcohol (0.64 mL, 11 mmol) and MeCN (0.010 L) as solvent. Chromatographic 
purification (hexanes / EtOAc 1:0 → 4:1) afforded the title product as a viscous amber 
oil (1.55 g, 88%).  
1H NMR (400 MHz, CDCl3): δ 8.30 (t, J = 1.9 Hz, 1 H), 8.19 (ddd, J = 8.4, 2.3, 1.1 Hz, 1 
H), 7.75 (dt, J = 7.7, 1.3 Hz, 1 H), 7.52 (t, J = 8.0 Hz, 1 H), 4.54 (d, J = 6.2 Hz, 2 H), 




General procedure A was followed using 2-iodo-4-nitroanisole (2.8 g, 0.010 mol), CuI 
(76 mg, 0.40 mmol), Pd(PPh3)2Cl2 (0.14 g, 0.20 mmol), NEt3 (6.3 mL, 45 mmol), 
propargyl alcohol (0.64 mL, 11 mmol) and MeCN (15 mL) as solvent. Chromatographic 
purification (hexanes / EtOAc 9:1 → 3:1) afforded the title product as a pale yellow solid 
(1.1 g, 53%).  
m.p.: 117–118 °C.  
1H NMR (500 MHz, CDCl3): δ 8.31 (d, J = 2.8 Hz, 1 H), 8.22 (dd, J = 9.2, 2.8 Hz, 1 H), 
6.96 (d, J = 9.2 Hz, 1 H), 4.57 (d, J = 6.3 Hz, 2 H), 4.00 (s, 3 H), 1.77 (t, J = 6.3 Hz, 1 
H).  
13C NMR (126 MHz, CDCl3): δ 164.7, 141.2, 129.5, 126.0, 113.0, 110.4, 93.5, 79.8, 
56.8, 51.8.  
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IR (film): 3381, 3090, 2978, 2945, 1605, 1576, 1510, 1493, 1439, 1352, 1279, 1238, 
1188, 1144, 1095, 1015, 974, 899, 879, 820, 746, 723, 638 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M+H]+ (C10H10NO4) requires m/z 




General procedure A was followed using 2-iodobenzonitrile (2.3 g, 0.010 mol), CuI (76 
mg, 0.40 mmol), Pd(PPh3)2Cl2 (0.14 mg, 0.20 mmol), NEt3 (6.3 mL, 45 mmol), propargyl 
alcohol (0.64 mL, 11 mmol) and MeCN (15 mL) as solvent. Chromatographic 
purification (hexanes / EtOAc 4:1 → 3:2) afforded the title product as a tan solid (1.41 g, 
90%). 
m.p.: 60–61 °C.  
1H NMR (400 MHz, CDCl3): δ 7.68–7.60 (m, 1 H), 7.59–7.50 (m, 2 H), 7.47–7.37 (m, 1 









General procedure A was followed using 1,2-dichloro-4-iodobenzene (2.72 g, 10.0 
mmol), CuI (76 mg, 0.40 mmol), Pd(PPh3)2Cl2 (0.14 g, 0.20 mmol), NEt3 (6.3 mL, 45 
mmol), propargyl alcohol (0.64 mL, 11 mmol) and MeCN (0.010 L) as solvent. 
Chromatographic purification (hexanes / EtOAc 1:0 → 5:1) afforded the title product as 
a pale brown solid (1.70 g, 85%).  
m.p.: 64–65 °C.  
1H NMR (400 MHz, CDCl3): δ 7.53 (d, J = 1.9 Hz, 1 H), 7.40 (d, J = 8.3 Hz, 1 H), 




4-Bromoaniline (2.6 g, 15 mmol) was added to an oven-dried 250 mL Schlenk flask. 
THF (0.050 L) and pyridine (1.8 mL, 23 mmol) were injected, and the solution was 
cooled to 0 °C. A solution of trifluoroacetic anhydride (2.5 mL, 18 mmol) in THF (0.010 
L) was slowly injected over a 5 min period, and the reaction was stirred at 0 °C for 1.5 h. 
The solution was allowed to warm to rt, stirred for an additional 1.5 h, and then 
quenched with brine (50 mL). The mixture was extracted with EtOAc (100 mL, 2 x 50 
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mL), and the combined organic solution was washed with 1 N HCl (2 x 75 mL), NaHCO3 
(aq.) (50 mL), and brine (50 mL). The solution was dried over MgSO4, and filtered through 
a pad of silica gel (eluted with 100 mL EtOAc). The solvent was removed in vacuo to 
provide N-(4-bromophenyl)-2,2,2-trifluoroacetamide as a brown solid (3.7 g, 92 %).  
1H NMR (400 MHz, CDCl3): δ 7.84 (s, 1 H), 7.56–7.51 (m, 2 H), 7.51–7.46 (m, 2 H).  
N-(4-bromophenyl)-2,2,2-trifluoroacetamide (1.7 g, 6.4 mmol), CuI (0.12 g, 0.32 mmol), 
and NaI (1.9 g, 13 mmol) were added to a 50 mL Schlenk flask. The flask was 
evacuated and backfilled with dry N2 (3x), and trans-N,N’-dimethyl-1,2-
cyclohexanediamine (0.050 mL, 0.64 mmol) and 1,4-dioxane (6.4 mL) were injected. 
The flask was sealed with a screw-top PTFE stopper, and immersed in a 110 °C oil 
bath. After 16 h, the mixture was allowed to cool to rt, and poured onto 1 N HCl (25 mL). 
The mixture was extracted with EtOAc (3 x 25 mL), and the combined organic layers 
were washed with H2O (50 mL) and brine (50 mL). The organic solution was dried over 
MgSO4, filtered through a pad of silica gel, and the solvent was removed in vacuo. 
Analysis of the material by GC revealed a 3:1 mixture of ArI / ArBr, and the material was 
used without further purification. General procedure A was followed using the haloarene 
mixture, CuI (34 mg, 0.18 mmol), Pd(PPh3)2Cl2 (62 mg, 0.090 mmol), NEt3 (2.8 mL, 
0.020 mol), propargyl alcohol (0.28 mL, 4.9 mmol) and MeCN (0.010 L) as solvent. 
Chromatographic purification (DCM / acetone 1:0 → 9:1) afforded the title product as a 
tan solid (0.51 g, 33% over 2 steps).  
m.p.: 148–149 °C.  
1H NMR (400 MHz, CDCl3): δ 7.87 (s, 1 H), 7.58–7.52 (m, 2 H), 7.51–7.45 (m, 2 H), 
4.51 (s, 2 H), 1.64 (s, 1 H).  
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13C NMR (126 MHz, CDCl3): δ 154.8 (q, J = 37.7 Hz), 135.2, 132.9, 120.7, 120.3, 115.7 
(q, J = 288.8 Hz), 88.1, 84.9, 51.8.  
19F NMR (376 MHz, CDCl3): δ –76.68 (s, 3 F). 
IR (film): 3421, 3308, 3200, 3074, 3065, 1720, 1609, 1549, 1510, 1412, 1358, 1281, 
1244, 1215, 1182, 1153, 1014, 953, 903, 837, 741, 685 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M+H]+ (C11H9NO2F3) requires m/z 




General procedure A was followed using 4-iodoanisole (2.34 g, 10.0 mmol), CuI (76 mg, 
0.40 mmol), Pd(PPh3)2Cl2 (0.14 g, 0.20 mmol), NEt3 (6.3 mL, 45 mmol), propargyl 
alcohol (0.64 mL, 11 mmol) and MeCN (0.010 L) as solvent. Chromatographic 
purification (hexanes / EtOAc 1:0 → 4:1) afforded the title product as a pale yellow solid 
(1.56 g, 96%).  
m.p.: 67–68 °C (lit.6 62.5–64.5 °C).  
1H NMR (400 MHz, CDCl3):  7.427.35 (m, 2 H), 6.896.81 (m, 2 H), 4.49 (d, J = 6.1 






NaOH (1.7 g, 43 mmol) was added to a solution of indole (2.0 g, 17 mmol) in DMF 
(0.030 L). The mixture was stirred for 15 min, after which I2 (4.4 g, 17 mmol) was added 
to the reaction. After 4 h of stirring at 22 °C, the mixture was poured over ice H2O (400 
mL), and the resulting precipitate was collected by filtration, washed with ice H2O (3 x 
20 mL), and dried via azeotropic distillation with toluene. The crude material was 
dissolved in DCM (0.050 L). 4-(dimethylamino)pyridine (210 mg, 1.7 mmol) and NEt3 
(3.6 mL, 26 mmol) were added. The solution was cooled to 0 °C, and di-tert-butyl 
dicarbonate (4.1 g, 19 mmol) was added. The reaction was allowed to warm to rt, and 
stirred for 12 h. DCM (150 mL) was added, and the mixture was washed with NH4Cl (aq.) 
(2 x 100 mL), H2O (100 mL), and brine (100 mL). The organic solution was dried over 
MgSO4, filtered, and the solvent was removed in vacuo. The material was filtered 
through a pad of silica (hexanes / EtOAc 19:1), and then the solvent was removed in 
vacuo. The crude material was transferred to a 50 mL Schlenk flask, and then CuI (130 
mg, 0.68 mmol) and Pd(PPh3)2Cl2 (240 mg, 0.34 mmol) were added to the flask. The 
system was sealed with a rubber septum, and the flask was evacuated and backfilled 
with N2 three times. MeCN (25 mL) and NEt3 (11 mL, 77 mmol) were injected into the 
flask, and then the solution was cooled to –10 °C. Next, propargyl alcohol (1.1 mL, 19 
mmol) was added to the reaction. After 1 h, the mixture was allowed to warm to 22 °C, 
and stirred for 12 h. The reaction mixture was poured over NH4Cl (aq.) (50 mL), and 
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diluted with EtOAc (200 mL). The phases were separated, and the organic layer was 
washed with NH4Cl (aq.) (100 mL), H2O (100 mL), and brine (100 mL). The organic layer 
was dried over MgSO4, filtered, and the solvent was removed in vacuo. 
Chromatographic purification (hexanes / EtOAc 1:0 → 7:3) afforded the title compound 
as a brown solid (3.2 g, 69%). 
m.p.: 73–75 °C.  
1H NMR (400 MHz, CDCl3): δ 8.14 (d, J = 8.2 Hz, 1 H), 7.78 (s, 1 H), 7.67 (dt, J = 7.5, 
1.0 Hz, 1 H), 7.37 (ddd, J = 8.4, 7.2, 1.4 Hz, 1 H), 7.30 (td, J = 7.5, 1.1 Hz, 1 H), 4.58 (s, 
2 H), 1.87 (s, 1 H) 1.68 (s, 9 H).  
13C NMR (126 MHz, CDCl3): δ 149.2, 134.7, 130.5, 129.4, 125.3, 123.4, 120.1, 115.4, 
102.8, 90.8, 84.6, 77.9, 52.0, 28.3.  
IR (film): 3396, 3153, 3053, 2978, 2932, 2866, 1734, 1609, 1558, 1474, 1450, 1373, 
1308, 1275, 1232, 1155, 1099, 1049, 1034, 1013, 912, 852, 746 cm-1.  
HRMS (EI+): exact mass calculated for [M]+ (C16H17NO3) requires m/z 271.1208, found 




CBr4 (33.2 g, 0.100 mol) was added to an oven-dried 500 mL round bottom flask. DCM 
(75 mL) was injected, and the solution was cooled to 0 °C. A solution of PPh3 (52.5 g, 
0.200 mol) in DCM (75 mL) was added over 15 min, resulting in a brown mixture. The 
reaction was stirred for 10 additional minutes, after which a solution of 2-
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naphthaldehyde (7.81 g, 50.0 mmol) in DCM (50 mL) was slowly added. After stirring for 
1 h at 0 °C, the reaction was quenched with H2O (100 mL), and the organic phase was 
further washed with NaHCO3 (aq) (100 mL), NH4Cl (aq), and brine (100 mL). The solution 
was dried over MgSO4, filtered, and the solvent was removed in vacuo. 
Chromatographic purification (hexanes) provided 2-(2,2-dibromovinyl)naphthalene as a 
pale tan solid (12.9 g, 41.3 mmol, 83%). The material was added to an oven-dried 1 L 
Schlenk flask, which was sealed with a rubber septum and evacuated and backfilled 
with N2 three times. THF (0.300 L) was added as solvent, and the solution was cooled 
to –78 °C. A solution of nBuLi (2.15 M in hexanes, 40.4 mL, 86.8 mmol) was injected 
over a 10 min period, and the dark brown solution was stirred at –78 °C for 1 h. The 
flask was placed under a positive pressure of N2, the rubber septum was removed, and 
paraformaldehyde (3.72 g, 124 mmol) was added. The flask was resealed, the mixture 
was allowed to warm to rt and stir for an additional 12 h. The reaction was cooled to 0 
°C and quenched with NH4Cl (aq.) (150 mL). The aqueous phase was extracted with 
Et2O (2 x 150 mL), and the organic extracts were washed with H2O (2 x 300 mL) and 
brine (300 mL). The solution was dried over MgSO4, filtered, and the solvent was 
removed in vacuo. Chromatographic purification (hexanes / EtOAc 9:1 → 3:1) afforded 
the title compound as a pale tan solid (6.48 g, 86%).  
m.p.: 61–63 °C.  
1H NMR (400 MHz, CDCl3): δ 8.00–7.96 (m, 1 H), 7.85–7.75 (m, 3 H), 7.53–7.46 (m, 3 






General procedure B was followed using m-anisaldehyde (0.61 mL, 5.0 mmol), a 
solution of ethynylmagnesium bromide (12 mL, 0.5 M in THF, 6.0 mmol), and THF 
(0.010 L) as solvent. Chromatographic purification (hexanes / EtOAc 1:0 → 9:1) 
afforded the title product as a yellow oil (0.67 g, 83%).  
1H NMR (400 MHz, CDCl3): δ 7.32 (t, J = 7.9 Hz, 1 H), 7.17–7.10 (m, 2 H), 6.93–6.86 




General procedure B was followed using 3-bromobenzaldehyde (0.58 mL, 5.0 mmol), a 
solution of ethynylmagnesium bromide (12 mL, 0.5 M in THF, 6.0 mmol), and THF 
(0.010 L) as solvent. Chromatographic purification (hexanes / EtOAc 1:0 → 9:1) 
afforded the title product as a yellow oil (0.80 g, 76%).  
1H NMR (400 MHz, CDCl3): δ 7.73 (t, J = 1.9 Hz, 1 H), 7.48 (dd, J = 7.9, 1.8 Hz, 2 H), 







General procedure B was followed using 5-bromo-2-((4-
methoxybenzyl)oxy)benzaldehyde10 (1.61 g, 5.0 mmol), a solution of ethynylmagnesium 
bromide (12 mL, 0.5 M in THF, 6.0 mmol), and THF (0.010 L) as solvent. 
Chromatographic purification (hexanes / EtOAc 19:1 → 4:1) afforded the title product as 
a colorless solid (0.67 g, 83%).  
m.p.: 89–91 °C  
1H NMR (400 MHz, CDCl3): δ 7.70 (d, J = 2.5 Hz, 1 H), 7.40 (dd, J = 8.7, 2.5 Hz, 1 H), 
7.38 – 7.33 (m, 2 H), 6.96–6.90 (m, 2 H), 6.87 (d, J = 8.7 Hz, 1 H), 5.67 (dd, J = 6.3, 2.3 
Hz, 1 H), 5.07 (d, J = 2.1 Hz, 2 H), 3.83 (s, 3 H), 2.92 (d, J = 6.3 Hz, 1 H), 2.65 (d, J = 
2.3 Hz, 1 H).  
13C NMR (126 MHz, CDCl3): δ 159.8, 155.1, 132.5, 130.9, 130.8, 129.3, 128.1, 114.3, 
114.2, 113.5, 82.6, 74.8, 70.7, 60.7, 55.5.  
IR (film): 3427, 3290, 3070, 3001, 2934, 2835, 2118, 1612, 1589, 1514, 1485, 1464, 
1441, 1406, 1381, 1304, 1277, 1244, 1175, 1122, 1032, 951, 849, 822, 810, 654 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M–OH]+ (C17H14O2Br) requires m/z 






General procedure B was followed using 5-(furan-2-yl)-1-methyl-1H-pyrazole-3-
carbaldehyde11 (0.35 mL, 2.0 mmol), a solution of ethynylmagnesium bromide (5.0 mL, 
0.5 M in THF, 2.5 mmol), and THF (7.0 mL) as solvent. Chromatographic purification 
(hexanes / EtOAc 19:1 → 14:1) afforded the title product as a yellow oil (0.37 g, 91%).  
1H NMR (500 MHz, CDCl3): δ 7.51 (dd, J = 1.9, 0.8 Hz, 1 H), 6.61 (s, 1 H), 6.57 (dd, J = 
3.4, 0.8 Hz, 1 H), 6.51 (dd, J = 3.4, 1.8 Hz, 1 H), 5.56 (d, J = 2.2 Hz, 1 H), 4.03 (s, 3 H), 
3.23 (s, 1 H), 2.63 (d, J = 2.2 Hz, 1 H).  
13C NMR (126 MHz, CDCl3): δ 150.9, 144.5, 143.0, 135.4, 111.6, 109.0, 103.0, 83.0, 
73.8, 58.9, 38.8.  
IR (film): 3290, 3130, 2951, 2881, 2118, 1529, 1483, 1433, 1381, 1366, 1288, 1232, 
1221, 1161, 1067, 1009, 935, 901, 885, 783, 743, 665, 592 cm–1.  
HRMS (ESI+): mass calculated for [M+Na]+ (C11H10N2O2Na) requires m/z 225.0640, 









General procedure B was followed using 3-bromobenzaldehyde (0.82 mL, 7.0 mmol), a 
solution of propynylmagnesium bromide (21 mL, 0.5 M in THF, 11 mmol), and THF 
(0.020 L) as solvent. Chromatographic purification (hexanes / EtOAc 1:0 → 4:1) 
afforded the title product as a yellow oil (1.5 g, 95%).  
1H NMR (400 MHz, CDCl3): δ 7.70 (d, J = 1.9 Hz, 1 H), 7.48–7.43 (m, 2 H), 7.28–7.21 
(m, 1 H), 5.43–5.37 (m, 1 H), 2.22 (d, J = 4.8 Hz, 1 H), 1.92 (d, J = 2.2 Hz, 3 H).  
13C NMR (101 MHz, CDCl3): δ 143.4, 131.2, 130.1, 129.7, 125.2, 122.6, 83.8, 78.6, 
64.1, 3.7.  
IR (film): 3346, 3061, 2959, 2918, 2853, 2226, 1593, 1572, 1472, 1427, 1377, 1313, 
1298, 1275, 1258, 1188, 1138, 1092, 1070, 997, 889, 862, 766, 700, 671, 635 cm–1.  




An oven-dried Schlenk flask was charged with CuI (9.5 mg, 0.050 mmol), Pd(PPh3)2Cl2 
(0.070 g, 0.10 mmol), and a magnetic stir bar. The flask was evacuated and backfilled 
with N2 three times. MeCN (0.010 mL), 3-bromobenzaldehyde (0.58 mL, 5.0 mmol), 
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NEt3 (0.010 mL), and but-3-yn-2-ol (0.47 mL, 6.0 mmol) were sequentially injected. The 
flask was placed in a 60 °C oil bath for 14 h. The reaction was allowed to cool, and the 
solvent was removed in vacuo. The residue was dissolved in Et2O (50 mL), and washed 
with 1 N HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic solution was dried 
over Na2SO4, filtered, and the solvent was removed in vacuo. Chromatographic 
purification (hexanes / EtOAc 1:0 → 3:1) afforded the title product as a yellow oil (0.72 
g, 82%).  
1H NMR (500 MHz, CDCl3): δ 9.99 (s, 1 H), 7.94–7.90 (m, 1 H), 7.83 (dt, J = 7.7, 1.5 
Hz, 1 H), 7.67 (dt, J = 7.7, 1.5 Hz, 1 H), 7.49 (t, J = 7.7 Hz, 1 H), 4.78 (q, J = 6.6 Hz, 1 
H), 2.13 (s, 1 H), 1.58 (d, J = 6.6 Hz, 3 H).  
13C NMR (126 MHz, CDCl3): δ 191.7, 137.3, 136.5, 133.2, 129.3, 129.2, 124.0, 92.7, 
82.7, 58.9, 24.4. 
IR (film): 3385, 2982, 2932, 2868, 2833, 2729, 1699, 1597, 1576, 1477, 1435, 1389, 
1329, 1279, 1161, 1103, 1078, 1038, 957, 903, 822, 797, 725, 685, 648 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M+H]+ (C11H11O2) requires m/z 




General procedure A was followed using iodobenzene (1.1 g, 0.010 mol), CuI (19 mg, 
0.10 mmol), Pd(PPh3)2Cl2 (0.14 g, 0.20 mmol), 3-butyn-2-ol (0.86 mL, 11 mmol) NEt3 
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(0.010 L) and MeCN (0.010 L). Chromatographic purification (hexanes / EtOAc 1:0 → 
4:1) afforded the title product as a brown oil (1.3 g, 91%).  
1H NMR (400 MHz, CDCl3): δ 7.46–7.41 (m, 2 H), 7.32 (dd, J = 5.0, 1.9 Hz, 3 H), 4.77 
(q, J = 6.6 Hz, 1 H), 2.01 (s, 1 H), 1.57 (d, J = 6.6 Hz, 3 H). 
 
Synthesis of Propargyl Bromodifluoroacetates: 
General Procedure C:  
Bromodifluoroacetic acid (BDFA, 1.4 equiv) was added to an oven-dried round bottom 
flask sealed with a rubber septum. DCM was injected as solvent, and an oil bubbler was 
attached to the flask. DMF (0.30 equiv) and oxalyl chloride (1.3 equiv) were sequentially 
injected (caution: rapid evolution of noxious gases), and the solution was allowed to 
react for 2 h. In a separate oven-dried round bottom flask sealed with a rubber septum, 
substituted propargyl alcohol (1.0 equiv) was added to a solution of DCM (0.1–0.4 M), 
NEt3 (2.0 equiv), and DMAP (for 2° alcohol substrates, 0.2 equiv). The solution was 
cooled to 0 °C, and an oil bubbler was attached to the flask. The solution of acid 
chloride was transferred to the solution of alcohol via syringe. The mixture was allowed 
to warm to rt, and stirred for 2–14 h. The reaction was quenched with 1 N HCl, diluted 
with DCM, and the organic phase was washed with H2O and brine. The organic solution 
was dried over Na2SO4 and filtered, and the solvent was removed in vacuo. 
Chromatographic purification using a minimum amount of silica gel afforded the desired 
propargyl bromodifluoroacetate. [Note: some propargyl bromodifluoroacetates are prone 






General Procedure C was followed using 3-phenylprop-2-yn-1-ol (1.2 mL, 0.010 mol), 
BDFA (2.5 g, 14 mmol), oxalyl chloride (1.1 mL, 13 mmol), DMF (0.23 mL, 3.0 mmol), 
NEt3 (2.8 mL, 0.020 mol), with DCM (25 mL) as solvent. Workup and chromatographic 
purification (hexanes / EtOAc 49:1) afforded the title compound as a yellow oil (2.1 g, 
76%).  
1H NMR (400 MHz, CDCl3): δ 7.53–7.47 (m, 2 H), 7.43–7.33 (m, 3 H), 5.19 (s, 2 H).  
13C NMR (126 MHz, CDCl3): δ 159.0 (t, J = 32.0 Hz), 132.0, 129.3, 128.4, 121.4, 108.4 
(t, J = 314.3 Hz), 88.7, 80.2, 56.4. 
19F NMR (376 MHz, CDCl3): δ –61.74 (s, 2 F).  
IR (film): 3054, 2996, 2941, 1778, 1596, 1482, 1438, 1401, 1357, 1292, 1148, 1130, 
1081, 1073, 942, 906, 850, 756, 714, 601 cm–1.  









General Procedure C was followed using 4.1d.1 (0.52 g, 3.00 mmol), BDFA (0.74 g, 4.2 
mmol), oxalyl chloride (0.33 mL, 3.9 mmol), DMF (0.070 mL, 0.90 mmol), NEt3 (0.84 
mL, 6.0 mmol), with DCM (0.010 L) as solvent. Workup and chromatographic 
purification (hexanes / EtOAc 1:0 → 49:1) afforded the title compound as a yellow oil 
(0.74 g, 74%).  
1H NMR (400 MHz, CDCl3): δ 7.987.89 (m, 2 H), 7.57 (d, J = 8.4 Hz, 2 H), 5.19 (s, 2 
H), 2.62 (s, 3 H).  
13C NMR (126 MHz, CDCl3): δ 197.3, 159.1 (t, J = 32.1 Hz), 137.2, 132.2, 128.3, 126.2, 
108.4 (t, J = 314.3 Hz), 87.8, 83.3, 56.2, 26.8.  
19F NMR (376 MHz, CDCl3): δ 62.16 (s, 2 F).  
IR (film): 3060, 2956, 1782, 1685, 1602, 1359, 1290, 1261, 1166, 1120, 1016, 948, 
833, 707, 634 cm–1.  
HRMS (EI+): mass calculated for [M]+ (C13H9BrF2O3) requires m/z 329.9703, found m/z 







General Procedure C was followed using 4.1e.1 (612 mg, 3.00 mmol), BDFA (735 mg, 
4.20 mmol), oxalyl chloride (0.33 mL, 3.9 mmol), DMF (0.070 mL, 0.90 mmol), NEt3 
(0.84 mL, 6.0 mmol), with DCM (0.010 L) as solvent. Workup and chromatographic 
purification (hexanes / EtOAc 1:0 → 19:1) afforded the title compound as a pale green 
oil (650 mg, 60%).  
1H NMR (400 MHz, CDCl3): δ 8.16 (t, J = 1.7 Hz, 1 H), 8.05 (dt, J = 7.9, 1.4 Hz, 1 H), 
7.65 (dt, J = 7.8, 1.4 Hz, 1 H), 7.43 (t, J = 7.8 Hz, 1 H), 5.18 (s, 2 H), 4.40 (q, J = 7.1 Hz, 
2 H), 1.41 (t, J = 7.1 Hz, 3 H).  
13C NMR (126 MHz, CDCl3): δ 165.7, 159.1, 136.1, 133.2, 131.0, 130.3, 128.6, 121.9, 
108.4, 87.7, 81.1, 61.4, 56.3, 14.4.  
19F NMR (376 MHz, CDCl3): δ –62.35 (s, 2 F).  
IR (film): 3070, 2983, 1782, 1720, 1433, 1369, 1294, 1232, 1168, 1120, 1027, 952, 
754, 682 cm–1.  
HRMS (EI+): mass calculated for [M]+ (C14H11BrF2O4) requires m/z 359.9809, found m/z 







General Procedure C was followed using 4.1f.1 (0.60 g, 3.0 mmol), BDFA (0.74 g, 4.2 
mmol), oxalyl chloride (0.33 mL, 3.9 mmol), DMF (0.070 mL, 0.90 mmol), NEt3 (0.84 
mL, 6.0 mmol), with DCM (0.010 L) as solvent. Workup and chromatographic 
purification (hexanes) afforded the title compound as a colorless oil (0.58 g, 54%).  
1H NMR (400 MHz, CDCl3): δ 7.64–7.57 (m, 4 H), 5.18 (s, 2 H).  
13C NMR (126 MHz, CDCl3): δ 159.1 (t, J = 32.1 Hz), 132.4, 131.2 (q, J = 32.8 Hz), 
125.5 (q, J = 3.8 Hz), 125.3 (q, J = 1.4 Hz), 123.9 (q, J = 272.3 Hz), 108.5 (t, J = 314.3 
Hz), 87.3, 82.7, 56.2.  
19F NMR (376 MHz, CDCl3): δ –62.19 (s, 2 F), –63.46 (s, 3 F).  
IR (film): 3062, 2952, 1782, 1616, 1569, 1438, 1406, 1375, 1325, 1124, 1068, 1018, 
950, 842, 717, 702, 597 cm-1.  
HRMS (EI+): mass calculated for [M]+ (C12H6BrF5O2) requires m/z 355.9471, found m/z 









General Procedure C was followed using 4.1g.1 (0.53 g, 3.0 mmol), BDFA (0.74 g, 4.2 
mmol), oxalyl chloride (0.33 mL, 3.9 mmol), DMF (0.070 mL, 0.90 mmol), NEt3 (0.84 
mL, 6.0 mmol), with DCM (0.010 L) as solvent. Workup and chromatographic 
purification (hexanes / EtOAc 1:0 → 49:1) afforded the title compound as a colorless oil 
(0.53 g, 53%).  
1H NMR (400 MHz, CDCl3): δ 8.34 (t, J = 1.9 Hz, 1 H), 8.24 (ddd, J = 8.4, 2.3, 1.1 Hz, 1 
H), 7.79 (dt, J = 7.7, 1.3 Hz, 1 H), 7.56 (t, J = 8.0 Hz, 1 H), 5.19 (s, 2 H).  
13C NMR (126 MHz, CDCl3): δ 159.0 (t, J = 32.2 Hz), 148.2, 137.7, 129.7, 126.9, 124.1, 
123.3, 108.3 (t, J = 314.3 Hz), 86.1, 82.9, 55.9.  
19F NMR (376 MHz, CDCl3): δ 62.40 (s, 2 F).  
IR (film): 3085, 2925, 1782, 1531, 1352, 1292, 1166, 1124, 1024, 952, 808, 736, 673 
cm–1.  
HRMS (EI+): mass calculated for [M]+ (C11H6NBrF2O4) requires m/z 332.9448, found 







General Procedure B was followed using 4.1h.1 (520 mg, 2.5 mmol), BDFA (610 mg, 
3.5 mmol), oxalyl chloride (0.28 mL, 3.3 mmol), DMF (58 μL, 0.30 mmol), NEt3 (0.70 
mL, 5.0 mmol), with DCM (0.010 L) as solvent. Workup and chromatographic 
purification (DCM) afforded the title compound as a pale yellow solid (0.64 g, 70%). 
m.p.: 120–121 °C.  
1H NMR (500 MHz, CDCl3): δ 8.34 (d, J = 2.8 Hz, 1 H), 8.26 (dd, J = 9.2, 2.8 Hz, 1 H), 
6.98 (d, J = 9.2 Hz, 1 H), 5.21 (s, 2 H), 4.01 (s, 3 H).  
13C NMR (126 MHz, CDCl3): δ 165.0, 159.1 (t, J = 32.2 Hz), 141.1, 129.7, 126.8, 111.9, 
110.6, 108.5 (t, J = 314.3 Hz), 86.3, 82.8, 56.8, 56.3.  
19F NMR (376 MHz, CDCl3): δ –61.77 (s, 2 F).  
IR (film): 3090, 2997, 2957, 1786, 1607, 1580, 1518, 1491, 1462, 1441, 1371, 1348, 
1283, 1167, 1148, 1119, 1099, 1018, 1007, 947, 910, 885, 833, 804, 748, 727, 708, 636 
cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M+H]+ (C12H9NO5F2Br) requires m/z 






General Procedure B was followed using 4.1i.1 (470 mg, 3.0 mmol), BDFA (740 mg, 4.2 
mmol), oxalyl chloride (0.33 mL, 3.9 mmol), DMF (10 μL, 0.9 mmol), NEt3 (0.84 mL, 6.0 
mmol), with DCM (0.010 L) as solvent. Workup and chromatographic purification 
(hexanes / EtOAc 1:0 → 4:1) afforded the title compound as an orange oil (0.67 g, 
72%).  
1H NMR (500 MHz, CDCl3): δ 7.71–7.66 (m, 1 H), 7.63–7.56 (m, 2 H), 7.49 (ddd, J = 
7.8, 6.9, 2.1 Hz, 1 H), 5.23 (s, 2 H).  
13C NMR (126 MHz, CDCl3): δ 159.0 (t, J = 32.3 Hz), 133.0, 132.9, 132.6, 129.6, 125.3, 
117.2, 115.7, 108.4 (t, J = 314.3 Hz), 86.6, 84.6, 55.9.  
19F NMR (376 MHz, CDCl3): δ –63.16 (s, 2 F).  
IR (film): 3070, 3001, 2955, 2231, 1782, 1593, 1566, 1483, 1447, 1437, 1373, 1290, 
1169, 1122, 1040, 1014, 993, 951, 901, 835, 806, 764, 712, 683, 617 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M+H]+ (C12H7NO2F2Br) requires m/z 







General Procedure C was followed using 4.1j.1 (0.60 g, 3.0 mmol), BDFA (0.74 g, 4.2 
mmol), oxalyl chloride (0.33 mL, 3.9 mmol), DMF (0.070 mL, 0.90 mmol), NEt3 (0.84 
mL, 6.0 mmol), with DCM (0.010 L) as solvent. Workup and chromatographic 
purification (hexanes) afforded the title compound as a pale yellow oil (0.91 g, 84%).  
1H NMR (400 MHz, CDCl3): δ 7.57 (d, J = 1.9 Hz, 1 H), 7.467.39 (m, 1 H), 7.30 (dd, J 
= 8.3, 1.8 Hz, 1 H), 5.15 (s, 2 H).  
13C NMR (126 MHz, CDCl3): δ 159.0 (t, J = 32.2 Hz), 134.0, 133.7, 132.9, 131.2, 130.6, 
121.4, 108.4 (t, J = 314.3 Hz), 86.3, 82.2, 56.1.  
19F NMR (376 MHz, CDCl3): δ 62.42 (s, 2 F).  
IR (film): 3093, 2948, 1782, 1463, 1375, 1292, 1170, 1120, 950, 819, 802, 682 cm–1.  
HRMS (EI+): mass calculated for [M]+ (C11H5BrCl2F2O2) requires m/z 355.8818, found 









General Procedure C was followed using 4.1k.1 (0.35 g, 1.4 mmol), BDFA (0.35 g, 2.0 
mmol), oxalyl chloride (0.16 mL, 1.9 mmol), DMF (0.033 mL, 0.43 mmol), NEt3 (0.40 
mL, 2.9 mmol), with DCM (0.010 L) as solvent. Workup and chromatographic 
purification (DCM : acetone 99:1) afforded the title compound as a tan solid (0.33 g, 
58%).  
m.p.: 116–117 °C.  
1H NMR (500 MHz, CDCl3): δ 7.86 (s, 1 H), 7.61–7.56 (m, 2 H), 7.55–7.49 (m, 2 H), 
5.17 (s, 2 H).  
13C NMR (126 MHz, CDCl3): δ 159.2 (t, J = 31.9 Hz), 154.8 (q, J = 37.7 Hz), 135.9, 
133.3, 120.2, 119.3 (d, J = 53.8 Hz), 115.7 (d, J = 288.7 Hz), 108.5 (t, J = 314.4 Hz), 
87.8, 81.1, 56.4.  
19F NMR (376 MHz, CDCl3): δ –60.86 (s, 2 F), –75.67 (s, 3 F).  
IR (film): 3296, 3198, 3134, 2957, 1776, 1703, 1674, 1607, 1543, 1512, 1437, 1410, 
1377, 1283, 1265, 1244, 1227, 1202, 1155, 1113, 1018, 945, 906, 837, 806, 741, 719, 
689, 619 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M]+ (C13H7NO3F5Br) requires m/z 






General Procedure C was followed using 4.1l.1 (486 mg, 3.00 mmol), BDFA (0.74 g, 4.2 
mmol), oxalyl chloride (0.33 mL, 3.9 mmol), DMF (0.070 mL, 0.90 mmol), NEt3 (0.84 
mL, 6.0 mmol), with DCM (0.010 L) as solvent. Workup and chromatographic 
purification (hexanes / EtOAc 19:1) afforded the title compound as a colorless oil (540 
mg, 56%).  
1H NMR (400 MHz, CDCl3): δ 7.477.38 (m, 2 H), 6.916.79 (m, 2 H), 5.16 (s, 2 H), 
3.83 (s, 3 H).  
13C NMR (126 MHz, CDCl3): δ 160.4, 159.2 (t, J = 31.9 Hz), 133.7, 114.1, 113.5, 108.6 
(t, J = 314.4 Hz), 88.9, 79.1, 56.8, 55.4.  
19F NMR (376 MHz, CDCl3): δ 62.30 (s, 2 F).  
IR (film): 3010, 2839, 1780, 1606, 1510, 1290, 1249, 1172, 1120, 1031, 946, 833, 709, 
603 cm–1.  
HRMS (EI+): exact mass calculated for [M]+ (C12H9BrF2O3) requires m/z 317.9703, 







General Procedure B was followed using 4.1m.1 (1.1 g, 4.2 mmol), BDFA (1.0 g, 5.8 
mmol), oxalyl chloride (0.46 mL, 5.41 mmol), DMF (0.10 mL, 1.3 mmol), NEt3 (1.2 mL, 
8.3 mmol), with DCM (0.040 L) as solvent. Workup (H2O was used in place of 1 N HCl 
to quench reaction) and chromatographic purification (hexanes / DCM 7:3) afforded the 
title compound as a tan solid (1.3 g, 73%).  
m.p.: 49–50 °C.  
1H NMR (500 MHz, CDCl3): δ 8.15 (d, J = 8.3 Hz, 1 H), 7.85 (s, 1 H), 7.67 (ddd, J = 7.7, 
1.4, 0.7 Hz, 1 H), 7.38 (ddd, J = 8.4, 7.2, 1.3 Hz, 1 H), 7.32 (ddd, J = 8.2, 7.3, 1.1 Hz, 1 
H), 5.24 (s, 2 H), 1.68 (s, 9 H).  
13C NMR (126 MHz, CDCl3): δ 159.2 (t, J = 32.0 Hz), 149.0, 134.7, 130.5, 130.3, 125.5, 
123.6, 120.1, 115.5, 108.6 (t, J = 314.6 Hz), 101.8, 84.8, 83.9, 81.4, 56.8, 28.3.  
19F NMR (376 MHz, CDCl3): δ –61.86 (s, 2 F). 
IR (film): 3153, 3055, 2982, 2935, 1782, 1742, 15558, 1475, 1452, 1371, 1277, 1234, 
1155, 1121, 1101, 1051, 1032, 1014, 957, 935, 854, 746 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M+H]+ (C18H17NO4F2Br) requires 






General Procedure C was followed using 5-phenylpent-2-yn-1-ol12 (481 mg, 3.00 mmol), 
BDFA (0.74 g, 4.2 mmol), oxalyl chloride (0.33 mL, 3.9 mmol), DMF (0.070 mL, 0.90 
mmol), NEt3 (0.84 mL, 6.0 mmol), with DCM (0.010 L) as solvent. Workup and 
chromatographic purification (hexanes / EtOAc 49:1) afforded the title compound as a 
colorless oil (752 mg, 79%).  
1H NMR (400 MHz, CDCl3): δ 7.35–7.28 (m, 2 H), 7.26–7.20 (m, 3 H), 4.91 (t, J = 2.2 
Hz, 2 H), 2.85 (t, J = 7.5 Hz, 2 H), 2.55 (tt, J = 7.5, 2.2 Hz, 2 H).  
13C NMR (126 MHz, CDCl3): δ 159.1 (t, J = 31.8 Hz), 140.3, 128.6, 128.6, 126.6, 108.6 
(t, J = 314.3 Hz), 89.5, 72.6, 56.5, 34.6, 21.1.  
19F NMR (376 MHz, CDCl3): δ –61.83 (s, 2 F).  
IR (film): 3086, 3063, 3028, 2947, 3932, 2864, 1780, 1603, 1497, 1454, 1375, 1294, 
1169, 1121, 1018, 953, 839, 806, 746, 698 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M]+ (C13H11O2F2Br) requires m/z 








General Procedure C was followed using 4.1o.1 (3.00 g, 16.5 mmol), BDFA (4.03 g, 
23.0 mmol), oxalyl chloride (1.82 mL, 21.5 mmol), DMF (0.39 mL, 5.0 mmol), NEt3 (4.60 
mL, 33.0 mmol), with DCM (75 mL) as solvent. Workup and chromatographic 
purification (hexanes / EtOAc 49:1) afforded the title compound as a light yellow oil 
(4.70 g, 84%).  
1H NMR (500 MHz, CDCl3): δ 8.04 (d, J = 1.4 Hz, 1 H), 7.87–7.80 (m, 3 H), 7.57–7.50 
(m, 3 H), 5.23 (s, 2 H).  
13C NMR (126 MHz, CDCl3): δ 159.2 (t, J = 32.0 Hz), 133.4, 132.9, 132.6, 128.3, 128.3, 
128.0, 127.9, 127.3, 126.9, 118.8, 108.6 (t, J = 314.4 Hz), 89.2, 80.6, 56.7.  
19F NMR (376 MHz, CDCl3): δ –61.76 (s, 2 F).  
IR (film): 3059, 2949, 2237, 1780, 1597, 1501, 1437, 1375, 1290, 1169, 1121, 1014, 
1005, 955, 939, 895, 860, 818, 746, 710 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M]+ (C15H9O2F2Br) requires m/z 







General Procedure C was followed using 4.1p.1 (0.49 g, 3.0 mmol), BDFA (0.74 g, 4.2 
mmol), oxalyl chloride (0.33 mL, 3.9 mmol), DMF (0.070 mL, 0.90 mmol), NEt3 (0.84 
mL, 6.0 mmol), with DCM (0.010 L) as solvent. Workup and chromatographic 
purification (pentane / Et2O 19:1) afforded the title compound as a colorless oil (0.90 g, 
94%).  
1H NMR (500 MHz, CDCl3): δ 7.38–7.33 (m, 1 H), 7.15 (ddt, J = 7.6, 1.5, 0.7 Hz, 1 H), 
7.11 (dd, J = 2.5, 1.7 Hz, 1 H), 6.97 (ddd, J = 8.3, 2.6, 1.0 Hz, 1 H), 6.50 (d, J = 2.3 Hz, 
1 H), 3.85 (s, 3 H), 2.83 (d, J = 2.3 Hz, 1 H). 
13C NMR (126 MHz, CDCl3): δ 160.0, 158.5 (t, J = 32.0 Hz), 135.7, 130.2, 120.2, 115.7, 
113.4, 108.6 (t, J = 314.6 Hz), 78.0, 77.8, 69.6, 55.5.  
19F NMR (471 MHz, CDCl3): δ –62.06 (s, 2 F). 
IR (film): 3296, 3007, 2962, 2943, 2839, 2131, 1778, 1605, 1589, 1491, 1466, 1456, 
1437, 1323, 1271, 1167, 1126, 1051, 1018, 957, 908, 868, 835, 785, 752, 694, 656 cm–
1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M]+ (C12H9O3F2Br) requires m/z 






General Procedure C was followed using 4.1q.1 (0.63 g, 3.0 mmol), BDFA (0.74 g, 4.2 
mmol), oxalyl chloride (0.33 mL, 3.9 mmol), DMF (0.070 mL, 0.90 mmol), NEt3 (0.84 
mL, 6.0 mmol), with DCM (0.010 L) as solvent. Workup and chromatographic 
purification (hexanes / EtOAc 19:1) afforded the title compound as a colorless oil (1.0 g, 
91%).  
1H NMR (500 MHz, CDCl3): δ 7.74 (t, J = 1.9 Hz, 1 H), 7.58 (ddd, J = 8.0, 2.0, 1.1 Hz, 1 
H), 7.52–7.47 (m, 1 H), 7.32 (t, J = 7.9 Hz, 1 H), 6.47 (d, J = 2.3 Hz, 1 H), 2.86 (d, J = 
2.3 Hz, 1 H).  
13C NMR (126 MHz, CDCl3): δ 158.4 (t, J = 32.2 Hz), 136.3, 133.3, 131.0, 130.7, 126.6, 
123.0, 108.4 (t, J = 314.7 Hz), 78.6, 77.2, 68.7.  
19F NMR (376 MHz, CDCl3): δ –62.16 (d, J = 3.8 Hz, 2 F).  
IR (film): 3300, 3065, 2926, 2854, 2131, 1780, 1597, 1574, 1475, 1431, 1333, 1281, 
1252, 1173, 1124, 1074, 1001, 957, 920, 899, 874, 812, 785, 712, 692, 673 cm–1.  







General Procedure C was followed using 4.1r.1 (1.04 g, 3.0 mmol), BDFA (0.74 g, 4.2 
mmol), oxalyl chloride (0.33 mL, 3.9 mmol), DMF (0.070 mL, 0.90 mmol), NEt3 (0.84 
mL, 6.0 mmol), with DCM (0.010 L) as solvent. Workup and chromatographic 
purification (hexanes / EtOAc 19:1) afforded the title compound as a tan solid (1.07 g, 
71%).  
m.p.: 65–68 °C.  
1H NMR (500 MHz, CDCl3): δ 7.85 (d, J = 2.5 Hz, 1 H), 7.48 (dd, J = 8.8, 2.5 Hz, 1 H), 
7.30–7.27 (m, 2 H), 6.93–6.89 (m, 2 H), 6.88–6.85 (m, 2 H), 5.04 (s, 2 H), 3.82 (s, 3 H), 
2.82 (d, J = 2.3 Hz, 1 H).  
13C NMR (126 MHz, CDCl3): δ 159.8, 158.2 (t, J = 31.8 Hz), 155.3, 134.2, 132.3, 129.1, 
127.8, 124.7, 114.2, 114.1, 113.2, 108.6 (t, J = 314.7 Hz), 78.2, 77.1, 70.6, 64.1, 55.4.  
19F NMR (376 MHz, CDCl3): δ –61.88 (s, 2 F).  
IR (film): 3294, 3011, 2959, 2935, 1776, 1612, 1516, 1487, 1466, 1331, 1288, 1246, 
1175, 1124, 1034, 999, 959, 905, 874, 812 cm–1.  







General Procedure C was followed using 4.1s.1 (1.04 g, 3.0 mmol), BDFA (0.74 g, 4.2 
mmol), oxalyl chloride (0.33 mL, 3.9 mmol), DMF (0.070 mL, 0.90 mmol), NEt3 (0.84 
mL, 6.0 mmol), with DCM (0.010 L) as solvent. Workup and chromatographic 
purification (hexanes / EtOAc 19:1) afforded the title compound as a light yellow oil 
(1.07 g, 71%).  
1H NMR (500 MHz, CDCl3): δ 7.54 (dd, J = 1.8, 0.7 Hz, 1 H), 6.71 (s, 1 H), 6.61 (dd, J = 
3.4, 0.7 Hz, 1 H), 6.58 (d, J = 2.3 Hz, 1 H), 6.53 (dd, J = 3.4, 1.8 Hz, 1 H), 4.07 (s, 3 H), 
2.80 (d, J = 2.3 Hz, 1 H).  
13C NMR (126 MHz, CDCl3): δ 158.3 (t, J = 32.1 Hz), 145.0, 144.0, 143.1, 135.6, 111.6, 
109.2, 108.5 (t, J = 314.7 Hz), 104.5, 77.0, 63.9, 39.0.  
19F NMR (471 MHz, CDCl3): δ [–61.88]–[–61.96] (m, 2 F).  
IR (film): 3298, 3132, 2953, 2131, 1778, 1531, 1474, 1431, 1381, 1366, 1331, 1283, 
1234, 1221, 1165, 1124, 1011, 984, 953, 903, 887, 856, 800, 775, 743, 719, 689, 654, 
592 cm–1.  
HRMS (ESI+): mass calculated for [M+H]+ (C13H10BrF2N2O3) requires m/z 358.9843, 






General Procedure C was followed using 4.1t.1 (0.68 g, 3.0 mmol), BDFA (0.74 g, 4.2 
mmol), oxalyl chloride (0.33 mL, 3.9 mmol), DMF (0.070 mL, 0.90 mmol), NEt3 (0.84 
mL, 6.0 mmol), with DCM (0.010 L) as solvent. Workup and chromatographic 
purification (hexanes / EtOAc 19:1) afforded the title compound as a colorless oil (0.57 
g, 50%). 
1H NMR (400 MHz, CDCl3): δ 7.72 (t, J = 1.9 Hz, 1 H), 7.55 (ddd, J = 8.0, 2.0, 1.0 Hz, 1 
H), 7.47 (dt, J = 7.8, 1.3 Hz, 1 H), 7.30 (t, J = 7.9 Hz, 1 H), 6.45 (q, J = 2.3 Hz, 1 H), 
1.96 (d, J = 2.2 Hz, 3 H).  
13C NMR (101 MHz, CDCl3): δ 158.5 (t, J = 31.9 Hz), 137.6, 132.9, 131.0, 130.5, 126.6, 
122.9, 108.7 (t, J = 314.8 Hz), 87.5, 73.2, 69.8, 4.0.  
19F NMR (376 MHz, CDCl3): δ –61.99 (d, J = 2.1 Hz, 2 F).  
IR (film): 3063, 2961, 2922, 2243, 1776, 1595, 1574, 1474, 1431, 1335, 1317, 1281, 
1254, 1171, 1124, 1072, 959, 918, 897, 874, 781, 708, 692 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M]+ (C12H8O2F2Br2) requires m/z 






General Procedure C was followed using 4.1u.1 (0.70 g, 4.0 mmol), BDFA (0.98 g, 5.6 
mmol), oxalyl chloride (0.44 mL, 5.2 mmol), DMF (0.093 mL, 1.2 mmol), NEt3 (1.1 mL, 
8.0 mmol), DMAP (98 mg, 0.80 mmol) with DCM (15 mL) as solvent. Workup and 
chromatographic purification (hexanes / EtOAc 19:1 → 9:1) afforded the title compound 
as a yellow oil (1.2 g, 88%).  
1H NMR (500 MHz, CDCl3): δ 10.01 (s, 1H), 7.97 (td, J = 1.7, 0.6 Hz, 1 H), 7.88 (dt, J = 
7.7, 1.4 Hz, 1 H), 7.71 (dt, J = 7.7, 1.4 Hz, 1 H), 7.53 (t, J = 7.7 Hz, 1 H), 5.82 (q, J = 6.7 
Hz, 1 H), 1.75 (d, J = 6.7 Hz, 3 H).  
13C NMR (126 MHz, CDCl3): δ 191.4, 158.7 (t, J = 31.8 Hz), 137.6, 136.6, 133.4, 130.0, 
129.3, 122.9, 108.7 (t, J = 314.7 Hz), 86.3, 85.4, 65.5, 21.1.  
19F NMR (376 MHz, CDCl3): δ [–61.60]–[–62.04] (m, 1 F), [–62.05]–[–62.48] (m, 1 F).  
IR (film): 3069, 2995, 2837, 2241, 1778, 1705, 1601, 1578, 1481, 1447, 1379, 1346, 
1323, 1286, 1171, 1136, 1121, 1088, 1024, 955, 847, 797, 756, 714, 683, 604 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M]+ (C13H9F2BrO3) requires m/z 






4-Ethynyl-1-tosylpiperidin-4-ol was prepared using a previously reported procedure.13 
General Procedure C was followed using 4-ethynyl-1-tosylpiperidin-4-ol (0.58 g, 2.1 
mmol), BDFA (0.54 g, 3.1 mmol), oxalyl chloride (0.23 mL, 2.7 mmol), DMF (0.048 mL, 
0.63 mmol), NEt3 (0.58 mL, 4.2 mmol), DMAP (26 mg, 0.21 mmol) with DCM (0.010 L) 
as solvent. Workup and chromatographic purification (DCM) afforded the title compound 
as a colorless solid (0.71 g, 78%).  
m.p.: 129–131 °C.  
1H NMR (500 MHz, CDCl3): δ 7.68–7.64 (m, 2 H), 7.36–7.33 (m, 2 H), 3.27–3.20 (m, 2 
H), 3.17–3.08 (m, 2 H), 2.72 (s, 1 H), 2.44 (s, 3 H), 2.38–2.26 (m, 4 H).  
13C NMR (126 MHz, CDCl3): δ 156.9 (t, J = 31.8 Hz), 144.1, 132.8, 129.9, 127.9, 108.3 
(t, J = 315.6 Hz), 79.3, 77.7, 76.6, 42.3, 35.4, 21.7.  
19F NMR (376 MHz, CDCl3): δ –62.21 (s, 2 F).  
IR (film): 3279, 3032, 2978, 2939, 2862, 2120, 1782, 1597, 1495, 1468, 1456, 1356, 
1346, 1327, 1304, 1259, 1215, 1167, 1124, 1094, 1051, 1030, 951, 928, 872, 829, 818, 
723, 650, 598, 548 cm–1.  
HRMS (ESI+): mass calculated for [M+K]+ (C16H16BrF2NO4SK) requires m/z 473.9589, 






1-Tosylpiperidin-4-ol was prepared using a previously reported procedure.14 A 500 mL 
Schlenk flask was oven-dried was capped with a rubber septum, evacuated and 
backfilled with dry N2 (3x), and attached to an oil bubbler. Oxalyl chloride (1.5 mL, 18 
mmol) and DCM (0.10 L) were injected, and the solution was cooled to –78 °C. A 
solution of DMSO (1.9 mL, 26 mmol) in DCM (0.010 L) was injected dropwise over a 5 
min period (rapid evolution of noxious gas). After 1 h, a solution of 1-tosylpiperidin-4-ol 
(2.3 g, 8.8 mmol) in DCM (0.020 mL) was added over a 2 min period. After an additional 
1 h, NEt3 (6.1 mL, 44 mmol) was injected, and the mixture was vigorously stirred. After 
15 min, the reaction was allowed to warm to 0 °C and stirred for an additional 1 h. The 
reaction mixture was washed with H2O (100 mL) and brine (100 mL). The organic 
solution was dried over Na2SO4, filtered, and the solvent was removed in vacuo. 
Chromatographic purification (DCM / MeOH 1:0 → 99:1) afforded 1-tosylpiperidin-4-
one15 as a colorless solid (1.9 g, 85%).  
1H NMR (400 MHz, CDCl3): δ 7.69 (d, J = 8.3 Hz, 2 H), 7.35 (d, J = 8.0 Hz, 2 H), 3.39 (t, 
J = 6.2 Hz, 4 H), 2.55 (t, J = 6.2 Hz, 4 H), 2.45 (s, 3 H). 
 An oven-dried 100 mL Schlenk flask was sealed with a rubber septum, and evacuated 
and backfilled with dry N2 (3x). 1-Hexyne (0.45 mL, 3.9 mmol) and THF (0.010 L) were 
injected, and the solution was cooled to 0 °C. A solution of nBuLi (2.5 M in hexane, 1.3 
mL, 3.3 mmol) was injected dropwise over a 2 min period. The solution was stirred for 
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30 min, and a solution of 1-tosylpiperidin-4-one (0.76 g, 3.0 mmol) in THF (0.020 L) was 
injected over a 5 min period. The solution was allowed to warm to rt, and after 6 h, the 
reaction was quenched with NH4Cl (aq) (30 mL). The aqueous phase was extracted with 
DCM (3 x 20 mL), and the organic extracts were combined. The solution was dried over 
Na2SO4, filtered, and the solvent was removed in vacuo. Chromatographic purification 
(DCM / MeOH 99:1 → 49:1) provided a 4:1 mixture of 4-(hex-1-yn-1-yl)-1-tosylpiperidin-
4-ol : 1-tosylpiperidin-4-one, which was used without further purification. General 
Procedure C was followed using BDFA (0.74 g, 4.2 mmol), oxalyl chloride (0.33 mL, 3.9 
mmol), DMF (0.070 mL, 0.90 mmol), NEt3 (0.84 mL, 6.0 mmol), DMAP (73 mg, 0.60 
mmol) with DCM (0.010 L) as solvent.. Workup and chromatographic purification (DCM) 
afforded the title compound as a colorless solid (1.0 g, 68% over two steps).  
m.p.: 96–97 °C.  
1H NMR (400 MHz, CDCl3): δ 7.66 (d, J = 8.2 Hz, 2 H), 7.34 (d, J = 8.1 Hz, 2 H), 3.15 (t, 
J = 5.8 Hz, 4 H), 2.43 (s, 3 H), 2.32–2.20 (m, 4 H), 2.16 (t, J = 6.9 Hz, 2 H), 1.44–1.33 
(m, 2 H), 1.34–1.24 (m, 2 H), 0.85 (t, J = 7.2 Hz, 3 H).  
13C NMR (101 MHz, CDCl3): δ 156.9 (t, J = 31.3 Hz), 143.9, 132.8, 129.8, 127.9, 108.6 
(t, J = 315.7 Hz), 90.9, 77.9, 76.0, 42.6, 35.9, 30.2, 21.9, 21.6, 18.3, 13.6.  
19F NMR (376 MHz, CDCl3): δ –62.12 (s, 2 F).  
IR (film): 3030, 2959, 2935, 2862, 2249, 1780, 1597, 1495, 1468, 1454, 1431, 1381, 
1358, 1323, 1294, 1259, 1209, 1165, 1130, 1101, 1051, 1018, 949, 912, 866, 818, 802, 
731, 717, 650 cm–1.  
HRMS (ESI+): mass calculated for [M+Na]+ (C20H24BrF2NO4SNa) requires m/z 






General Procedure C was followed using 4.1x.1 (0.44 g, 3.0 mmol), BDFA (0.74 g, 4.2 
mmol), oxalyl chloride (0.33 mL, 3.9 mmol), DMF (0.070 mL, 0.90 mmol), NEt3 (0.84 
mL, 6.0 mmol), DMAP (74 mg, 0.60 mmol) with DCM (12 mL) as solvent. Workup and 
chromatographic purification (hexanes / EtOAc 49:1 → 19:1) afforded the title 
compound as a yellow oil (0.78 g, 86%).  
1H NMR (500 MHz, CDCl3): δ 7.49–7.45 (m, 2 H), 7.39–7.31 (m, 3 H), 5.82 (q, J = 6.7 
Hz, 1 H), 1.73 (d, J = 6.7 Hz, 3 H).  
13C NMR (126 MHz, CDCl3): δ 158.8 (t, J = 31.6 Hz), 132.1, 129.3, 128.5, 121.7, 108.8 
(t, J = 314.7 Hz), 87.0, 84.8, 65.9, 21.2.  
19F NMR (376 MHz, CDCl3): δ [–61.57]–[–62.01] (m, 1 F) , [–62.02]–[–62.46] (m, 1 F).  
IR (film): 3059, 2995, 2939, 1778, 1599, 1491, 1445, 1379, 1346, 1323, 1286, 1169, 
1136, 1117, 1086, 1018, 953, 914, 843, 825, 756, 717, 690, 604, 546 cm–1.  







4-Methyl-1-phenylpent-1-yn-3-yl 2-bromo-2,2-difluoroacetate  
4-Methyl-1-phenylpent-1-yn-3-ol was prepared using a previously reported procedure.16 
General Procedure C was followed using 4-methyl-1-phenylpent-1-yn-3-ol (0.35 g, 2.0 
mmol), BDFA (0.49 g, 2.8 mmol), oxalyl chloride (0.22 mL, 2.6 mmol), DMF (0.046 mL, 
0.60 mmol), NEt3 (0.56 mL, 4.0 mmol), DMAP (49 mg, 0.40 mmol) with DCM (8.0 mL) 
as solvent. Workup and chromatographic purification (hexanes / EtOAc 49:1 → 19:1) 
afforded the title compound as a colorless oil (0.45 g, 68%).  
1H NMR (500 MHz, CDCl3): δ 7.49–7.45 (m, 2 H), 7.39–7.31 (m, 3 H), 5.56 (d, J = 5.7 
Hz, 1 H), 2.24 (pd, J = 6.8, 5.7 Hz, 1 H), 1.16 (d, J = 6.7 Hz, 3 H), 1.13 (d, J = 6.8 Hz, 3 
H).  
13C NMR (126 MHz, CDCl3): δ 158.9 (t, J = 31.5 Hz), 132.1, 129.2, 128.5, 121.8, 108.8 
(t, J = 314.7 Hz), 88.1, 82.8, 74.2, 32.9, 18.1, 17.8.  
19F NMR (376 MHz, CDCl3): δ –61.78 (s, 2 F). 
IR (film): 3059, 2970, 2934, 2878, 1778, 1491, 1470, 1445, 1391, 1364, 1340, 1292, 
1169, 1124, 1099, 1070, 1030, 991, 957, 937, 895, 864, 854, 756, 690 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M]+ (C14H13F2BrO2) requires m/z 






Cu/DMEDA Catalyzed Trifluoromethylation of Propargylic Bromodifluoroacetates: 
General procedure D: 
KF (23 mg, 0.40 mmol) was added to a resealable 15 mL test-tube and dried in a 
vacuum oven for a minimum of 24 h. The vial was removed from the oven, sealed with a 
PTFE septum, and cooled under N2. CuI (3.8 mg, 0.020 mmol) and NaO2CCF2Br (9.8 
mg, 0.050 mmol) were added, and the vial was evacuated and backfilled with N2 three 
times. DMEDA (2.2 μL, 0.020 mmol) and DMF (0.20 mL) were injected, and the vial was 
placed in a 50 °C oil bath. The mixture was heated for 10 min, during which bubbling 
was observed and the solution changed from teal/blue to yellow. Next, propargyl 
bromodifluoroacetate (0.20 mmol) was injected, and heating was maintained for 14 h. 
The reaction mixture was diluted with EtOAc (3 mL), and TFT (24.6 μL, 0.200 mmol) 
was added as an internal standard. An aliquot was removed, and a 19F NMR spectrum 
was obtained. The aliquot was recombined, and the reaction mixture was further diluted 
with EtOAc (15 mL). The organic solution was washed with NH4Cl(aq) (10 mL) and 
brine (10 mL), dried over anhydrous Na2SO4 and filtered, and the solvent was removed 
in vacuo. Chromatographic purification afforded a mixture of propargyl trifluoromethane 
(A) and trifluoromethyl allene (B). The ratio or regioisomers was determined by 1H NMR 








Synthesis of Compounds in Schemes 4.3–4.5: 
 
General procedure D was followed using 4.1l (64 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), DMEDA (2.2 μL, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), with DMF (0.20 mL) as solvent. Workup and chromatographic purification 
(Hexanes / EtOAc 1:0 → 49:1) afforded a mixture of regioisomers as a yellow oil (31 
mg, 72%). Analysis of the 1H NMR spectrum revealed a 4.0 : 1 ratio of 4.2l : 4.3l.17,18 
1H NMR (400 MHz, CDCl3): δ = 7.43–7.34 (m, 2 H, 4.2l/4.3l), 6.94–6.89 (m, 2 H, 4.3l), 
6.88–6.82 (m, 2 H, 4.2l), 5.51 (q, J = 3.4 Hz, 2 H, 4.3l), 3.83 (s, 3 H, 4.3l), 3.82 (s, 3 H, 
4.2l), 3.26 (q, J = 9.6 Hz, 2 H, 4.2l). 
19F NMR (376 MHz, CDCl3): δ = –61.76 (t, J = 3.6 Hz, 3 F, 4.3l), –67.76 (t, J = 10.0 Hz, 
3 F, 4.2l). 
 
 
General procedure D was followed using 4.1h (73 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), DMEDA (2.2 μL, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), with DMF (0.20 mL) as solvent. Workup and chromatographic purification 
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(Hexanes / EtOAc 1:0 → 3:1) afforded a mixture of regioisomers as a colorless solid (36 
mg, 70%). Analysis of the 1H NMR spectrum revealed a 2.1 : 1 ratio of 4.2h : 4.3h. 
m.p.: 76–81 °C. 
1H NMR (400 MHz, CDCl3): δ = 8.31 (d, J = 2.8 Hz, 1 H, 4.2h), 8.28 (dd, J = 9.1, 2.8 
Hz, 1 H, 4.3h), 8.24–8.20 (m, 1 H, 4.2h/4.3h), 7.01 (d, J = 9.1 Hz, 1 H, 4.3h), 6.96 (d, J 
= 9.2 Hz, 1 H, 4.2h), 5.42 (q, J = 3.4 Hz, 2 H, 4.3h), 4.00 (s, 3 H, 4.2h), 3.96 (s, 3 H, 
4.3h), 3.35 (q, J = 9.5 Hz, 2 H, 4.2h). 
13C{1H} NMR (126 MHz, CDCl3): δ = 209.4 (q, J = 3.7 Hz, 4.3h), 165.0 (4.2h), 162.4 
(4.3h), 141.2 (4.3h), 141.1 (4.2h), 129.6 (4.2h), 126.7 (4.3h), 126.5 (4.3h), 126.2 (4.2h), 
124.1 (q, J = 277.0 Hz, 4.2h), 122.9 (q, J = 273.9 Hz, 4.3h), 119.9 (4.3h), 112.6 (4.2h), 
111.0 (4.3h), 110.5 (4.2h), 95.7 (q, J = 37.2 Hz, 4.3h), 83.9 (q, J = 5.0 Hz, 4.2h), 82.2 
(4.3h), 78.6 (4.2h), 56.8 (4.2h), 56.6 (4.3h), 27.2 (q, J = 34.9 Hz, 4.2h). 
19F NMR (376 MHz, CDCl3): δ = –62.45 (t, J = 3.5 Hz, 3 F, 4.3h), –67.35 (t, J = 9.9 Hz, 
3 F, 4.2h). 
IR (film): 3119, 3094, 2947, 2920, 2847, 1983, 1610, 1580, 1514, 1493, 1492, 1439, 
1418, 1344, 1275, 1246, 1190, 1148, 1103, 1018, 968, 906, 891, 868, 833, 797, 750, 
735, 694, 665, 638 cm–1. 






General procedure D was followed using 4.1e (72 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), DMEDA (2.2 μL, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), with DMF (0.20 mL) as solvent. Workup and chromatographic purification 
(Hexanes / EtOAc 1:0 → 49:1) afforded a mixture of regioisomers as a pale green oil 
(0.040 g, 78%). Analysis of the 1H NMR spectrum revealed a 2.3 : 1 ratio of 4.2e : 4.3e. 
1H NMR (400 MHz, CDCl3): δ = 8.16–8.09 (m, 1 H, 4.2e/4.3e), 8.05–7.97 (m, 1 H, 
4.2e/4.3e), 7.66–7.60 (m, 1 H, 4.2e/4.3e), 7.47 (t, J = 7.8 Hz, 1 H, 4.3e), 7.41 (t, J = 7.8 
Hz, 1 H, 4.2e), 5.61 (q, J = 3.4 Hz, 2 H, 4.3e), 4.46–4.33 (m, 2 H, 4.2e/4.3e), 3.30 (q, J 
= 9.5 Hz, 2H, 4.2e), 1.41 (t, J = 7.1 Hz, 3 H, 4.2e : 4.3e). 
13C{1H} NMR (126 MHz, CDCl3): δ = 208.7 (q, J = 4.0 Hz, 4.3e), 166.2 (4.3e), 165.9 
(4.2e), 136.0 (4.2e), 133.1 (4.2e), 131.27 (4.3e), 131.26 (q, J = 1.3 Hz, 4.3e), 130.9 
(4.2e), 129.9 (4.2e), 129.8 (4.3e), 129.4 (4.3e), 128.9 (4.3e), 128.6 (4.2e), 128.4 (4.3e), 
124.2 (q, J = 277.4 Hz, 4.2e), 123.3 (q, J = 273.9 Hz, 4.3e), 122.7 (4.2e), 101.4 (q, J = 
35.7 Hz, 4.3e), 84.2 (4.3e), 83.6 (4.2e), 78.6 (q, J = 5.1 Hz, 4.2e), 61.4 (4.2e), 61.4 
(4.3e), 26.9 (q, J = 34.9 Hz, 4.2e), 14.5 (4.2e/4.3e). 
19F NMR (376 MHz, CDCl3): δ = –61.59 (t, J = 3.6 Hz, 3 F, 4.3e), –67.51 (t, J = 10.0 Hz, 
3 F, 4.2e). 
IR (film): 3067, 2984, 2932, 2854, 1971, 1720, 1472, 1367, 1298, 1256, 1231, 1173, 
1148, 1111, 1084, 1026, 908, 872, 754 cm–1. 
253 
 
MS (CI): mass calculated for [M]+ (C13H11F3O2) requires m/z 256.1, found m/z 256.1. 
 
 
General procedure D was followed using 4.1d (66 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), DMEDA (2.2 μL, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), with DMF (0.20 mL) as solvent. Workup and chromatographic purification 
(Hexanes / EtOAc 1:0 → 49:1) afforded a mixture of regioisomers as a yellow oil (0.030 
g, 66%). Analysis of the 1H NMR spectrum revealed a 2.6 : 1 ratio of 4.2d : 4.3d. 
1H NMR (400 MHz, CDCl3): δ = 7.99–7.94 (m, 2 H, 4.3d), 7.94–7.89 (m, 2 H, 4.2d), 
7.57–7.52 (m, 2 H, 4.2d/4.3d), 5.64 (q, J = 3.3 Hz, 2 H, 4.3d), 3.32 (q, J = 9.5 Hz, 2 H, 
4.2d), 2.62 (s, 3 H, 4.3d), 2.61 (s, 3 H, 4.2d). 
13C{1H} NMR (126 MHz, CDCl3): δ = 209.2 (q, J = 3.9 Hz, 4.3d), 197.5 (4.3d), 197.4 
(4.2d), 136.8 (4.2d), 136.6 (4.3d), 134.1 (4.3d), 132.2 (4.2d), 130.0 (4.2d), 128.9 (4.3d), 
128.4 (4.2d), 127.1 (q, J = 1.3 Hz, 4.3d), 127.1 (4.2d), 124.1 (q, J = 277.4 Hz, 4.2d) 
123.2 (q, J = 273.9 Hz, 4.3d), 101.7 (4.3d), 84.5 (4.3d), 83.7 (4.2d), 81.0 (q, J = 5.1 Hz, 
4.2d), 27.0 (q, J = 35.0 Hz, 4.2d), 26.81 (A), 26.78 (4.3d). 
19F NMR (376 MHz, CDCl3): δ = (–63.30)–(–63.53) (m, 3 F, 4.3d), –67.66 (t, J = 10.0 
Hz, 3 F, 4.2d). 
IR (film): 3067, 2964, 2932, 3854, 1969, 1933, 1686, 1603, 1558, 1418, 1404, 1362, 
1306, 1263, 1178, 1150, 1109, 1016, 957, 935, 906, 833, 717, 679, 628, 592 cm–1. 





General procedure D was followed using 4.1m (86 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), DMEDA (2.2 μL, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), with DMF (0.20 mL) as solvent. Workup and chromatographic purification 
(Hexanes / EtOAc 1:0 → 9:1) afforded a mixture of regioisomers as viscous orange oil 
(38 mg, 59%). Analysis of the 1H NMR spectrum revealed a 3.0 : 1 ratio of 4.2m : 4.3m. 
1H NMR (400 MHz, CDCl3): δ = 8.19 (d, J = 8.5 Hz, 1 H, 4.3m), 8.15 (d, J = 8.2 Hz, 1 H, 
4.2m), 7.87 (dt, J = 8.0, 1.0 Hz, 1 H, 4.3m), 7.79 (s, 1 H, 4.2m), 7.73 (s, 1 H, 4.3m), 
7.68–7.60 (m, 1 H, 4.2m), 7.37 (td, J = 8.3, 7.7, 1.4 Hz, 1 H, 4.2m/4.3m), 7.31 (td, J = 
7.5, 1.1 Hz, 1 H, 4.2m), 7.29–7.24 (m, 1 H, 4.3m), 5.69 (qd, J = 3.0, 0.9 Hz, 2 H, 4.3m), 
3.37 (q, J = 9.6 Hz, 2 H, 4.2m), 1.70 (s, 9 H, 4.3m), 1.68 (s, 9 H, 4.2m). 
13C{1H} NMR (126 MHz, CDCl3): δ = 208.9 (q, J = 3.7 Hz, 4.3m), 149.5 (4.3m), 149.1 
(4.2m), 135.5 (4.3m), 134.7 (4.2m), 130.53 (4.2m), 129.6 (4.2m), 128.4 (4.3m), 125.4 
(4.2m), 125.2 (4.3m), 124.4 (q, J = 277.1 Hz, 4.2m), 124.2 (q, J = 1.3 Hz, 4.3m), 123.4 
(4.2m), 123.3 (q, J = 273.7 Hz, 4.3m), 123.1 (4.3m), 120.1 (4.2m), 119.9 (4.3m), 115.5 
(4.3m), 115.4 (4.2m), 108.0 (4.3m), 102.4 (4.2m), 95.7 (q, J = 36.1 Hz, 4.3m), 84.59 
(4.2m), 84.58 (4.2m), 84.52 (4.3m), 81.1 (q, J = 5.1 Hz, 4.2m), 76.6 (4.3m) 28.3 (4.3m), 
28.3 (4.2m), 27.2 (q, J = 34.8 Hz, 4.2m). 
19F NMR (376 MHz, CDCl3): δ = –63.41 (t, J = 3.5 Hz, 3 F, 4.3m), –67.66 (t, J = 9.9 Hz, 
3 F, 4.2m). 
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IR (film): 3159, 3055, 2980, 2932, 2851, 1740, 1558, 1475, 1454, 1420, 1375, 1357, 
1308, 1279, 1234, 1256, 1234, 1111, 1049, 1032, 854, 831, 746, 729 cm–1. 
MS (CI): exact mass calculated for [2M + Na]+ (C34H32F6N2O4Na) requires m/z 
669.2164, found m/z 669.2179 (2.2 ppm). 
 
 
General procedure D was followed using 4.1k (0.080 g, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), DMEDA (2.2 μL, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), with DMF (0.20 mL) as solvent. Workup and chromatographic purification 
(Hexanes / DCM 1:0 → 1:1) afforded a mixture of regioisomers as a colorless solid (24 
mg, 40%). Analysis of the 1H NMR spectrum revealed a 6.3 : 1 ratio of 4.2k : 4.3k. 
1H NMR (400 MHz, CDCl3): δ = 7.89 (s, 1 H, 4.2k), 7.83 (s, 1 H, 4.3k), 7.62–7.58 (m, 2 
H, 4.3k), 7.58–7.54 (m, 2 H, 4.2k), 7.52–7.45 (m, 2 H, 4.2k/4.3k), 5.60 (q, J = 3.4 Hz, 2 
H, 4.3k), 3.29 (q, J = 9.5 Hz, 2 H, 4.2k). 
13C{1H} NMR (126 MHz, CDCl3): δ = 208.7 (q, J = 4.4 Hz, 4.3k), 154.9 (q, J = 37.5 Hz, 
4.3k),154.8 (q, J = 37.5 Hz, 4.2k), 135.4 (4.2k), 135.00 (4.3k), 133.1 (4.2k), 128.2 (q, J 
= 1.5 Hz, 4.3k), 124.3 (q, J = 276.9 Hz, 4.2k), 123.3 (q, J = 275.6 Hz, 4.3k), 120.7 
(4.2k), 120.32 (4.3k), 120.25 (4.2k), 120.18 (4.3k), 115.70 (q, J = 288.8, 4.3k), 115.69 
(q, J = 288.8 Hz, 4.2k), 101.2 (q, J = 35.4 Hz, 4.3k), 84.3 (4.3k), 83.5 (4.2k), 78.5 (q, J = 
5.0 Hz, 4.2k), 26.9 (q, J = 34.8 Hz, 4.2k). 
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19F NMR (376 MHz, CDCl3): δ = –61.55 (t, J = 3.0 Hz, 3 F, 4.3k), –67.35 (t, J = 9.5 Hz, 
3 F, 4.2k), –76.69 (3 F, 4.2k/4.3k). 
IR (film): 3200, 3202, 3136, 2964, 1705, 1607, 1547 1512, 1410, 1366, 1281, 1246, 
1202, 1155, 1155, 1107, 959, 906, 839, 727, 704, 654 cm–1. 
MS (CI): mass calculated for [M]+ (C12H7F6NO) requires m/z 295.0, found m/z 295.0. 
 
 
General procedure D was followed using 4.1j (72 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), DMEDA (2.2 μL, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), with DMF (0.20 mL) as solvent. Workup and chromatographic purification 
(Hexanes) afforded a mixture of regioisomers as a pale yellow oil (0.040 g, 79%). 
Analysis of the 1H NMR spectrum revealed a 2.2 : 1 ratio of 4.2j : 4.3j. 
1H NMR (400 MHz, CDCl3): δ = 7.55 (d, J = 2.0 Hz, 1 H, 4.2j), 7.52 (d, J = 2.2 Hz, 1 H, 
4.3j), 7.45 (d, J = 8.5 Hz, 1 H, 4.3j), 7.40 (d, J = 8.3 Hz, 1 H, 4.2j), 7.30–7.26 (m, 2 H, 
4.2j/4.3j), 5.63 (q, J = 3.3 Hz, 2 H, 4.3j), 3.28 (q, J = 9.5 Hz, 2 H, 4.2j). 
13C{1H} NMR (126 MHz, CDCl3): δ = 208.6 (q, J = 3.9 Hz, 4.3j), 133.6 (4.2j), 133.4 
(4.2j), 133.2 (4.3j), 132.8 (4.2j), 132.6 (4.3j), 131.1 (4.2j), 130.8 (4.3j), 130.5 (4.2j), 
129.4 (4.3j), 129.0 (q, J = 1.7 Hz, 4.3j), 126.3 (q, J = 1.7 Hz, 4.3j), 124.1 (q, J = 276.9 
Hz, 4.2j), 123.0 (q, J = 273.1 Hz, 4.3j), 122.2 (4.2j), 100.6 (q, J = 35.2 Hz, 4.3j), 84.7 
(4.3j), 82.3 (4.2j), 79.8 (q, J = 5.1 Hz, 4.2j), 26.9 (q, J = 34.9 Hz, 4.2j). 
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19F NMR (376 MHz, CDCl3): δ = –61.59 (t, J = 3.6 Hz, 3 F, 4.3j), –67.51 (t, J = 10.0 Hz, 
3 F, 4.2j). 
IR (film): 3074, 2928, 1973, 1533, 1475, 1466, 1364, 1352, 1281, 1254, 1178, 1151, 
1130, 1111, 1034, 906, 881, 822 cm–1. 
HRMS (EI): mass calculated for [M]+ (C10H5Cl2F3) requires m/z 251.9720, found m/z 
251.9721 (0.3 ppm). 
 
 
General procedure D was followed using 4.1f (71 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), DMEDA (2.2 μL, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), with DMF (0.20 mL) as solvent. Workup and chromatographic purification 
(Hexanes / EtOAc 1:0 → 49:1) afforded a mixture of regioisomers as a colorless oil (35 
mg, 70%). Analysis of the 1H NMR spectrum revealed a 1.7 : 1 ratio of 4.2f : 4.3f. 
1H NMR (400 MHz, CDCl3): δ = 7.67–7.53 (m, 4 H, 4.2f/4.3f), 5.64 (q, J = 3.4 Hz, 2 H, 
4.3f), 3.31 (q, J = 9.5 Hz, 2 H, 4.2f). 
13C{1H} NMR (126 MHz, CDCl3): δ = 209.0 (q, J = 4.1 Hz, 4.3f), 133.1 (q, J = 1.6 Hz, 
4.3f), 132.3 (4.2f), 130.6 (q, J = 32.7 Hz, 4.2f), 130.4 (q, J = 32.7 Hz, 4.3f), 127.4 (q, J = 
1.6 Hz, 4.3f), 126.1 (q, J = 1.7 Hz, 4.2f), 125.8 (q, J = 3.8 Hz, 4.3f), 125.4 (q, J = 3.9 Hz, 
4.2f), 124.2 (q, J = 278.6 Hz, 4.2f), 124.0 (q, J = 272.2 Hz, 4.3f), 123.9 (q, J = 271.8 Hz, 
4.2f), 123.1 (q, J = 274.8 Hz, 4.3f), 101.3 (q, J = 35.0 Hz, 4.3f), 84.5 (4.3f), 83.2 (4.2f), 
80.2 (q, J = 5.1 Hz, 4.2f), 27.0 (q, J = 34.9 Hz, 4.2f). 
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19F NMR (376 MHz, CDCl3): δ = –61.50 (t, J = 3.5 Hz, 3 F, 4.3f), –63.79 (3 F, 4.3f), –
63.93 (3 F, 4.2f), –67.42 (t, J = 9.9 Hz, 3 F, 4.2f). 
IR (film): 3063, 2934, 1971, 1927, 1618, 1406, 1366, 1329, 1281, 1267, 1151, 1130, 
1105, 1068, 1018, 937, 906, 870, 843, 735, 723 cm–1. 
MS (CI): mass calculated for [M]+ (C11H6F6) requires m/z 252.0, found m/z 252.0. 
 
 
General procedure D was followed using 4.1o (2.4 g, 7.0 mmol), CuI (130 mg, 0.70 
mmol), DMEDA (75 μL, 0.70 mmol), NaO2CCF2Br (0.35 g, 1.8 mmol), KF (0.81 g, 14 
mmol), with DMF (7.0 mL) as solvent. Workup and chromatographic purification 
(Hexanes / EtOAc 1:0 → 49:1) afforded a mixture of regioisomers as a pale yellow solid 
(0.93 g, 57%). Analysis of the 1H NMR spectrum revealed a 3.8 : 1 ratio of 4.2o : 
4.3o.17,18 
m.p.: 42–45 °C. 
1H NMR (400 MHz, CDCl3): δ = 8.00 (s, 1 H, 4.2o), 7.93 (s, 1 H, 4.3o), 7.88–7.77 (m, 3 
H, 4.2o/4.3o), 7.57–7.47 (m, 3 H, 4.2o/4.3o), 5.63 (q, J = 3.3 Hz, 2 H, 4.3o), 3.34 (q, J = 
9.6 Hz, 2 H, 4.2o). 
19F NMR (376 MHz, CDCl3): δ = –61.30 (t, J = 3.6 Hz, 3 F, 4.3o), –67.56 (t, J = 10.1 Hz, 





General procedure D was followed using 4.1n (63 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), DMEDA (2.2 μL, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), with DMF (0.20 mL) as solvent. Workup and chromatographic purification 
(Hexanes) afforded a mixture of regioisomers as a tan oil (0.030 g, 70%). Analysis of 
the 1H NMR spectrum revealed a 1 : 2.1 ratio of 4.2n : 4.3n. 
1H NMR (400 MHz, CDCl3): δ = 7.37–7.28 (m, 2 H, 4.2n/4.3n), 7.26–7.19 (m, 3 H, 
4.2n/4.3n), 5.18 (h, J = 3.6 Hz, 2 H, 4.3n), 3.01 (qt, J = 9.7, 2.4 Hz, 2 H, 4.2n), 2.90–
2.73 (m, 2 H, 4.2n/4.3n), 2.54–2.41 (m, 2 H, 4.2n/4.3n). 
13C{1H} NMR (126 MHz, CDCl3): δ = 206.7 (q, J = 4.1 Hz, 4.3n), 140.8 (4.3n), 140.5 
(4.2n), 128.59 (4.2n/4.3n), 128.56 (4.3n), 128.52 (4.2n), 126.5 (4.2n), 126.35 (4.3n), 
124.5 (q, J = 277.8 Hz, 4.2n), 123.9 (q, J = 274.5 Hz, 4.3n), 98.1 (q, J = 34.0 Hz, 4.3n), 
84.3 (4.2n), 82.5 (4.3n), 69.2 (q, J = 5.1 Hz, 4.2n), 34.9 (4.2n), 33.6 (4.3n), 27.7 (4.3n), 
26.3 (q, J = 34.6 Hz, 4.2n), 21.0 (4.2n). 
19F NMR (376 MHz, CDCl3): δ = –61.60 (t, J = 3.7 Hz, 4.3n), –67.54 (t, J = 10.0 Hz, 
4.2n). 
IR (film): 3088, 3065, 3030, 2932, 2862, 1985, 1954, 1605, 1497, 1454, 1366, 1333, 
1281, 1261, 1200, 1157, 1115, 1055, 980, 908, 864, 744, 700 cm–1. 





General procedure D was followed using 4.1b (0.070 g, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), DMEDA (2.2 μL, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), with DMF (0.20 mL) as solvent. Workup and chromatographic purification 
(Hexanes : EtOAc 1:0 → 9:1) afforded a mixture of regioisomers as a yellow oil (0.020 
g, 41%). Analysis of the 1H NMR spectrum revealed a 1.6 : 1 ratio of 4.2b : 4.3b. 
1H NMR (400 MHz, CDCl3): δ = 8.41–8.37 (m, 1 H, 4.2b), 8.32–8.24 (m, 1 H, 
4.2b/4.3b), 8.14–8.20 (m, 1 H, 4.3b), 7.85–7.80 (m, 1 H, 4.2b), 7.79–7.73 (m, 1 H, 
4.3b), 7.63–7.53 (m, 1 H, 4.2b/4.3b), 6.08 (qt, J = 7.5, 3.1 Hz, 1 H, 4.3b), 4.43 (qq, J = 
7.8, 2.5 Hz, 1 H, 4.2b), 1.97–1.93 (m, 3 H, 4.2b/4.3b). 
13C{1H} NMR (126 MHz, CDCl3): δ = 205.6 (q, J = 3.9 Hz, 4.3b), 148.7 (4.3b), 148.5 
(4.2b), 135.5 (4.2b), 134.6 (4.3b), 132.7 (q, J = 1.8 Hz, 4.3b), 129.8 (4.3b), 129.7 
(4.2b), 124.62 (4.2b) 124.61 (4.3b), 124.1 (q, J = 280.4 Hz, 4.2b), 124.0 (4.2b), 123.1 
(q, J = 274.8 Hz, 4.3b), 122.9 (4.2b), 122.2 (q, J = 1.8 Hz, 4.3b), 100.1 (q, J = 35.3 Hz, 
4.3b), 96.6 (4.3b), 83.6 (4.2b), 70.3 (q, J = 3.4 Hz, 4.2b), 43.3 (q, J = 31.8 Hz, 4.2b), 
13.4 (4.3b), 3.8 (4.2b). 
19F NMR (376 MHz, CDCl3): δ = –61.70 (s, 3 F, 4.3b), –71.74 (d, J = 7.5 Hz, 3 F, 4.2b). 
IR (film): 3090, 2961, 2926, 2856, 1963, 1535, 1481, 1441, 1352, 1327, 1248, 1178, 
1155, 1119, 980, 964, 926, 901, 806, 739, 710, 687 cm–1. 





General procedure D was followed using 4.1c (83 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), DMEDA (2.2 μL, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), with DMF (0.20 mL) as solvent. Workup and chromatographic purification 
(Hexanes) afforded a mixture of regioisomers as an amorphous tan solid (0.050 g, 
81%). Analysis of the 1H NMR spectrum revealed a 2.0 : 1 ratio of 4.2c : 4.3c. 
1H NMR (400 MHz, CDCl3): δ = 7.73–7.69 (m, 2 H, 4.3c), 7.69–7.64 (m, 2 H, 4.2c), 
7.21–7.15 (m, 2 H, 4.2c/4.3c), 5.56 (q, J = 3.4 Hz, 2 H, 4.3c), 3.27 (q, J = 9.5 Hz, 1 H, 
4.2c). 
13C{1H} NMR (126 MHz, CDCl3): δ = 208.5 (q, J = 4.0 Hz, 4.3c), 138.0 (4.3c), 137.7 
(4.2c), 133.5 (4.2c/4.3c), 128.87 (q, J = 1.5 Hz, 4.3c), 124.2 (q, J = 276.9 Hz, 4.2c), 
123.2 (q, J = 273.6 Hz, 4.3c), 121.8 (4.2c), 94.9 (4.2c), 94.1 (4.3c), 84.2 (4.2c), 83.6 
(4.3c), 79.1 (q, J = 5.1 Hz, 4.2c), 27.0 (q, J = 34.9 Hz, 4.2c). Note: Terminal substituted 
carbon of 4.3c could not be distinguished from the baseline (expected to be a quartet (J 
≈ 35 Hz) between δ 102–100). 
19F NMR (376 MHz, CDCl3): δ = –61.60 (t, J = 3.7 Hz, 3 F, 4.3c), –67.54 (t, J = 10.0 Hz, 
3 F, 4.2c). 
IR (film): 3065, 2978, 1961, 1541, 1485, 1391, 1366, 1319, 1279, 1263, 1254, 1173, 
1148, 1111, 1061, 1007, 935, 906, 868, 820, 743, 665 cm–1. 
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MS (CI): mass calculated for [M]+ (C10H6F3I) requires m/z 310.0, found m/z 310.0. 
 
Cu/phen Catalyzed Trifluoromethylation of Propargylic Bromodifluoroacetates: 
General procedure E: 
KF (23 mg, 0.4 mmol) was added to a 15 mL screw-top vial, and dried in a vacuum 
oven for a minimum of 24 h. The vial was removed from the oven, sealed with a PTFE 
septum, and allowed to cool under a dry atmosphere of N2. CuI (3.8 mg, 0.020 mmol), 
NaO2CCF2Br (9.8 mg, 0.050 mmol), and 1,10-phenanthroline (phen, 3.6 mg, 0.020 
mmol) or 2,2’:6’,2”-terpyridine (terpy, 4.6 mg, 0.020 mmol) were added to the vial. The 
system was resealed, and evacuated and backfilled with dry N2. DMF (0.2 mL) was 
injected as solvent, and the mixture was placed in a 50 °C or 60 °C heating block. After 
10 min, propargyl bromodifluoroactetate (0.20 mmol) was added to the vial, and heating 
was maintained for 14 or 24 h. The mixture was cooled to rt, diluted with EtOAc (4 mL), 
and α,α,α-trifluorotoluene (0.025 mL, 0.20 mmol) was injected as a standard. After 
thorough mixing, an aliquot was withdrawn, and analyzed by 19F NMR spectroscopy. 
The aliquot was recombined with the reaction mixture, which was further diluted with 
EtOAc (20 mL). The mixture was washed with H2O (20 mL) and brine (20 mL), dried 
over Na2SO4, filtered, and the solvent was removed in vacuo. The crude material was 
subjected the silica gel chromatography to provide trifluoromethylallenes. The ratio of 






General procedure F: 
KF (23 mg, 0.4 mmol) was added to a 15 mL screw-top vial, and dried in a vacuum 
oven for a minimum of 24 h. The vial was removed from the oven, sealed with a PTFE 
septum, and allowed to cool under a dry atmosphere of N2. Propargyl 
bromodifluoroacetate (0.2 mmol), CuI (3.8 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 
0.050 mmol), and 1,10-phenanthroline (phen, 3.6 mg, 0.020 mmol) or 2,2’:6’,2”-
terpyridine (terpy, 4.6 mg, 0.020 mmol) were added to the vial. The system was 
resealed, and evacuated and backfilled with dry N2. DMF (0.2 mL) was injected as 
solvent, and the mixture was placed in a 50 °C or 60 °C heating block for 14 or 24 h. 
The mixture was cooled to rt, diluted with EtOAc (4 mL), and α,α,α-trifluorotoluene 
(0.025 mL, 0.20 mmol) was injected as a standard. After thorough mixing, an aliquot 
was withdrawn, and analyzed by 19F NMR spectroscopy. The aliquot was recombined 
with the reaction mixture, which was further diluted with EtOAc (20 mL). The mixture 
was washed with H2O (20 mL) and brine (20 mL), dried over Na2SO4, filtered, and the 
solvent was removed in vacuo. The crude material was subjected the silica gel 
chromatography to afford trifluoromethylallenes. The ratio of allene / alkyne products 




General procedure E was followed using 4.1a (0.29 g, 1.0 mmol), CuI (19 mg, 0.10 
mmol), phen (18 mg, 0.020 mmol), NaO2CCF2Br (49 mg, 0.25 mmol), KF (0.12 g, 2.0 
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mmol), and DMF (1.0 mL) as solvent. After activation, the reaction was heated at 50 °C 
for 14 h. Workup and chromatographic purification (pentane) afforded the title 
compound as a colorless oil (0.13 g, 70%). Analysis of the 1H NMR spectrum revealed a 
<1:100 ratio of 4.2a : 4.3a.   
1H NMR (400 MHz, CDCl3): δ 7.49 (d, J = 7.8 Hz, 2 H), 7.45–7.39 (m, 2 H), 7.38–7.32 
(m, 1 H), 5.57 (q, J = 3.4 Hz, 2 H).  




General procedure E was followed using 4.1d (66 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
50 °C for 14 h. Workup and chromatographic purification (hexanes / EtOAc 1:0 → 49:1) 
afforded the title compound as a yellow oil (31 mg, 69%). Analysis of the 1H NMR 
spectrum revealed a 1:33 ratio of 4.2d : 4.3d.  
1H NMR (400 MHz, CDCl3): δ 7.99–7.94 (m, 2 H), 7.55 (d, J = 8.2 Hz, 2 H), 5.64 (q, J = 
3.3 Hz, 2 H), 2.62 (s, 3 H).  
13C NMR (126 MHz, CDCl3): δ 209.2 (q, J = 4.1 Hz), 197.5, 136.6, 134.1, 128.8, 127.2 
(q, J = 1.7 Hz), 123.2 (q, J = 273.9 Hz), 101.63 (q, J = 34.9 Hz), 84.5, 26.8.  
19F NMR (376 MHz, CDCl3): δ –61.41 (t, J = 3.4 Hz).  
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IR (film): 3066, 2358, 2341, 1969, 2341, 1969, 1934, 1685, 1605, 1433, 1359, 1307, 
1267, 1124, 1107, 935, 869, 840, 717, 609 cm–1.  
HRMS (EI+): mass calculated for [M]+ (C12H9F3O) requires m/z 226.0605, found m/z 




General procedure E was followed using 4.1e (72 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
50 °C for 14 h. Workup and chromatographic purification (hexanes / EtOAc 1:0 → 49:1) 
afforded the title compound as a pale yellow oil (39 mg, 76%). Analysis of the 1H NMR 
spectrum revealed a 1:33 ratio of 4.2e : 4.3e.  
1H NMR (400 MHz, CDCl3): δ 8.16–8.08 (m, 1 H), 8.00 (dt, J = 7.8, 1.4 Hz, 1 H), 7.68–
7.59 (m, 1 H), 7.46 (t, J = 7.8 Hz, 1 H), 5.61 (q, J = 3.4 Hz, 2 H), 4.40 (q, J = 7.1 Hz, 2 
H), 1.41 (t, J = 7.1 Hz, 3 H).  
13C NMR (126 MHz, CDCl3): δ 208.7 (q, J = 4.0 Hz), 166.2, 131.3, 131.2 (q, J = 1.4 Hz), 
129.8, 129.4, 128.9, 128.4, 123.3 (q, J = 273.8 Hz), 101.4 (q, J = 34.9 Hz), 84.2, 61.4, 
14.4.  
19F NMR (376 MHz, CDCl3): δ –61.34 (t, J = 3.4 Hz, 3 F).  
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IR (film): 3068, 2985, 1973, 1938, 1720, 1606, 1583, 1446, 1367, 1309, 1174, 1124, 
1024, 873, 757, 692, 651 cm–1. 
HRMS (EI+): mass calculated for [M]+ (C13H11F3O2) requires m/z 256.0711, found m/z 




General procedure E was followed using 4.1f (71 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
50 °C for 14 h. Workup and chromatographic purification (hexanes / EtOAc 1:0 → 49:1) 
afforded the title compound as a colorless oil (33 mg, 66%). Analysis of the 1H NMR 
spectrum revealed a 1:40 ratio of 4.2f : 4.3f.  
1H NMR (400 MHz, CDCl3): δ 7.64 (d, J = 8.5 Hz, 2 H), 7.57 (d, J = 8.4 Hz, 2 H), 5.64 
(q, J = 3.4 Hz, 2 H).  
13C NMR (126 MHz, CDCl3): δ 209.0 (q, J = 4.1 Hz), 133.1 (q, J = 1.6 Hz), 130.4 (q, J = 
32.7 Hz), 127.4 (q, J = 1.6 Hz), 125.8 (q, J = 3.8 Hz), 124.0 (q, J = 272.2 Hz), 123.1 (q, 
J = 274.8 Hz), 101.3 (q, J = 35.0 Hz), 84.5.  
19F NMR (376 MHz, CDCl3): δ –61.50 (t, J = 3.5 Hz, 3 F), –63.79 (s, 3 F).  
IR (film): 3076, 2930, 1971, 1933, 1622, 1435, 1410, 1331, 1308, 1267, 1173, 1130, 
1105, 1068, 1018, 937, 868, 843, 735 cm–1.  
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HRMS (EI+): mass calculated for [M]+ (C11H6F6) requires m/z 252.0374, found m/z 




General procedure E was followed using 4.1g (67 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
50 °C for 14 h. Workup and chromatographic purification (hexanes / EtOAc 1:0 → 9:1) 
afforded the title compound as a yellow oil (31 mg, 68%). Analysis of the 1H NMR 
spectrum revealed a 1:29 ratio of 4.2g : 4.3g.  
1H NMR (400 MHz, CDCl3): δ 8.31 (s, 1 H), 8.23–8.14 (m, 1 H), 7.83–7.73 (m, 1 H), 
7.58 (t, J = 8.1 Hz, 1 H), 5.71 (q, J = 3.3 Hz, 2 H).  
13C NMR (101 MHz, CDCl3): δ 208.9 (q, J = 4.0 Hz), 148.7, 132.7 (q, J = 1.6 Hz), 131.4, 
129.9, 123.1, 123.0 (q, J = 273.9 Hz), 122.2 (q, J = 1.7 Hz), 100.8 (q, J = 35.5 Hz), 85.2.  
19F NMR (376 MHz, CDCl3): δ –62.65 (t, J = 3.6 Hz, 3 F). 
IR (film): 3078, 2995, 1974, 1930, 1531, 1350, 1309, 1182, 983, 871, 806, 707, 684 
cm–1. 
HRMS (EI+): mass calculated for [M]+ (C10H6F3NO2) requires m/z 229.0351, found m/z 
229.0322 (12.7 ppm).  






General procedure E was followed using 4.1h (73 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
50 °C for 14 h. Workup and chromatographic purification (hexanes / EtOAc 1:0 → 4:1) 
afforded the title compound as a yellow oil (38 mg, 74%). Analysis of the 1H NMR 
spectrum revealed a 1:10 ratio of 4.2h : 4.3h. 
1H NMR (500 MHz, CDCl3): δ 8.28 (dd, J = 9.1, 2.8 Hz, 1 H), 8.23 (d, J = 2.8 Hz, 1 H), 
7.01 (d, J = 9.1 Hz, 1 H), 5.42 (q, J = 3.4 Hz, 2 H), 3.97 (s, 3 H).  
13C NMR (126 MHz, CDCl3): δ 209.4 (q, J = 3.6 Hz), 162.4, 141.3, 126.7, 126.5, 122.9 
(q, J = 273.9 Hz), 119.9, 111.0, 95.8 (q, J = 37.2 Hz), 82.2, 56.6.  
19F NMR (376 MHz, CDCl3): δ –62.07 (t, J = 3.6 Hz, 3 F).  
IR (film): 3082, 2995, 2949, 2847, 1981, 1612, 1585, 1518, 1497, 1464, 1346, 1298, 
1273, 1180, 1144, 1121, 1084, 1020, 968, 910, 868, 825, 754, 733, 694, 663, 636 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M+H]+ (C11H9F3NO3) requires m/z 






General procedure E was followed using 4.1i (63 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
50 °C for 14 h. Workup and chromatographic purification (hexanes / EtOAc 1:0 → 9:1) 
afforded the title compound as a colorless oil (27 mg, 64%). Analysis of the 1H NMR 
spectrum revealed a <1:100 ratio of 4.2i : 4.3i.  
1H NMR (500 MHz, CDCl3): δ 7.77–7.73 (m, 1 H), 7.67–7.60 (m, 2 H), 7.52–7.47 (m, 1 
H), 5.63 (q, J = 3.4 Hz, 2 H).  
13C NMR (126 MHz, CDCl3): δ 208.3 (q, J = 3.7 Hz), 134.0, 133.0, 132.9, 129.2, 129.1 
(q, J = 1.4 Hz), 127.8 (q, J = 273.8 Hz), 117.2, 113.7, 98.2 (q, J = 36.7 Hz), 84.8.  
19F NMR (376 MHz, CDCl3): δ –62.10 (t, J = 3.7 Hz, 3 F).  
IR (film): 3074, 2995, 2928, 2854, 2230, 1979, 1936, 1597, 1487, 1448, 1421, 1308, 
1259, 1182, 1122, 1101, 1041, 939, 868, 766, 748, 725, 654, 609, 582, 554, 509 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M+H]+ (C11H7NF3) requires m/z 







General procedure E was followed using 4.1j (72 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
50 °C for 14 h. Workup and chromatographic purification (hexanes) afforded the title 
compound as a colorless oil (41 mg, 80%). Analysis of the 1H NMR spectrum revealed a 
1:29 ratio of 4.2j : 4.3j.  
1H NMR (400 MHz, CDCl3): δ 7.53 (d, J = 2.1 Hz, 1 H), 7.45 (d, J = 8.5 Hz, 1 H), 7.31–
7.26 (m, 1 H), 5.63 (q, J = 3.3 Hz, 2 H).  
13C NMR (126 MHz, CDCl3): δ 208.6 (q, J = 3.9 Hz), 133.2, 132.6, 130.8, 129.4, 129.0 
(q, J = 1.7 Hz), 126.3 (q, J = 1.7 Hz), 123.0 (q, J = 273.1 Hz), 100.6 (q, J = 35.3 Hz), 
84.7.  
19F NMR (376 MHz, CDCl3): δ –61.66 (t, J = 3.3 Hz, 3 F).  
IR (film): 3070, 2927, 1973, 1930, 1226, 1475, 1309, 1255, 1178, 1126, 1031, 958, 
869, 821, 723 cm–1.  
HRMS (EI+): mass calculated for [M]+ (C10H5Cl2F3) requires m/z 251.9720, found m/z 






General procedure E was followed using 4.1k (0.080 g, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
50 °C for 14 h. Workup (wash with 1 N HCl before H2O and brine washes) and 
chromatographic purification (hexanes / EtOAc 19:1 → 4:1) afforded the title compound 
as an amorphous tan solid (27 mg, 46%). Analysis of the 1H NMR spectrum revealed an 
1:8 ratio of 4.2k : 4.3k.  
1H NMR (500 MHz, CDCl3): δ 7.90 (s, 1 H), 7.63–7.58 (m, 2 H), 7.51–7.45 (m, 2 H), 
5.60 (q, J = 3.4 Hz, 2 H).  
13C NMR (126 MHz, CDCl3): δ 208.7 (q, J = 3.9 Hz), 154.9 (q, J = 37.5 Hz), 135.0, 
133.1, 128.2 (d, J = 1.6 Hz), 123.3 (d, J = 273.9 Hz), 120.7, 115.7 (q, J = 288.8 Hz), 
101.3 (q, J = 34.8 Hz), 84.2. 
19F NMR (376 MHz, CDCl3): δ –60.57 (t, J = 3.6 Hz, 3 F), –75.70 (s, 3 F).  
IR (film): 3302, 2926, 1973, 1705, 1610, 1595, 1541, 1518, 1433, 1410, 1318, 1290, 
1265, 1173, 1113, 966, 937, 912, 872, 837, 766, 729, 702, 660, 634, 600 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M]+ (C12H7NOF6) requires m/z 






General procedure E was followed using 4.1l (64 mg, 0.20 mmol), CuI (3.8 mg, 0.020 mmol), 
phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 0.40 mmol), and 
DMF (0.20 mL) as solvent. After activation, the reaction was heated at 50 °C for 14 h. Workup 
and chromatographic purification (hexanes / DCM 19:1) afforded the title compound as a 
colorless oil (32 mg, 75%). Analysis of the 1H NMR spectrum revealed a <1:100 ratio of 4.2l : 
4.3l.  
1H NMR (400 MHz, CDCl3): δ 7.41–7.35 (m, 2 H), 6.95–6.89 (m, 2 H), 5.52 (q, J = 3.4 
Hz, 2 H), 3.83 (s, 3 H).  




General procedure F was followed using 4.1m (86 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
50 °C for 14 h. Workup and chromatographic purification (hexanes / DCM 19:1 → 9:1) 
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afforded the title compound as a colorless oil (30 mg, 47%). Analysis of the 1H NMR 
spectrum revealed a 1:100 ratio of 4.2m : 4.3m.  
1H NMR (400 MHz, CDCl3): δ 8.20 (d, J = 8.3 Hz, 1 H), 7.88 (dt, J = 8.0, 1.0 Hz, 1 H), 
7.74 (s, 1 H), 7.38 (ddd, J = 8.4, 7.2, 1.3 Hz, 1 H), 7.27 (dt, J = 15.2, 0.9 Hz, 1 H), 5.70 
(qd, J = 2.9, 0.9 Hz, 2 H), 1.70 (s, 9 H).  
13C NMR (126 MHz, CDCl3): δ 208.9 (q, J = 3.7 Hz), 149.5, 135.5, 128.4, 125.2, 123.3 
(q, J = 274.3 Hz), 124.2 (q, J = 2.6 Hz), 123.1, 119.9, 115.5, 108.0, 95.7 (q, J = 36.1 
Hz), 84.6, 84.5, 28.3.  
19F NMR (376 MHz, CDCl3): δ [–61.83]–[–61.87] (m, 3 F).  
IR (film): 3165, 3055, 2982, 2934, 1971, 1940, 1736, 1562, 1452, 1375, 1310, 1290, 
1244, 1148, 1117, 1084, 1041, 1024, 883, 854, 762, 746, 729, 692 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M+H]+ (C17H17NO2F3) requires m/z 




General procedure E was followed using 4.1n (63 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), terpy (4.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
50 °C for 14 h. Workup and chromatographic purification (pentane) afforded the title 
compound as a colorless oil (22 mg, 51%). Analysis of the 1H NMR spectrum revealed a 
1:9 ratio of 4.2n : 4.3n.  
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1H NMR (400 MHz, CDCl3): δ 7.36–7.29 (m, 2 H), 7.27–7.20 (m, 3 H), 5.19 (h, J = 3.5 
Hz, 2 H), 2.86–2.75 (m, 2 H), 2.47 (ddt, J = 11.0, 7.2, 3.3 Hz, 2 H).  
13C NMR (101 MHz, CDCl3): δ 206.6 (q, J = 4.3 Hz), 140.7, 128.44, 128.41, 126.2, 
123.8 (q, J = 273.1 Hz), 98.0 (q, J = 33.9 Hz), 82.4, 33.5, 27.6.  
19F NMR (376 MHz, CDCl3): δ –62.24 (s, 3 F).  
IR (film): 3088, 3065, 3030, 2928, 2860, 1985, 1954, 1605, 1497, 1454, 1333, 1263, 
1202, 1155, 1119, 1082, 1055, 1030, 980, 864, 744, 700 cm–1.  




KF (813 mg, 14.0 mmol) and a stir bar were added to a 25 mL round-bottom flask, and 
placed in a 200 °C vacuum-oven. After 24 h, the flask was equipped with a 3-way 
flushing adaptor, and allowed to cool under an atmosphere of dry N2. The flask was 
charged with CuI (133 mg, 0.700 mmol), phen (126 mg, 0.700 mmol), and NaO2CCF2Br 
(345 mg, 1.75 mmol). The system was evacuated and backfilled with dry N2 (3x), and 
remained under a positive pressure of N2 during the course of the reaction. DMF (7.00 
mL) was injected, and the flask was immersed in a 50 °C oil bath (Note: evolution of 
CO2). After 10 min, 4.1o (2.37 g, 7.00 mmol) was injected, and the mixture was stirred 
for 14 h. The reaction was allowed to cool to rt, and diluted with EtOAc (100 mL). The 
mixture was washed with 1 N HCl (100 mL), water (100 mL), and brine (100 mL). The 
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organic phase was dried over MgSO4, filtered, and the solvent was removed in vacuo. 
Chromatographic purification (hexanes / EtOAc 19:1) afforded the title compound as an 
amorphous yellow solid (1.33 g, 81%) Analysis of the 1H NMR spectrum revealed a 1:40 
ratio of 4.2o : 4.3o.  
1H NMR (400 MHz, CDCl3): δ 7.93 (s, 1 H), 7.89–7.80 (m, 3 H), 7.54 (dd, J = 8.8, 1.9 
Hz, 1 H), 7.53–7.48 (m, 2 H), 5.63 (q, J = 3.3 Hz, 2 H).  




 General procedure E was followed using 4.1p (64 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
50 °C for 14 h. Workup and chromatographic purification (pentane / Et2O 49:1 → 19:1) 
afforded the title compound as a colorless oil (35 mg, 82%). Alkyne 4.2p was not 
observed by 1H or 19F NMR spectroscopy.  
1H NMR (500 MHz, CDCl3): δ 7.31–7.26 (m, 1 H), 6.92 (dt, J = 7.8, 1.2 Hz, 1 H), 6.88–
6.83 (m, 2 H), 6.65 (dq, J = 6.4, 3.8 Hz, 1 H), 5.89 (p, J = 5.9 Hz, 1 H), 3.83 (s, 3 H).  
13C NMR (126 MHz, CDCl3): δ 207.1 (q, J = 5.8 Hz), 160.1, 132.2 (q, J = 1.7 Hz), 130.1, 
122.5 (q, J = 271.1 Hz), 120.3, 114.4, 112.9, 101.4, 89.8 (q, J = 39.2 Hz), 55.4.  
19F NMR (471 MHz, CDCl3): δ [–61.15]–[–61.21] (m, 3 F). 
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IR (film): 3007, 2962, 2943, 2839, 1969, 1599, 1583, 1493, 1470, 1441, 1414, 1398, 
1306, 1286, 1263, 1225, 1130, 1047, 885, 872, 841, 785, 754, 735, 689, 648, 636 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M+H]+ (C11H10F3O) requires m/z 




General procedure E was followed using 4.1q (74 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
50 °C for 14 h. Workup and chromatographic purification (hexanes / EtOAc 49:1 → 
19:1) afforded the title compound as a colorless oil (39 mg, 74%). Alkyne 4.2q was not 
observed by 1H or 19F NMR spectroscopy.  
1H NMR (500 MHz, CDCl3): δ 7.46–7.42 (m, 2 H), 7.26–7.22 (m, 2 H), 6.62 (dq, J = 6.4, 
3.8 Hz, 1 H), 5.94 (p, J = 5.9 Hz, 1 H).  
13C NMR (126 MHz, CDCl3): δ 207.1 (q, J = 5.7 Hz), 133.1 (d, J = 1.7 Hz), 131.7, 130.6, 
130.4, 126.2, 123.2, 122.3 (q, J = 271.2 Hz), 100.4, 90.3 (q, J = 39.4 Hz).  
19F NMR (376 MHz, CDCl3): δ [–61.34]–[–61.42] (m, 3 F). 
IR (film): 3069, 2957, 1967, 1705, 1593, 1572, 1475, 1429, 1416, 1371, 1348, 1259, 
1192, 1163, 1132, 1074, 1018, 997, 883, 856, 787, 750, 694, 673 cm–1.  
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HRMS (APCI–hexane/PhMe): mass calculated for [M]+ (C10H6F3Br) requires m/z 




General procedure E was followed using 4.1r (101 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
50 °C for 14 h. Workup and chromatographic purification (hexanes / DCM 4:1) afforded 
the title compound as a colorless oil (32 mg, 40%). Alkyne 4.2r was not observed by 1H 
or 19F NMR spectroscopy.  
1H NMR (400 MHz, CDCl3): δ 7.41 (d, J = 2.5 Hz, 1 H), 7.36–7.31 (m, 3 H), 6.99 (dq, J 
= 6.6, 4.0 Hz, 1 H), 6.96–6.91 (m, 2 H), 6.84 (d, J = 8.8 Hz, 1 H), 5.82 (p, J = 5.9 Hz, 1 
H), 5.02 (s, 2 H), 3.84 (s, 3 H).  
13C NMR (126 MHz, CDCl3): δ 207.5 (q, J = 5.8 Hz), 159.6, 154.7, 132.3, 131.1, 129.3, 
128.0, 122.4 (q, J = 271.0 Hz), 121.9 (q, J = 1.7 Hz), 114.3, 114.1, 113.3, 94.9, 89.2 (q, 
J = 39.1 Hz), 70.6, 55.3.  
19F NMR (376 MHz, CDCl3): δ [–61.23]–[–61.31] (m, 3 F).  
IR (film): 3016, 2957, 2935, 2837, 1967, 1612, 1587, 1516, 1491, 1466, 1416, 1404, 
1379, 1304, 1246, 1175, 1130, 1036, 1001, 887, 864, 824, 806, 690, 646 cm–1.  
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HRMS (APCI–hexane/PhMe): mass calculated for [M–H]+ (C18H13O2F3Br) requires m/z 




General procedure E was followed using 4.1s (72 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
50 °C for 14 h. Workup and chromatographic purification (hexanes / DCM 4:1) afforded 
the title compound as a colorless oil (36 mg, 70%). Alkyne 4.2s was not observed by 1H 
or 19F NMR spectroscopy.  
1H NMR (500 MHz, CDCl3): δ 7.53 (dd, J = 1.9, 0.8 Hz, 1 H), 6.75 (dq, J = 6.6, 3.8 Hz, 1 
H), 6.59 (dd, J = 3.4, 0.8 Hz, 1 H), 6.52 (dd, J = 3.4, 1.8 Hz, 1 H), 6.49 (s, 1 H), 5.86 
(dq, J = 5.8, 6.5 Hz, 1 H), 4.04 (s, 3 H).  
13C NMR (126 MHz, CDCl3): δ 207.8 (q, J = 5.8 Hz), 144.4, 143.1, 142.4 (q, J = 1.9 Hz), 
135.8, 122.3 (q, J = 271.0 Hz), 111.7, 109.2, 103.6, 94.1, 89.3 (q, J = 39.2 Hz), 38.9.  
19F NMR (471 MHz, CDCl3): δ [–61.31]–[–61.35] (m, 3 F).  
IR (film): 3126, 3013, 2955, 1975, 1531, 1472, 1427, 1394, 1367, 1294, 1269, 1252, 
1221, 1128, 1007, 903, 885, 841, 797, 741, 710, 687, 592, 571 cm–1. 
HRMS (ESI+): mass calculated for [M+H]+ (C12H10F3N2O) requires m/z 255.0745, found 





General procedure E was followed using 4.1t (76 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
50 °C for 14 h. Workup and chromatographic purification (hexanes / EtOAc 49:1) 
afforded the title compound as a colorless oil (39 mg, 70%). Alkyne 4.2t was not 
observed by 1H or 19F NMR spectroscopy.  
1H NMR (500 MHz, CDCl3): δ 7.43–7.39 (m, 2 H), 7.25–7.20 (m, 2 H), 6.47 (hept, J = 
3.1 Hz, 1 H), 1.99 (d, J = 3.0 Hz, 3 H). 
13C NMR (126 MHz, CDCl3): δ 204.2 (q, J = 4.0 Hz), 134.4, 131.3, 130.5, 130.3, 126.1, 
123.5 (q, J = 273.9 Hz), 123.1, 99.1, 98.6 (q, J = 35.4 Hz), 13.2.  
19F NMR (376 MHz, CDCl3): δ –66.59 (d, J = 3.2 Hz, 3 F).  
IR (film): 3063, 3001, 2962, 2932, 2862, 1971, 1742, 1703, 1593, 1568, 1477, 1464, 
1429, 1381, 1302, 1267, 1211, 1190, 1153, 1122, 1090, 1072, 1036, 997, 976, 947, 
903, 883, 862, 845, 825, 779, 760, 744, 683, 671, 646, 615 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M]+ (C11H8F3Br) requires m/z 






General procedure E was followed using 4.1u (66 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
60 °C for 24 h. Workup and chromatographic purification (hexanes / EtOAc 49:1 → 9:1) 
afforded the title compound as a yellow oil (19 mg, 43%). Analysis of the 1H NMR 
spectrum revealed a 1:25 ratio of 4.2u : 4.3u.  
1H NMR (500 MHz, CDCl3): δ 10.04 (s, 1 H), 7.94–7.91 (m, 1 H), 7.83 (dt, J = 7.7, 1.4 
Hz, 1 H), 7.70 (ddt, J = 7.9, 2.0, 1.0 Hz, 1 H), 7.55 (t, J = 7.7 Hz, 1 H), 6.02 (qd, J = 7.4, 
3.7 Hz, 1 H), 1.93 (d, J = 7.4 Hz, 3 H).  
13C NMR (126 MHz, CDCl3): δ 205.4 (q, J = 4.0 Hz), 192.0, 136.9, 132.8 (t, J = 1.6 Hz), 
131.6, 129.5, 129.2, 128.4, 123.3 (q, J = 273.9 Hz), 100.5 (q, J = 35.0 Hz), 95.9, 13.4.  
19F NMR (376 MHz, CDCl3): δ –61.53 (d, J = 3.1 Hz, 3 F).  
IR (film): 3067, 2961, 2930, 2853, 2822, 2729, 1961, 1707, 1601, 1583, 1485, 1443, 
1398, 1373, 1310, 1246, 1194, 1157, 1121, 1070, 1034, 982, 968, 916, 837, 800, 733, 
692, 681, 660, 646, 590, 538 cm–1. 
HRMS (APCI–hexane/PhMe): mass calculated for [M+H]+ (C12H10OF3) requires m/z 






General procedure F was followed using 4.1v (87 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), terpy (4.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
60 °C for 24 h. Workup (DCM used in place of EtOAc for extraction) and 
chromatographic purification (DCM) afforded the title compound as a colorless solid (41 
mg, 62%). Alkyne 4.2v was not observed by 1H or 19F NMR spectroscopy.  
m.p.: 102–103 °C. 
1H NMR (400 MHz, CDCl3): δ 7.68–7.63 (m, 2 H), 7.37–7.31 (m, 2 H), 5.35 (qp, J = 6.4, 
2.2 Hz, 1 H), 3.24 (dt, J = 11.3, 5.6 Hz, 2 H), 3.11–3.03 (m, 2 H), 2.45 (s, 3 H), 2.42 
(ddt, J = 7.0, 3.8, 1.4 Hz, 4 H).  
13C NMR (126 MHz, CDCl3): δ 200.2 (q, J = 5.8 Hz), 144.0, 133.4, 130.0, 127.7, 122.6 
(q, J = 270.5 Hz), 105.2, 85.3 (q, J = 39.1 Hz), 46.7, 29.5 (q, J = 1.3 Hz), 21.7.  
19F NMR (376 MHz, CDCl3): δ –61.72 (d, J = 6.0 Hz, 3 F).  
IR (film): 3032, 2962, 2918, 2849, 1985, 1597, 1464, 1437, 1354, 1339, 1306, 1277, 
1250, 1198, 1167, 1122, 1038, 1018, 976, 924, 843, 816, 725, 689, 654, 627, 563 cm–1.  
HRMS (ESI+): mass calculated for [M+Na]+ (C15H16F3NO2SNa) requires m/z 354.0752, 






General procedure F was followed using 4.1w (0.20 g, 0.40 mmol), CuI (7.6 mg, 0.040 
mmol), phen (7.2 mg, 0.040 mmol), NaO2CCF2Br (0.020 g, 0.10 mmol), KF (46 mg, 0.80 
mmol), and DMF (0.40 mL) as solvent. The reaction was heated at 60 °C for 24 h. 
Workup (DCM used in place of EtOAc for extraction) and chromatographic purification 
(DCM) afforded the title compound as a colorless solid (0.13 g, 81%). Alkyne 4.2w was 
not observed by 1H or 19F NMR spectroscopy. 
m.p.: 73–74 °C.   
1H NMR (400 MHz, CDCl3): δ 7.67 (d, J = 8.3 Hz, 2 H), 7.35 (d, J = 8.1 Hz, 2 H), 3.25 
(dt, J = 11.2, 5.4 Hz, 2 H), 3.04 (dt, J = 11.7, 5.9 Hz, 2 H), 2.46 (s, 3 H), 2.39 (t, J = 5.7 
Hz, 4 H), 2.09 (t, J = 7.0 Hz, 2 H), 1.42 – 1.24 (m, 4 H), 0.85 (t, J = 7.0 Hz, 3 H).  
13C NMR (126 MHz, CDCl3): δ 197.1 (q, J = 4.4 Hz), 143.9, 133.5, 129.9, 127.7, 123.8 
(q, J = 273.5 Hz), 105.1, 98.3 (q, J = 33.5 Hz), 47.0, 30.0, 29.6, 26.1, 22.0, 21.7, 13.9.  
19F NMR (376 MHz, CDCl3): δ –65.39 (s, 3 F).  
IR (film): 3030, 2959, 2930, 2860, 1979, 1597, 1495, 1466, 1456, 1441, 1427, 1356, 
1339, 1290, 1248, 1211, 1198, 1167, 1117, 1103, 1040, 1018, 980, 970, 933, 922, 816, 
800, 719, 689, 677, 654, 635 cm–1.  
HRMS (ESI+): mass calculated for [M+Na]+ (C19H24F3NO2SNa) requires m/z 410.1378, 






General procedure E was followed using 4.1x (61 mg, 0.20 mmol), CuI (3.8 mg, 0.020 
mmol), phen (3.6 mg, 0.020 mmol), NaO2CCF2Br (9.8 mg, 0.050 mmol), KF (23 mg, 
0.40 mmol), and DMF (0.20 mL) as solvent. After activation, the reaction was heated at 
60 °C for 24 h. Workup and chromatographic purification (pentane) afforded the title 
compound as a colorless oil (17 mg, 42%). Analysis of the 1H NMR spectrum revealed a 
<1:100 ratio of 4.2x : 4.3x.  
1H NMR (400 MHz, CDCl3): δ 7.47–7.42 (m, 2 H), 7.40–7.34 (m, 2 H), 7.34–7.28 (m, 1 
H), 5.93 (qq, J = 6.9, 3.2 Hz, 1 H), 1.89 (d, J = 7.3 Hz, 3 H).  
19F NMR (376 MHz, CDCl3): δ –61.46 (d, J = 3.1 Hz, 3 F). 
 




In a N2 filled glovebox, a 15 mL screw-top vial was charged with CuCl (1.0 mg, 0.010 
mmol), 1,3-bis(2,6-diisopropylphenyl)imidazolium chloride (4.3 mg, 0.010 mmol), 
NaOtBu (7.7 mg, 0.080 mmol) and THF (1.0 mL), and the solution was stirred for 1 h. 
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Bis(pinacolato)diboron (56 mg, 0.22 mmol) was added, and the mixture was stirred for 
30 min. Allene 4.3o (47 mg, 0.20 mmol) and MeOH (49 μL, 1.2 mmol) were added, and 
the vial was sealed and removed from the glovebox and stirred for 14 h. The mixture 
was filtered through a pad of SiO2, and the pad was rinsed with Et2O (3 x 4 mL). The 
solvent was removed in vacuo to provide a brown oil. Chromatographic purification 
(hexanes / EtOAc 1:0 → 19:1) afforded the title compound as a colorless solid (59 mg, 
82%). 
m.p.: 84–86.  
1H NMR (500 MHz, CDCl3): δ 7.88–7.79 (m, 4 H), 7.53–7.44 (m, 3 H), 6.20 (s, 1 H), 
6.07 (s, 1 H), 4.57 (q, J = 9.8 Hz, 1 H), 1.19 (s, 6 H), 1.09 (s, 6 H).  
13C NMR (126 MHz, CDCl3): δ 135.5, 133.3, 132.9, 132.2, 132.2, 129.1, 128.2, 128.1, 
127.7, 127.6, 126.5 (q, J = 281.3 Hz), 126.3, 126.2, 84.1, 52.6 (q, J = 26.8 Hz), 24.8, 
24.5.  
19F NMR (376 MHz, CDCl3): δ –66.62 (d, J = 9.7 Hz).  
IR (film): 3059, 2978, 2930, 1701, 1622, 1601, 1437, 1381, 1373, 1362, 1337, 1321, 
1258, 1213, 1140, 1097, 964, 872, 856, 843, 816, 746, 723 cm–1.  
HRMS (APCI–hexane/PhMe): mass calculated for [M]+ (C20H22O2F3B) requires m/z 








In a N2 filled glovebox, a 15 mL screw-top vial was charged with chloro[1,3-bis(2,6-
diisopropylphenyl)imidazole-2-ylidene]gold(I) (12 mg, 0.020 mmol), AgOTf (5.2 mg, 
0.020 mmol), and PhMe (0.20 mL). The mixture was stirred for 5 min, after which a 
solution of allene 4.3o (47 mg, 0.20 mmol) and 2-phenylethanol (26 μL, 0.22 mmol) in 
PhMe (0.30 mL) was injected. The vial was sealed and removed from the glovebox. 
After stirring for 36 h at rt, the solvent was removed in vacuo. Chromatographic 
purification (hexanes / DCM 1:0 → 4:1) afforded the title compound as a colorless oil 
(56 mg, 78%).  
1H NMR (500 MHz, CDCl3): δ 7.92–7.83 (m, 3 H), 7.72 (s, 1 H), 7.59–7.51 (m, 2 H), 
7.35 (dd, J = 8.5, 1.7 Hz, 1 H), 7.32–7.26 (m, 2 H), 7.24–7.21 (m, 1 H), 7.21–7.17 (m, 2 
H), 6.64 (tq, J = 5.9, 1.5 Hz, 1 H), 4.02 (dq, J = 6.1, 2.0 Hz, 2 H), 3.59 (t, J = 7.1 Hz, 2 
H), 2.86 (t, J = 7.1 Hz, 2 H).  
13C NMR (126 MHz, CDCl3): δ 138.7, 133.7 (q, J = 5.4 Hz), 133.3, 133.1 (q, J = 30.2 
Hz), 133.0, 129.1, 129.0, 129.0, 128.5, 128.4, 128.3, 127.9, 127.0, 126.7, 126.7, 126.4, 
123.3 (q, J = 273.4 Hz), 71.9, 67.2, 36.4.  
19F NMR (376 MHz, CDCl3): δ –66.81 (m, 3 F). 
IR (film): 3061, 3021, 2935, 2920, 2862, 1601, 1504, 1497, 1477, 1454, 1350, 1331, 
1296, 1244, 1177, 1163, 1121, 999, 968, 926, 899, 860, 820, 750, 719, 698 cm–1.  
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HRMS (APCI–hexane/PhMe): mass calculated for [M]+ (C22H19OF3) requires m/z 






In a N2 filled glovebox, a 15 mL screw-top vial was charged with allylpalladium(II) 
chloride dimer (1.8 mg, 0.0050 mmol), 1,1’-bis(diphenylphosphino)ferrocene (5.5 mg, 
0.010 mmol), and THF (0.50 mL). The mixture was stirred for 5 min, after which allene 
4.3o (47 mg, 0.20 mmol) and imidazole (16 mg, 0.24 mmol) were added. The vial was 
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sealed, removed from the glovebox, and placed in a 80 °C oil bath. After 24 h, the 
mixture was allowed to cool to rt and the solvent was removed in vacuo. 
Chromatographic purification (DCM / MeOH 1:0 → 19:1) afforded the title compound as 
an amorphous brown solid (41 mg, 67%).  
1H NMR (400 MHz, C6D6): δ 7.56–7.44 (m, 4 H), 7.27 (s, 1 H), 7.23–7.17 (m, 2 H), 
7.14–7.08 (m, 1 H), 7.01 (s, 1 H), 6.38 (t, J = 1.3 Hz, 1 H), 5.08 (m, 1 H), 4.86 (m, 1 H), 
4.07 (q, J = 8.9 Hz, 1 H).  
13C NMR (126 MHz, CDCl3): δ 137.3, 136.1, 133.5, 133.3, 130.2, 129.3, 129.2, 128.4, 
128.2, 127.9, 127.2, 127.0, 126.0, 124.9 (q, J = 280.4 Hz), 118.0, 111.2 (q, J = 2.1 Hz), 
54.8 (q, J = 28.5 Hz).  
19F NMR (376 MHz, CDCl3): δ –67.34 (d, J = 8.6 Hz). 
IR (film): 3113, 3057, 3024, 2918, 1653, 1601, 1510, 1487, 1373, 1348, 1315, 1256, 
1163, 1126, 1107, 1072, 1005, 903, 858, 818, 748, 689, 658 cm–1.  
HRMS (ESI+): exact mass calculated for [M+H]+ (C17H14F3N2) requires m/z 303.1109, 
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